activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	177495	CHEMBL803491	Inhibition of Ribosomal S6 kinase 2	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ncc(C(F)(F)F)cc1Cl		CHEMBL111620	=	Activity	%	77.0	CHEMBL3906	Homo sapiens	Activity	%	77.0
	177495	CHEMBL803491	Inhibition of Ribosomal S6 kinase 2	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1ncc(C(F)(F)F)cc1Cl		CHEMBL111620	=	Activity	%	77.0	CHEMBL3906	Homo sapiens	Activity	%	77.0
	178808	CHEMBL803491	Inhibition of Ribosomal S6 kinase 2	B	COCCCn1cc(C2=C(c3ccccc3O)C(=O)NC2=O)c2cccnc21		CHEMBL109944	=	Activity	%	54.0	CHEMBL3906	Homo sapiens	Activity	%	54.0
	182555	CHEMBL803491	Inhibition of Ribosomal S6 kinase 2	B	COc1ccccc1C1=C(c2cn(CCCNC(=O)OC(C)(C)C)c3ncccc23)C(=O)NC1=O		CHEMBL109981	=	Activity	%	31.0	CHEMBL3906	Homo sapiens	Activity	%	31.0
Not Active	1650099	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554		Kd			CHEMBL3906	Homo sapiens	Kd		
	1650100	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Kd	nM	8100.0	CHEMBL3906	Homo sapiens	Kd	uM	8.1
Not Active	1650101	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253		Kd			CHEMBL3906	Homo sapiens	Kd		
	1650102	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	58.0	CHEMBL3906	Homo sapiens	Kd	uM	0.058
Not Active	1650103	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660		Kd			CHEMBL3906	Homo sapiens	Kd		
	1650104	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Kd	nM	1500.0	CHEMBL3906	Homo sapiens	Kd	uM	1.5
Not Active	1650105	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336		Kd			CHEMBL3906	Homo sapiens	Kd		
	1650106	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	=	Kd	nM	3200.0	CHEMBL3906	Homo sapiens	Kd	uM	3.2
	1650107	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	1600.0	CHEMBL3906	Homo sapiens	Kd	uM	1.6
	1651874	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	10.0	CHEMBL3906	Homo sapiens	Kd	uM	0.01
Not Active	1651875	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041		Kd			CHEMBL3906	Homo sapiens	Kd		
Not Active	1651876	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10		Kd			CHEMBL3906	Homo sapiens	Kd		
Not Active	1651877	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385		Kd			CHEMBL3906	Homo sapiens	Kd		
Not Active	1651878	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667		Kd			CHEMBL3906	Homo sapiens	Kd		
	1651879	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Kd	nM	2200.0	CHEMBL3906	Homo sapiens	Kd	uM	2.2
Not Active	1651880	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941		Kd			CHEMBL3906	Homo sapiens	Kd		
Not Active	1651881	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939		Kd			CHEMBL3906	Homo sapiens	Kd		
Not Active	1651882	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553		Kd			CHEMBL3906	Homo sapiens	Kd		
Not Active	1651883	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828		Kd			CHEMBL3906	Homo sapiens	Kd		
Not Active	1651884	CHEMBL860804	Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965		Kd			CHEMBL3906	Homo sapiens	Kd		
Not Active	1658711	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12		CHEMBL188678		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1728734	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccco3)ccc12		CHEMBL196964		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1728777	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccc(F)cc3)ccc12		CHEMBL197439		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1728820	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccsc3)ccc12		CHEMBL196764		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1728863	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccc4c3oc3ccccc34)ccc12		CHEMBL196759		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1728906	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cc4ccccc4s3)ccc12		CHEMBL381025		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1728959	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccc4c3Sc3ccccc3S4)ccc12		CHEMBL199216		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729002	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)ccc12		CHEMBL436767		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729045	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccc4ccccc34)ccc12		CHEMBL199050		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729088	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(/C=C/c3ccc(Cl)cc3)ccc12		CHEMBL199051		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729131	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccc4[nH]ccc4c3)ccc12		CHEMBL369969		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729174	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccc4ncccc4c3)ccc12		CHEMBL198740		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729217	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccc4c3Oc3ccccc3S4)ccc12		CHEMBL197239		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729260	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	Nc1cc(C(=O)O)cc(-c2ccc3c(=O)cc(N4CCOCC4)oc3c2)c1		CHEMBL370108		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729303	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccc4c3sc3ccccc34)ccc12		CHEMBL198801		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729349	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=C1c2ccccc2C(=O)N1Cc1cccc(-c2ccc3c(=O)cc(N4CCOCC4)oc3c2)c1		CHEMBL197219		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729392	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=C1c2ccccc2C(=O)N1Cc1ccc(-c2ccc3c(=O)cc(N4CCOCC4)oc3c2)cc1		CHEMBL197227		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729435	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3cccs3)ccc12		CHEMBL371968		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729478	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccc4ccccc4c3)ccc12		CHEMBL200299		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729521	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3csc4ccccc34)ccc12		CHEMBL199416		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729564	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	O=c1cc(N2CCOCC2)oc2cc(-c3ccc(OCc4ccccc4)cc3)ccc12		CHEMBL382501		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729622	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	Cc1ccc(-c2ccc3c(=O)cc(N4CCOCC4)oc3c2)c2ccccc12		CHEMBL200275		Activity			CHEMBL3906	Homo sapiens	Activity		
Not Determined	1729665	CHEMBL859303	Inhibitory activity against Rsk3 at 10 uM	B	COC(=O)/C=C/c1ccccc1-c1ccc2c(=O)cc(N3CCOCC3)oc2c1		CHEMBL199424		Activity			CHEMBL3906	Homo sapiens	Activity		
	1734085	CHEMBL862833	Residual activity at human Rsk2 at 10 uM in presence of 10 uM ATP relative to control	B	O=C1NC(=O)/C(=C/c2ccc(-c3ccc(F)cc3O)o2)S1		CHEMBL379156	=	Activity	%	86.0	CHEMBL3906	Homo sapiens	Activity	%	86.0
	2025195	CHEMBL887023	Inhibition of human Rsk2 at 1 uM relative to control	B	CN(C)c1cc2cc(n1)CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CCC2		CHEMBL247067	=	Inhibition	%	10.0	CHEMBL3906	Homo sapiens	Inhibition	%	10.0
	2025477	CHEMBL887023	Inhibition of human Rsk2 at 1 uM relative to control	B	CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CC2		CHEMBL1162963	=	Inhibition	%	32.0	CHEMBL3906	Homo sapiens	Inhibition	%	32.0
	2025478	CHEMBL887023	Inhibition of human Rsk2 at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1ccc(c(N3CCCC3)n1)CCCn1cc2c2ccccc21		CHEMBL396327	=	Inhibition	%	63.0	CHEMBL3906	Homo sapiens	Inhibition	%	63.0
	2025479	CHEMBL887023	Inhibition of human Rsk2 at 1 uM relative to control	B	O=C1NC(=O)C2=C1c1cn(c3ccccc13)CCCc1cc(nc(N3CCCC3)c1)CCCn1cc2c2ccccc21		CHEMBL397771	=	Inhibition	%	12.0	CHEMBL3906	Homo sapiens	Inhibition	%	12.0
	2025519	CHEMBL887037	Inhibition of human Rsk2	B	CN(C)c1nc2ccc1CCCn1cc(c3ccccc31)C1=C(C(=O)NC1=O)c1cn(c3ccccc13)CC2		CHEMBL1162963	=	IC50	nM	850.0	CHEMBL3906	Homo sapiens	IC50	nM	850.0
	2147383	CHEMBL922168	Activity of human Rsk3 kinase at 1 uM	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Activity	%	76.0	CHEMBL3906	Homo sapiens	Activity	%	76.0
	2157693	CHEMBL932648	Inhibition of RSK2 at 1 uM	B	NCC1(c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL406863	>	Inhibition	%	60.0	CHEMBL3906	Homo sapiens	Inhibition	%	60.0
	2206863	CHEMBL990538	Inhibition of RPSKA2	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	58.0	CHEMBL3906	Homo sapiens	Kd	nM	58.0
	2251077	CHEMBL1022315	Inhibition of RSK3 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O)C(N)=O		CHEMBL525385	=	Inhibition	%	99.0	CHEMBL3906	Homo sapiens	INH	%	99.0
	2251205	CHEMBL1009904	Inhibition of Rsk3	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	=	IC50	nM	1.0	CHEMBL3906	Homo sapiens	IC50	nM	1.0
	2595786	CHEMBL1019783	Binding affinity to RPS6KA2 kinase domain.2- C-terminal	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	Kd	nM	1400.0	CHEMBL3906	Homo sapiens	Kd	nM	1400.0
	2721716	CHEMBL1055120	Inhibition of Rsk3 at 1 uM	B	C[C@@H](Oc1cc(-c2cnc3ccccn23)sc1C(N)=O)c1ccc(CNC(C)(C)C)cc1OC(F)F		CHEMBL551079	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	2907665	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907666	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907667	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907668	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907669	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907670	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907671	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	310.0	CHEMBL3906	Homo sapiens	Kd	nM	310.0
	2907672	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907673	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907674	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907675	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907676	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907677	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907678	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907679	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907680	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907681	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907682	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907683	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907684	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Kd	nM	410.0	CHEMBL3906	Homo sapiens	Kd	nM	410.0
	2907685	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907686	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Kd	nM	280.0	CHEMBL3906	Homo sapiens	Kd	nM	280.0
	2907687	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907688	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907689	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907690	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	730.0	CHEMBL3906	Homo sapiens	Kd	nM	730.0
	2907691	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907692	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907693	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907694	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907695	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907696	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907697	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	8.9	CHEMBL3906	Homo sapiens	Kd	nM	8.9
	2907698	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	260.0	CHEMBL3906	Homo sapiens	Kd	nM	260.0
	2907699	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	17.0	CHEMBL3906	Homo sapiens	Kd	nM	17.0
	2907700	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	2000.0	CHEMBL3906	Homo sapiens	Kd	nM	2000.0
	2907701	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907702	CHEMBL1060342	Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907703	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907704	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907705	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	1100.0	CHEMBL3906	Homo sapiens	Kd	nM	1100.0
	2907706	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907707	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907708	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907709	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907710	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907711	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907712	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	Kd	nM	1400.0	CHEMBL3906	Homo sapiens	Kd	nM	1400.0
	2907713	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907714	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907715	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Kd	nM	8700.0	CHEMBL3906	Homo sapiens	Kd	nM	8700.0
	2907716	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907717	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	1500.0	CHEMBL3906	Homo sapiens	Kd	nM	1500.0
	2907718	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907719	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907720	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907721	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907722	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907723	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907724	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907725	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907726	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907727	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907728	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907729	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907730	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907731	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907732	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907733	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907734	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907735	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	190.0	CHEMBL3906	Homo sapiens	Kd	nM	190.0
	2907736	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	9600.0	CHEMBL3906	Homo sapiens	Kd	nM	9600.0
	2907737	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	8400.0	CHEMBL3906	Homo sapiens	Kd	nM	8400.0
	2907738	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907739	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2907740	CHEMBL1062786	Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	2921986	CHEMBL1052954	Inhibition of RPS6KA2 kinase domain 1 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	2921987	CHEMBL1052955	Inhibition of RPS6KA2 kinase domain 2 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	81.0	CHEMBL3906	Homo sapiens	Activity	%	81.0
	2938441	CHEMBL1036947	Inhibition of RSK3 at 1 uM	B	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(C(=O)N[C@H](CO)c2cccc(Cl)c2)c1		CHEMBL583042	=	Inhibition	%	7.0	CHEMBL3906	Homo sapiens	INH	%	7.0
	3052472	CHEMBL1072510	Residual activity of RPS6KA2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	91.0	CHEMBL3906	Homo sapiens	Residual activity	%	91.0
	3052724	CHEMBL1043803	Residual activity of RPS6KA2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	99.0	CHEMBL3906	Homo sapiens	Residual activity	%	99.0
	3054033	CHEMBL1071363	Residual activity of RPS6KA2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	39.0	CHEMBL3906	Homo sapiens	Residual activity	%	39.0
	3055320	CHEMBL1072510	Residual activity of RPS6KA2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	90.0	CHEMBL3906	Homo sapiens	Residual activity	%	90.0
	3055572	CHEMBL1043803	Residual activity of RPS6KA2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	88.0	CHEMBL3906	Homo sapiens	Residual activity	%	88.0
	3056877	CHEMBL1071363	Residual activity of RPS6KA2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	44.0	CHEMBL3906	Homo sapiens	Residual activity	%	44.0
	3057129	CHEMBL1072510	Residual activity of RPS6KA2 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	92.0	CHEMBL3906	Homo sapiens	Residual activity	%	92.0
	3058449	CHEMBL1043803	Residual activity of RPS6KA2 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	99.0	CHEMBL3906	Homo sapiens	Residual activity	%	99.0
	3059733	CHEMBL1071363	Residual activity of RPS6KA2 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	81.0	CHEMBL3906	Homo sapiens	Residual activity	%	81.0
	3214038	CHEMBL1103233	Inhibition of RSK3 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	9.0	CHEMBL3906	Homo sapiens	INH	%	9.0
	3219709	CHEMBL1114123	Inhibition of RSK3 at 100 nM relative to control	B	N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCNC(=O)[C@@H](CCCCN)NC(=O)CCCCCNC(=O)c1ccc(-c2ccnc(N)n2)s1)C(N)=O		CHEMBL1077375	=	Inhibition	%	97.0	CHEMBL3906	Homo sapiens	INH	%	97.0
	3224953	CHEMBL1101757	Inhibition of RSK3 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3226332	CHEMBL1101757	Inhibition of RSK3 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3332140	CHEMBL1167688	Inhibition of RPS6KA2 N-terminal domain1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3332141	CHEMBL1167689	Inhibition of RPS6KA2 C-terminal domain2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3333555	CHEMBL1167688	Inhibition of RPS6KA2 N-terminal domain1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3333556	CHEMBL1167689	Inhibition of RPS6KA2 C-terminal domain2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3334960	CHEMBL1167688	Inhibition of RPS6KA2 N-terminal domain1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3334961	CHEMBL1167689	Inhibition of RPS6KA2 C-terminal domain2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3336380	CHEMBL1167688	Inhibition of RPS6KA2 N-terminal domain1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3336381	CHEMBL1167689	Inhibition of RPS6KA2 C-terminal domain2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3337644	CHEMBL1167688	Inhibition of RPS6KA2 N-terminal domain1 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3337645	CHEMBL1167689	Inhibition of RPS6KA2 C-terminal domain2 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3338975	CHEMBL1167688	Inhibition of RPS6KA2 N-terminal domain1 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3338976	CHEMBL1167689	Inhibition of RPS6KA2 C-terminal domain2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3339229	CHEMBL1167688	Inhibition of RPS6KA2 N-terminal domain1 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3339230	CHEMBL1167689	Inhibition of RPS6KA2 C-terminal domain2 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3340532	CHEMBL1167688	Inhibition of RPS6KA2 N-terminal domain1 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3340533	CHEMBL1167689	Inhibition of RPS6KA2 C-terminal domain2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3341922	CHEMBL1167688	Inhibition of RPS6KA2 N-terminal domain1 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3341923	CHEMBL1167689	Inhibition of RPS6KA2 C-terminal domain2 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3343369	CHEMBL1167688	Inhibition of RPS6KA2 N-terminal domain1 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3343370	CHEMBL1167689	Inhibition of RPS6KA2 C-terminal domain2 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3358801	CHEMBL1175329	Inhibition of RSK3 N-terminal domain1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	9.5	CHEMBL3906	Homo sapiens	INH	%	9.5
	3358802	CHEMBL1175330	Inhibition of RSK3 C-terminal domain2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	30.0	CHEMBL3906	Homo sapiens	INH	%	30.0
	3359243	CHEMBL1175329	Inhibition of RSK3 N-terminal domain1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	0.7	CHEMBL3906	Homo sapiens	INH	%	0.7
	3359244	CHEMBL1175330	Inhibition of RSK3 C-terminal domain2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	87.0	CHEMBL3906	Homo sapiens	INH	%	87.0
	3368291	CHEMBL1176574	Inhibition of RSK3 at 1 uM	B	CCc1c[nH]c2ncnc(N3CC[C@](N)(CNC(=O)c4ccc(F)cc4F)C3)c12		CHEMBL1171647	>	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	3443516	CHEMBL1244282	Inhibition of RSK3 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	21.0	CHEMBL3906	Homo sapiens	INH	%	21.0
	3443733	CHEMBL1244282	Inhibition of RSK3 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	17.0	CHEMBL3906	Homo sapiens	INH	%	17.0
	3444888	CHEMBL1244282	Inhibition of RSK3 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	11.0	CHEMBL3906	Homo sapiens	INH	%	11.0
	3445296	CHEMBL1244971	Binding affinity to RPS6KA5(Kin.Dom.1-N-terminal)	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	42.0	CHEMBL3906	Homo sapiens	Kd	nM	42.0
	3445297	CHEMBL1244972	Binding affinity to RPS6KA5(Kin.Dom.2-C-terminal)	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	960.0	CHEMBL3906	Homo sapiens	Kd	nM	960.0
	3445512	CHEMBL1244282	Inhibition of RSK3 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	12.0	CHEMBL3906	Homo sapiens	INH	%	12.0
	3445729	CHEMBL1244282	Inhibition of RSK3 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	41.0	CHEMBL3906	Homo sapiens	INH	%	41.0
	3445922	CHEMBL1244282	Inhibition of RSK3 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	3.0	CHEMBL3906	Homo sapiens	INH	%	3.0
	3446112	CHEMBL1244282	Inhibition of RSK3 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	1.0	CHEMBL3906	Homo sapiens	INH	%	1.0
	3448618	CHEMBL1244971	Binding affinity to RPS6KA5(Kin.Dom.1-N-terminal)	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	3448619	CHEMBL1244972	Binding affinity to RPS6KA5(Kin.Dom.2-C-terminal)	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	3449045	CHEMBL1244971	Binding affinity to RPS6KA5(Kin.Dom.1-N-terminal)	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	240.0	CHEMBL3906	Homo sapiens	Kd	nM	240.0
	3449337	CHEMBL1244971	Binding affinity to RPS6KA5(Kin.Dom.1-N-terminal)	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	28.0	CHEMBL3906	Homo sapiens	Kd	nM	28.0
	3449505	CHEMBL1244972	Binding affinity to RPS6KA5(Kin.Dom.2-C-terminal)	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	1700.0	CHEMBL3906	Homo sapiens	Kd	nM	1700.0
	3449845	CHEMBL1244971	Binding affinity to RPS6KA5(Kin.Dom.1-N-terminal)	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	3449846	CHEMBL1244972	Binding affinity to RPS6KA5(Kin.Dom.2-C-terminal)	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	3450237	CHEMBL1244971	Binding affinity to RPS6KA5(Kin.Dom.1-N-terminal)	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	3450238	CHEMBL1244972	Binding affinity to RPS6KA5(Kin.Dom.2-C-terminal)	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	3450863	CHEMBL1244972	Binding affinity to RPS6KA5(Kin.Dom.2-C-terminal)	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	3451146	CHEMBL1244971	Binding affinity to RPS6KA5(Kin.Dom.1-N-terminal)	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	3451147	CHEMBL1244972	Binding affinity to RPS6KA5(Kin.Dom.2-C-terminal)	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	uM	10.0
	3463349	CHEMBL1251682	Inhibition of RPS6KA2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	85.0	CHEMBL3906	Homo sapiens	INH	%	85.0
	3463893	CHEMBL1251682	Inhibition of RPS6KA2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	55.0	CHEMBL3906	Homo sapiens	INH	%	55.0
	3464112	CHEMBL1251682	Inhibition of RPS6KA2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	63.0	CHEMBL3906	Homo sapiens	INH	%	63.0
	3502345	CHEMBL1259608	Inhibition of Rsk2 at 1 uM	B	Cc1c[nH]c2ncnc(N3CCN(C(=O)[C@H](N)C4Cc5ccccc5C4)CC3)c12		CHEMBL1257283	>	Inhibition	%	90.0	CHEMBL3906	Homo sapiens	INH	%	90.0
	5120272	CHEMBL1646643	Inhibition of human Rsk3 at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	90.0	CHEMBL3906	Homo sapiens	INH	%	90.0
	5123819	CHEMBL1645763	Inhibition of RPS6KA2 kinase domain1 at 1 uM	B	CCN1C(=O)CCC(C)(C)c2ccc(Nc3ncc(Cl)c(Nc4c(F)cccc4C(=O)NC)n3)cc21		CHEMBL1644812	=	Inhibition	%	99.0	CHEMBL3906	Homo sapiens	INH	%	99.0
	6169225	CHEMBL1769258	Inhibition of human RSK3 assessed as residual activity at 10 uM	B	CNc1nc(-c2ccc3c(N)n[nH]c3c2)cc(N2C[C@@H](C(=O)NC3CCCCC3)CC[C@H]2C)n1		CHEMBL1765740	=	Activity	%	14.0	CHEMBL3906	Homo sapiens	Activity	%	14.0
	6220061	CHEMBL1786959	Inhibition of RPS6KA5 at 10 uM	B	CCCc1cnc(N)c(CNC(=S)Nc2ccc(NC(=O)OC(C)(C)C)cc2)n1		CHEMBL1783708	>	Inhibition	%	70.0	CHEMBL3906	Homo sapiens	INH	%	70.0
	6339969	CHEMBL1826906	Activity of RPS6KA5(Kin.Dom.1-N-terminal) kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	82.0	CHEMBL3906	Homo sapiens	Activity	%	82.0
	6340916	CHEMBL1826940	Activity of RPS6KA2(Kin.Dom.1-N-terminal) kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	90.0	CHEMBL3906	Homo sapiens	Activity	%	90.0
	6385578	CHEMBL1837949	Inhibition of human RSK3 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCCc2ccccc2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CC1		CHEMBL1834114	<	Inhibition	%	35.0	CHEMBL3906	Homo sapiens	INH	%	35.0
	6385579	CHEMBL1837949	Inhibition of human RSK3 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c(F)c2c1c(=O)c(C(=O)O)cn2C1CCCC1		CHEMBL1834318	<	Inhibition	%	35.0	CHEMBL3906	Homo sapiens	INH	%	35.0
	6385580	CHEMBL1837949	Inhibition of human RSK3 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	C[C@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834323	<	Inhibition	%	35.0	CHEMBL3906	Homo sapiens	INH	%	35.0
	6385581	CHEMBL1837949	Inhibition of human RSK3 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	CC(C)[C@@H]1COc2c(NCCNc3ccccn3)c(F)c(N)c3c(=O)c(C(=O)O)cn1c23		CHEMBL1834324	<	Inhibition	%	35.0	CHEMBL3906	Homo sapiens	INH	%	35.0
	6385582	CHEMBL1837949	Inhibition of human RSK3 in HL60 cells lysate at 10 uM using post probe-labeling by LC-MS/MS analysis relative to control	B	Nc1c(F)c(NCCNc2ccccn2)c2c3c1c(=O)c(C(=O)O)cn3C1(CCCC1)CO2		CHEMBL1834330	<	Inhibition	%	35.0	CHEMBL3906	Homo sapiens	INH	%	35.0
	7567199	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7567546	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7567658	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	Kd	nM	600.0	CHEMBL3906	Homo sapiens	Kd	nM	600.0
	7568017	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	=	Kd	nM	4100.0	CHEMBL3906	Homo sapiens	Kd	nM	4100.0
	7568129	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7568485	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7568597	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7568917	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	260.0	CHEMBL3906	Homo sapiens	Kd	nM	260.0
	7569060	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7569172	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7569520	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7569632	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7569992	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7570104	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	150.0	CHEMBL3906	Homo sapiens	Kd	nM	150.0
	7570455	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7570552	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	8400.0	CHEMBL3906	Homo sapiens	Kd	nM	8400.0
	7570882	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	17.0	CHEMBL3906	Homo sapiens	Kd	nM	17.0
	7571036	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7571148	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	=	Kd	nM	700.0	CHEMBL3906	Homo sapiens	Kd	nM	700.0
	7571493	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7571605	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7571969	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7572102	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7572432	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7572518	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	160.0	CHEMBL3906	Homo sapiens	Kd	nM	160.0
	7573017	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7573129	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7573474	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7573586	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7573620	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7573950	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	1300.0	CHEMBL3906	Homo sapiens	Kd	nM	1300.0
	7574089	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7574385	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	33.0	CHEMBL3906	Homo sapiens	Kd	nM	33.0
	7574497	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7574995	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	58.0	CHEMBL3906	Homo sapiens	Kd	nM	58.0
	7575107	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7575456	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7575597	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7575950	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	730.0	CHEMBL3906	Homo sapiens	Kd	nM	730.0
	7576062	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7576358	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7576470	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	2300.0	CHEMBL3906	Homo sapiens	Kd	nM	2300.0
	7576969	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7577098	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7577428	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	5100.0	CHEMBL3906	Homo sapiens	Kd	nM	5100.0
	7577464	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7577576	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	7500.0	CHEMBL3906	Homo sapiens	Kd	nM	7500.0
	7577934	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7578046	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7578339	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	7700.0	CHEMBL3906	Homo sapiens	Kd	nM	7700.0
	7578451	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7578647	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7578977	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7579021	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7579351	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7579471	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	1500.0	CHEMBL3906	Homo sapiens	Kd	nM	1500.0
	7579833	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	620.0	CHEMBL3906	Homo sapiens	Kd	nM	620.0
	7579945	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7580302	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7580414	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7580705	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7580817	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7581005	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7581390	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7581723	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	=	Kd	nM	4300.0	CHEMBL3906	Homo sapiens	Kd	nM	4300.0
	7581835	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7582194	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7582306	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7582658	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7582770	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7583058	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	2000.0	CHEMBL3906	Homo sapiens	Kd	nM	2000.0
	7583170	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7583239	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7583351	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7583636	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7583748	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7584081	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7584193	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7584552	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	=	Kd	nM	220.0	CHEMBL3906	Homo sapiens	Kd	nM	220.0
	7584664	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7585014	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7585126	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	=	Kd	nM	390.0	CHEMBL3906	Homo sapiens	Kd	nM	390.0
	7585418	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7585569	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7585681	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7585977	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7586089	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7586423	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7586535	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7586894	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Kd	nM	280.0	CHEMBL3906	Homo sapiens	Kd	nM	280.0
	7587006	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7587348	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7587530	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7587642	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7587949	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7588061	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	1200.0	CHEMBL3906	Homo sapiens	Kd	nM	1200.0
	7588402	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7588514	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7588873	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7588994	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7589495	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7589607	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7589919	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	88.0	CHEMBL3906	Homo sapiens	Kd	nM	88.0
	7590031	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7590386	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	=	Kd	nM	2900.0	CHEMBL3906	Homo sapiens	Kd	nM	2900.0
	7590530	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7590869	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7590981	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7591468	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7591580	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	=	Kd	nM	1100.0	CHEMBL3906	Homo sapiens	Kd	nM	1100.0
	7591890	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	310.0	CHEMBL3906	Homo sapiens	Kd	nM	310.0
	7592002	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7592032	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7592362	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	=	Kd	nM	1200.0	CHEMBL3906	Homo sapiens	Kd	nM	1200.0
	7592393	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7592505	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7592846	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7592958	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7593435	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7593547	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7593870	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7594012	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7594373	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7594485	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7594825	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	3200.0	CHEMBL3906	Homo sapiens	Kd	nM	3200.0
	7594937	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7595403	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7595517	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7595879	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7595991	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7596350	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7596462	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7596797	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7596909	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	190.0	CHEMBL3906	Homo sapiens	Kd	nM	190.0
	7597045	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7597375	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7597386	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7597498	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7597859	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7597971	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7598329	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7598441	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL3906	Homo sapiens	Kd	nM	10000.0
	7598771	CHEMBL1908824	Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	8.9	CHEMBL3906	Homo sapiens	Kd	nM	8.9
	7598883	CHEMBL1908502	Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	9600.0	CHEMBL3906	Homo sapiens	Kd	nM	9600.0
	7922644	CHEMBL1919004	Inhibition of human recombinant RPS6KA2 at 0.5 uM by radiometric filter-binding assay	B	Clc1ccccc1Nc1nc2c(-c3nnc[nH]3)cccc2c2cnccc12		CHEMBL1915438	=	Inhibition	%	93.0	CHEMBL3906	Homo sapiens	INH	%	93.0
	8047168	CHEMBL1959393	Inhibition of RPS6KA2 Kin.Dom. 1 at 1 uM	B	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4ccc5c(c4)OCCO5)s3)cc2)CC1		CHEMBL1956070	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	8061247	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.29	CHEMBL3906	Homo sapiens	Inhibition	%	0.29
	8061424	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	1.82	CHEMBL3906	Homo sapiens	Inhibition	%	1.82
	8061648	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.41	CHEMBL3906	Homo sapiens	Inhibition	%	0.41
	8061755	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	2.91	CHEMBL3906	Homo sapiens	Inhibition	%	2.91
	8061946	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	1.73	CHEMBL3906	Homo sapiens	Inhibition	%	1.73
	8062170	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	7.9	CHEMBL3906	Homo sapiens	Inhibition	%	7.9
	8062286	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	8.32	CHEMBL3906	Homo sapiens	Inhibition	%	8.32
	8062672	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	3.38	CHEMBL3906	Homo sapiens	Inhibition	%	3.38
	8062770	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	1.68	CHEMBL3906	Homo sapiens	Inhibition	%	1.68
	8062994	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	0.12	CHEMBL3906	Homo sapiens	Inhibition	%	0.12
	8063126	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	1.53	CHEMBL3906	Homo sapiens	Inhibition	%	1.53
	8063517	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	2.22	CHEMBL3906	Homo sapiens	Inhibition	%	2.22
	8063625	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	1.67	CHEMBL3906	Homo sapiens	Inhibition	%	1.67
	8064031	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	1.2	CHEMBL3906	Homo sapiens	Inhibition	%	1.2
	8064146	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	41.43	CHEMBL3906	Homo sapiens	Inhibition	%	41.43
	8064370	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	17.39	CHEMBL3906	Homo sapiens	Inhibition	%	17.39
	8064580	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	2.54	CHEMBL3906	Homo sapiens	Inhibition	%	2.54
	8064718	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	1.32	CHEMBL3906	Homo sapiens	Inhibition	%	1.32
	8065108	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	1.1	CHEMBL3906	Homo sapiens	Inhibition	%	1.1
	8065224	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	1.65	CHEMBL3906	Homo sapiens	Inhibition	%	1.65
	8065448	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	1.65	CHEMBL3906	Homo sapiens	Inhibition	%	1.65
	8065623	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	2.46	CHEMBL3906	Homo sapiens	Inhibition	%	2.46
	8065962	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	63.59	CHEMBL3906	Homo sapiens	Inhibition	%	63.59
	8066172	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	3.79	CHEMBL3906	Homo sapiens	Inhibition	%	3.79
	8066308	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	4.35	CHEMBL3906	Homo sapiens	Inhibition	%	4.35
	8066532	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	1.42	CHEMBL3906	Homo sapiens	Inhibition	%	1.42
	8066698	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	1.69	CHEMBL3906	Homo sapiens	Inhibition	%	1.69
	8067046	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.4	CHEMBL3906	Homo sapiens	Inhibition	%	2.4
	8067221	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	1.99	CHEMBL3906	Homo sapiens	Inhibition	%	1.99
	8067566	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	0.67	CHEMBL3906	Homo sapiens	Inhibition	%	0.67
	8067776	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	26.89	CHEMBL3906	Homo sapiens	Inhibition	%	26.89
	8068135	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	5.35	CHEMBL3906	Homo sapiens	Inhibition	%	5.35
	8068299	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	1.14	CHEMBL3906	Homo sapiens	Inhibition	%	1.14
	8068648	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	-0.44	CHEMBL3906	Homo sapiens	Inhibition	%	-0.44
	8068822	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	2.47	CHEMBL3906	Homo sapiens	Inhibition	%	2.47
	8069046	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	2.14	CHEMBL3906	Homo sapiens	Inhibition	%	2.14
	8069171	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	1.19	CHEMBL3906	Homo sapiens	Inhibition	%	1.19
	8069466	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	3.37	CHEMBL3906	Homo sapiens	Inhibition	%	3.37
	8069627	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	1.32	CHEMBL3906	Homo sapiens	Inhibition	%	1.32
	8069851	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	2.57	CHEMBL3906	Homo sapiens	Inhibition	%	2.57
	8069977	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	1.7	CHEMBL3906	Homo sapiens	Inhibition	%	1.7
	8070373	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	3.12	CHEMBL3906	Homo sapiens	Inhibition	%	3.12
	8070498	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	1.17	CHEMBL3906	Homo sapiens	Inhibition	%	1.17
	8070796	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	20.48	CHEMBL3906	Homo sapiens	Inhibition	%	20.48
	8071177	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	1.19	CHEMBL3906	Homo sapiens	Inhibition	%	1.19
	8071303	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.29	CHEMBL3906	Homo sapiens	Inhibition	%	0.29
	8071527	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	1.84	CHEMBL3906	Homo sapiens	Inhibition	%	1.84
	8071700	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	1.97	CHEMBL3906	Homo sapiens	Inhibition	%	1.97
	8071825	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	1.83	CHEMBL3906	Homo sapiens	Inhibition	%	1.83
	8072049	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	3.19	CHEMBL3906	Homo sapiens	Inhibition	%	3.19
	8072139	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.64	CHEMBL3906	Homo sapiens	Inhibition	%	-0.64
	8072363	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	2.0	CHEMBL3906	Homo sapiens	Inhibition	%	2.0
	8072520	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.67	CHEMBL3906	Homo sapiens	Inhibition	%	1.67
	8072869	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.15	CHEMBL3906	Homo sapiens	Inhibition	%	-0.15
	8073036	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	2.85	CHEMBL3906	Homo sapiens	Inhibition	%	2.85
	8073385	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	13.06	CHEMBL3906	Homo sapiens	Inhibition	%	13.06
	8073504	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	0.05	CHEMBL3906	Homo sapiens	Inhibition	%	0.05
	8073728	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	3.92	CHEMBL3906	Homo sapiens	Inhibition	%	3.92
	8073961	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	-0.08	CHEMBL3906	Homo sapiens	Inhibition	%	-0.08
	8074113	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.89	CHEMBL3906	Homo sapiens	Inhibition	%	1.89
	8074467	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	1.29	CHEMBL3906	Homo sapiens	Inhibition	%	1.29
	8074624	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.2	CHEMBL3906	Homo sapiens	Inhibition	%	1.2
	8074848	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	3.57	CHEMBL3906	Homo sapiens	Inhibition	%	3.57
	8074975	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	1.37	CHEMBL3906	Homo sapiens	Inhibition	%	1.37
	8075310	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.61	CHEMBL3906	Homo sapiens	Inhibition	%	0.61
	8075547	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	0.59	CHEMBL3906	Homo sapiens	Inhibition	%	0.59
	8075688	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	1.79	CHEMBL3906	Homo sapiens	Inhibition	%	1.79
	8075912	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	1.6	CHEMBL3906	Homo sapiens	Inhibition	%	1.6
	8076054	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	0.69	CHEMBL3906	Homo sapiens	Inhibition	%	0.69
	8076426	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.71	CHEMBL3906	Homo sapiens	Inhibition	%	1.71
	8076560	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	3.33	CHEMBL3906	Homo sapiens	Inhibition	%	3.33
	8076886	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-0.22	CHEMBL3906	Homo sapiens	Inhibition	%	-0.22
	8077133	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	15.41	CHEMBL3906	Homo sapiens	Inhibition	%	15.41
	8077485	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	0.46	CHEMBL3906	Homo sapiens	Inhibition	%	0.46
	8077636	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	2.5	CHEMBL3906	Homo sapiens	Inhibition	%	2.5
	8078003	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.86	CHEMBL3906	Homo sapiens	Inhibition	%	1.86
	8078142	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	16.53	CHEMBL3906	Homo sapiens	Inhibition	%	16.53
	8078366	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	63.47	CHEMBL3906	Homo sapiens	Inhibition	%	63.47
	8078468	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.31	CHEMBL3906	Homo sapiens	Inhibition	%	0.31
	8078718	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	69.86	CHEMBL3906	Homo sapiens	Inhibition	%	69.86
	8079058	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	2.89	CHEMBL3906	Homo sapiens	Inhibition	%	2.89
	8079216	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.54	CHEMBL3906	Homo sapiens	Inhibition	%	-0.54
	8079440	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	3.27	CHEMBL3906	Homo sapiens	Inhibition	%	3.27
	8079582	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.48	CHEMBL3906	Homo sapiens	Inhibition	%	1.48
	8079945	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	11.96	CHEMBL3906	Homo sapiens	Inhibition	%	11.96
	8080050	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	1.01	CHEMBL3906	Homo sapiens	Inhibition	%	1.01
	8080274	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	3.16	CHEMBL3906	Homo sapiens	Inhibition	%	3.16
	8080302	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	5.76	CHEMBL3906	Homo sapiens	Inhibition	%	5.76
	8080526	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	35.51	CHEMBL3906	Homo sapiens	Inhibition	%	35.51
	8080641	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.9	CHEMBL3906	Homo sapiens	Inhibition	%	0.9
	8081029	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-1.68	CHEMBL3906	Homo sapiens	Inhibition	%	-1.68
	8081164	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.83	CHEMBL3906	Homo sapiens	Inhibition	%	1.83
	8081532	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	53.53	CHEMBL3906	Homo sapiens	Inhibition	%	53.53
	8081859	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	19.76	CHEMBL3906	Homo sapiens	Inhibition	%	19.76
	8082111	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	70.05	CHEMBL3906	Homo sapiens	Inhibition	%	70.05
	8082224	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.99	CHEMBL3906	Homo sapiens	Inhibition	%	0.99
	8082448	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	1.52	CHEMBL3906	Homo sapiens	Inhibition	%	1.52
	8082621	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.91	CHEMBL3906	Homo sapiens	Inhibition	%	0.91
	8082744	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.58	CHEMBL3906	Homo sapiens	Inhibition	%	1.58
	8082968	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	2.68	CHEMBL3906	Homo sapiens	Inhibition	%	2.68
	8083124	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	3.97	CHEMBL3906	Homo sapiens	Inhibition	%	3.97
	8083447	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	1.1	CHEMBL3906	Homo sapiens	Inhibition	%	1.1
	8083701	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	92.64	CHEMBL3906	Homo sapiens	Inhibition	%	92.64
	8084035	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	4.57	CHEMBL3906	Homo sapiens	Inhibition	%	4.57
	8084220	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	15.9	CHEMBL3906	Homo sapiens	Inhibition	%	15.9
	8084562	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.63	CHEMBL3906	Homo sapiens	Inhibition	%	1.63
	8084723	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	12.8	CHEMBL3906	Homo sapiens	Inhibition	%	12.8
	8085045	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	2.19	CHEMBL3906	Homo sapiens	Inhibition	%	2.19
	8085301	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-0.6	CHEMBL3906	Homo sapiens	Inhibition	%	-0.6
	8085633	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	2.93	CHEMBL3906	Homo sapiens	Inhibition	%	2.93
	8085822	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	61.69	CHEMBL3906	Homo sapiens	Inhibition	%	61.69
	8086161	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	3.42	CHEMBL3906	Homo sapiens	Inhibition	%	3.42
	8086323	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	3.56	CHEMBL3906	Homo sapiens	Inhibition	%	3.56
	8086547	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	7.9	CHEMBL3906	Homo sapiens	Inhibition	%	7.9
	8086646	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-0.05	CHEMBL3906	Homo sapiens	Inhibition	%	-0.05
	8086857	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	1.97	CHEMBL3906	Homo sapiens	Inhibition	%	1.97
	8087081	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	2.54	CHEMBL3906	Homo sapiens	Inhibition	%	2.54
	8087239	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	1.75	CHEMBL3906	Homo sapiens	Inhibition	%	1.75
	8087577	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	3.05	CHEMBL3906	Homo sapiens	Inhibition	%	3.05
	8087715	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.34	CHEMBL3906	Homo sapiens	Inhibition	%	3.34
	8087939	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	1.35	CHEMBL3906	Homo sapiens	Inhibition	%	1.35
	8088081	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	3.01	CHEMBL3906	Homo sapiens	Inhibition	%	3.01
	8088229	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-1.55	CHEMBL3906	Homo sapiens	Inhibition	%	-1.55
	8088453	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	0.47	CHEMBL3906	Homo sapiens	Inhibition	%	0.47
	8088581	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	3.03	CHEMBL3906	Homo sapiens	Inhibition	%	3.03
	8088898	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	68.49	CHEMBL3906	Homo sapiens	Inhibition	%	68.49
	8089250	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.95	CHEMBL3906	Homo sapiens	Inhibition	%	0.95
	8089398	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	2.5	CHEMBL3906	Homo sapiens	Inhibition	%	2.5
	8089742	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.2	CHEMBL3906	Homo sapiens	Inhibition	%	0.2
	8089922	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.63	CHEMBL3906	Homo sapiens	Inhibition	%	0.63
	8090311	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	2.89	CHEMBL3906	Homo sapiens	Inhibition	%	2.89
	8090478	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	3.24	CHEMBL3906	Homo sapiens	Inhibition	%	3.24
	8090841	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	1.62	CHEMBL3906	Homo sapiens	Inhibition	%	1.62
	8091046	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	3.11	CHEMBL3906	Homo sapiens	Inhibition	%	3.11
	8091407	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	3.72	CHEMBL3906	Homo sapiens	Inhibition	%	3.72
	8091562	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.09	CHEMBL3906	Homo sapiens	Inhibition	%	2.09
	8091902	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	4.52	CHEMBL3906	Homo sapiens	Inhibition	%	4.52
	8092263	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	0.51	CHEMBL3906	Homo sapiens	Inhibition	%	0.51
	8092414	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	3.28	CHEMBL3906	Homo sapiens	Inhibition	%	3.28
	8092786	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	0.38	CHEMBL3906	Homo sapiens	Inhibition	%	0.38
	8092915	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	6.66	CHEMBL3906	Homo sapiens	Inhibition	%	6.66
	8093139	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	1.47	CHEMBL3906	Homo sapiens	Inhibition	%	1.47
	8093227	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	1.69	CHEMBL3906	Homo sapiens	Inhibition	%	1.69
	8093591	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	0.98	CHEMBL3906	Homo sapiens	Inhibition	%	0.98
	8093730	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	16.4	CHEMBL3906	Homo sapiens	Inhibition	%	16.4
	8093954	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	0.86	CHEMBL3906	Homo sapiens	Inhibition	%	0.86
	8094074	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	4.26	CHEMBL3906	Homo sapiens	Inhibition	%	4.26
	8094254	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.44	CHEMBL3906	Homo sapiens	Inhibition	%	1.44
	8094478	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.92	CHEMBL3906	Homo sapiens	Inhibition	%	0.92
	8094653	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	8.2	CHEMBL3906	Homo sapiens	Inhibition	%	8.2
	8094809	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	7.6	CHEMBL3906	Homo sapiens	Inhibition	%	7.6
	8095033	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	3.38	CHEMBL3906	Homo sapiens	Inhibition	%	3.38
	8095173	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	2.2	CHEMBL3906	Homo sapiens	Inhibition	%	2.2
	8095376	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	4.28	CHEMBL3906	Homo sapiens	Inhibition	%	4.28
	8095600	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	1.03	CHEMBL3906	Homo sapiens	Inhibition	%	1.03
	8095741	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	19.23	CHEMBL3906	Homo sapiens	Inhibition	%	19.23
	8095889	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	2.97	CHEMBL3906	Homo sapiens	Inhibition	%	2.97
	8096113	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	3.65	CHEMBL3906	Homo sapiens	Inhibition	%	3.65
	8096230	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	2.37	CHEMBL3906	Homo sapiens	Inhibition	%	2.37
	8096593	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	-1.2	CHEMBL3906	Homo sapiens	Inhibition	%	-1.2
	8096749	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	2.95	CHEMBL3906	Homo sapiens	Inhibition	%	2.95
	8096973	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	3.52	CHEMBL3906	Homo sapiens	Inhibition	%	3.52
	8097120	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	1.25	CHEMBL3906	Homo sapiens	Inhibition	%	1.25
	8097427	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	2.43	CHEMBL3906	Homo sapiens	Inhibition	%	2.43
	8097651	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	2.28	CHEMBL3906	Homo sapiens	Inhibition	%	2.28
	8097801	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	12.94	CHEMBL3906	Homo sapiens	Inhibition	%	12.94
	8098158	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	2.0	CHEMBL3906	Homo sapiens	Inhibition	%	2.0
	8098278	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-0.15	CHEMBL3906	Homo sapiens	Inhibition	%	-0.15
	8098682	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	1.13	CHEMBL3906	Homo sapiens	Inhibition	%	1.13
	8098867	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	43.69	CHEMBL3906	Homo sapiens	Inhibition	%	43.69
	8099235	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	3.14	CHEMBL3906	Homo sapiens	Inhibition	%	3.14
	8099377	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.48	CHEMBL3906	Homo sapiens	Inhibition	%	2.48
	8099795	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	1.48	CHEMBL3906	Homo sapiens	Inhibition	%	1.48
	8099942	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	3.75	CHEMBL3906	Homo sapiens	Inhibition	%	3.75
	8100312	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	1.5	CHEMBL3906	Homo sapiens	Inhibition	%	1.5
	8100428	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	2.82	CHEMBL3906	Homo sapiens	Inhibition	%	2.82
	8100652	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	2.38	CHEMBL3906	Homo sapiens	Inhibition	%	2.38
	8100792	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.54	CHEMBL3906	Homo sapiens	Inhibition	%	0.54
	8101176	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	5.01	CHEMBL3906	Homo sapiens	Inhibition	%	5.01
	8101318	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	0.65	CHEMBL3906	Homo sapiens	Inhibition	%	0.65
	8101727	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	1.88	CHEMBL3906	Homo sapiens	Inhibition	%	1.88
	8101980	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	11.73	CHEMBL3906	Homo sapiens	Inhibition	%	11.73
	8102135	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	-1.89	CHEMBL3906	Homo sapiens	Inhibition	%	-1.89
	8102490	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	0.64	CHEMBL3906	Homo sapiens	Inhibition	%	0.64
	8102610	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	1.4	CHEMBL3906	Homo sapiens	Inhibition	%	1.4
	8102834	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-0.02	CHEMBL3906	Homo sapiens	Inhibition	%	-0.02
	8103012	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.34	CHEMBL3906	Homo sapiens	Inhibition	%	0.34
	8103208	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	3.19	CHEMBL3906	Homo sapiens	Inhibition	%	3.19
	8103570	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	1.27	CHEMBL3906	Homo sapiens	Inhibition	%	1.27
	8103720	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.5	CHEMBL3906	Homo sapiens	Inhibition	%	2.5
	8103944	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	2.72	CHEMBL3906	Homo sapiens	Inhibition	%	2.72
	8104129	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.54	CHEMBL3906	Homo sapiens	Inhibition	%	0.54
	8104277	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	4.8	CHEMBL3906	Homo sapiens	Inhibition	%	4.8
	8104501	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	5.72	CHEMBL3906	Homo sapiens	Inhibition	%	5.72
	8104647	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	7.28	CHEMBL3906	Homo sapiens	Inhibition	%	7.28
	8104985	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	3.07	CHEMBL3906	Homo sapiens	Inhibition	%	3.07
	8105125	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.99	CHEMBL3906	Homo sapiens	Inhibition	%	0.99
	8105349	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	2.01	CHEMBL3906	Homo sapiens	Inhibition	%	2.01
	8105515	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	4.54	CHEMBL3906	Homo sapiens	Inhibition	%	4.54
	8105653	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	6.88	CHEMBL3906	Homo sapiens	Inhibition	%	6.88
	8105877	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	1.71	CHEMBL3906	Homo sapiens	Inhibition	%	1.71
	8105933	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.46	CHEMBL3906	Homo sapiens	Inhibition	%	1.46
	8106157	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.33	CHEMBL3906	Homo sapiens	Inhibition	%	0.33
	8106322	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	1.91	CHEMBL3906	Homo sapiens	Inhibition	%	1.91
	8106478	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	2.72	CHEMBL3906	Homo sapiens	Inhibition	%	2.72
	8106702	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	7.65	CHEMBL3906	Homo sapiens	Inhibition	%	7.65
	8106831	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	1.51	CHEMBL3906	Homo sapiens	Inhibition	%	1.51
	8107176	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	0.38	CHEMBL3906	Homo sapiens	Inhibition	%	0.38
	8107348	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	2.33	CHEMBL3906	Homo sapiens	Inhibition	%	2.33
	8107549	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	10.65	CHEMBL3906	Homo sapiens	Inhibition	%	10.65
	8107773	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	2.17	CHEMBL3906	Homo sapiens	Inhibition	%	2.17
	8107908	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	1.94	CHEMBL3906	Homo sapiens	Inhibition	%	1.94
	8108290	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	2.3	CHEMBL3906	Homo sapiens	Inhibition	%	2.3
	8108465	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.67	CHEMBL3906	Homo sapiens	Inhibition	%	0.67
	8108836	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	22.35	CHEMBL3906	Homo sapiens	Inhibition	%	22.35
	8108978	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-0.87	CHEMBL3906	Homo sapiens	Inhibition	%	-0.87
	8109316	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	2.62	CHEMBL3906	Homo sapiens	Inhibition	%	2.62
	8109670	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	0.35	CHEMBL3906	Homo sapiens	Inhibition	%	0.35
	8109841	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	20.21	CHEMBL3906	Homo sapiens	Inhibition	%	20.21
	8110197	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	3.57	CHEMBL3906	Homo sapiens	Inhibition	%	3.57
	8110476	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	-1.41	CHEMBL3906	Homo sapiens	Inhibition	%	-1.41
	8110642	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	3.08	CHEMBL3906	Homo sapiens	Inhibition	%	3.08
	8111024	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	48.52	CHEMBL3906	Homo sapiens	Inhibition	%	48.52
	8111147	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.52	CHEMBL3906	Homo sapiens	Inhibition	%	1.52
	8111498	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	2.02	CHEMBL3906	Homo sapiens	Inhibition	%	2.02
	8111664	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	1.83	CHEMBL3906	Homo sapiens	Inhibition	%	1.83
	8111888	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	0.48	CHEMBL3906	Homo sapiens	Inhibition	%	0.48
	8112093	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	2.67	CHEMBL3906	Homo sapiens	Inhibition	%	2.67
	8112230	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	1.45	CHEMBL3906	Homo sapiens	Inhibition	%	1.45
	8112454	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	0.23	CHEMBL3906	Homo sapiens	Inhibition	%	0.23
	8112622	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	3.17	CHEMBL3906	Homo sapiens	Inhibition	%	3.17
	8112794	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	1.27	CHEMBL3906	Homo sapiens	Inhibition	%	1.27
	8113170	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	3.02	CHEMBL3906	Homo sapiens	Inhibition	%	3.02
	8113306	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.09	CHEMBL3906	Homo sapiens	Inhibition	%	1.09
	8113530	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	1.08	CHEMBL3906	Homo sapiens	Inhibition	%	1.08
	8113654	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	4.17	CHEMBL3906	Homo sapiens	Inhibition	%	4.17
	8113994	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	0.42	CHEMBL3906	Homo sapiens	Inhibition	%	0.42
	8114170	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	1.21	CHEMBL3906	Homo sapiens	Inhibition	%	1.21
	8114526	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	2.51	CHEMBL3906	Homo sapiens	Inhibition	%	2.51
	8114802	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	0.27	CHEMBL3906	Homo sapiens	Inhibition	%	0.27
	8114968	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	9.18	CHEMBL3906	Homo sapiens	Inhibition	%	9.18
	8115192	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	51.13	CHEMBL3906	Homo sapiens	Inhibition	%	51.13
	8115357	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-1.11	CHEMBL3906	Homo sapiens	Inhibition	%	-1.11
	8115477	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.5	CHEMBL3906	Homo sapiens	Inhibition	%	1.5
	8115701	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-0.57	CHEMBL3906	Homo sapiens	Inhibition	%	-0.57
	8115834	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	13.28	CHEMBL3906	Homo sapiens	Inhibition	%	13.28
	8116217	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	6.29	CHEMBL3906	Homo sapiens	Inhibition	%	6.29
	8116420	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	2.34	CHEMBL3906	Homo sapiens	Inhibition	%	2.34
	8116778	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	1.0	CHEMBL3906	Homo sapiens	Inhibition	%	1.0
	8116950	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	2.68	CHEMBL3906	Homo sapiens	Inhibition	%	2.68
	8117121	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	1.14	CHEMBL3906	Homo sapiens	Inhibition	%	1.14
	8117345	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	2.79	CHEMBL3906	Homo sapiens	Inhibition	%	2.79
	8117503	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	7.49	CHEMBL3906	Homo sapiens	Inhibition	%	7.49
	8117857	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	2.7	CHEMBL3906	Homo sapiens	Inhibition	%	2.7
	8117995	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	2.41	CHEMBL3906	Homo sapiens	Inhibition	%	2.41
	8118335	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	2.4	CHEMBL3906	Homo sapiens	Inhibition	%	2.4
	8118507	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	2.69	CHEMBL3906	Homo sapiens	Inhibition	%	2.69
	8118731	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	3.43	CHEMBL3906	Homo sapiens	Inhibition	%	3.43
	8118867	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	2.48	CHEMBL3906	Homo sapiens	Inhibition	%	2.48
	8119138	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	1.22	CHEMBL3906	Homo sapiens	Inhibition	%	1.22
	8119521	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	2.26	CHEMBL3906	Homo sapiens	Inhibition	%	2.26
	8119688	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	0.12	CHEMBL3906	Homo sapiens	Inhibition	%	0.12
	8120031	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	0.84	CHEMBL3906	Homo sapiens	Inhibition	%	0.84
	8120170	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.06	CHEMBL3906	Homo sapiens	Inhibition	%	1.06
	8120394	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.53	CHEMBL3906	Homo sapiens	Inhibition	%	1.53
	8120554	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.5	CHEMBL3906	Homo sapiens	Inhibition	%	-0.5
	8120755	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	5.77	CHEMBL3906	Homo sapiens	Inhibition	%	5.77
	8121107	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	2.15	CHEMBL3906	Homo sapiens	Inhibition	%	2.15
	8121279	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	2.02	CHEMBL3906	Homo sapiens	Inhibition	%	2.02
	8121670	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	7.37	CHEMBL3906	Homo sapiens	Inhibition	%	7.37
	8121833	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	3.5	CHEMBL3906	Homo sapiens	Inhibition	%	3.5
	8122178	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	5.3	CHEMBL3906	Homo sapiens	Inhibition	%	5.3
	8122316	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	2.42	CHEMBL3906	Homo sapiens	Inhibition	%	2.42
	8122540	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	16.5	CHEMBL3906	Homo sapiens	Inhibition	%	16.5
	8122660	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	2.98	CHEMBL3906	Homo sapiens	Inhibition	%	2.98
	8123051	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	4.59	CHEMBL3906	Homo sapiens	Inhibition	%	4.59
	8123193	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	2.5	CHEMBL3906	Homo sapiens	Inhibition	%	2.5
	8123471	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	11.51	CHEMBL3906	Homo sapiens	Inhibition	%	11.51
	8123845	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	7.02	CHEMBL3906	Homo sapiens	Inhibition	%	7.02
	8124012	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	-0.37	CHEMBL3906	Homo sapiens	Inhibition	%	-0.37
	8124355	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	-0.61	CHEMBL3906	Homo sapiens	Inhibition	%	-0.61
	8124718	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	1.76	CHEMBL3906	Homo sapiens	Inhibition	%	1.76
	8124883	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-1.02	CHEMBL3906	Homo sapiens	Inhibition	%	-1.02
	8125084	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	3.08	CHEMBL3906	Homo sapiens	Inhibition	%	3.08
	8125308	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	3.54	CHEMBL3906	Homo sapiens	Inhibition	%	3.54
	8125438	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.73	CHEMBL3906	Homo sapiens	Inhibition	%	0.73
	8125606	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	3.0	CHEMBL3906	Homo sapiens	Inhibition	%	3.0
	8125830	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.89	CHEMBL3906	Homo sapiens	Inhibition	%	0.89
	8125994	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.71	CHEMBL3906	Homo sapiens	Inhibition	%	-0.71
	8126158	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	4.96	CHEMBL3906	Homo sapiens	Inhibition	%	4.96
	8126382	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	2.26	CHEMBL3906	Homo sapiens	Inhibition	%	2.26
	8126497	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	37.68	CHEMBL3906	Homo sapiens	Inhibition	%	37.68
	8126857	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	66.09	CHEMBL3906	Homo sapiens	Inhibition	%	66.09
	8126979	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	3.61	CHEMBL3906	Homo sapiens	Inhibition	%	3.61
	8127203	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	3.8	CHEMBL3906	Homo sapiens	Inhibition	%	3.8
	8127370	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	4.07	CHEMBL3906	Homo sapiens	Inhibition	%	4.07
	8127512	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	8.42	CHEMBL3906	Homo sapiens	Inhibition	%	8.42
	8127736	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	7.44	CHEMBL3906	Homo sapiens	Inhibition	%	7.44
	8127800	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	2.77	CHEMBL3906	Homo sapiens	Inhibition	%	2.77
	8128024	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	14.4	CHEMBL3906	Homo sapiens	Inhibition	%	14.4
	8128176	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	0.28	CHEMBL3906	Homo sapiens	Inhibition	%	0.28
	8128343	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	0.82	CHEMBL3906	Homo sapiens	Inhibition	%	0.82
	8128567	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	-0.36	CHEMBL3906	Homo sapiens	Inhibition	%	-0.36
	8128686	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	2.4	CHEMBL3906	Homo sapiens	Inhibition	%	2.4
	8129047	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	10.8	CHEMBL3906	Homo sapiens	Inhibition	%	10.8
	8129218	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-0.08	CHEMBL3906	Homo sapiens	Inhibition	%	-0.08
	8129631	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	2.14	CHEMBL3906	Homo sapiens	Inhibition	%	2.14
	8129770	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	1.89	CHEMBL3906	Homo sapiens	Inhibition	%	1.89
	8130155	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	1.84	CHEMBL3906	Homo sapiens	Inhibition	%	1.84
	8130327	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	1.38	CHEMBL3906	Homo sapiens	Inhibition	%	1.38
	8130711	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	3.81	CHEMBL3906	Homo sapiens	Inhibition	%	3.81
	8130827	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	1.73	CHEMBL3906	Homo sapiens	Inhibition	%	1.73
	8131051	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	2.32	CHEMBL3906	Homo sapiens	Inhibition	%	2.32
	8131190	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.32	CHEMBL3906	Homo sapiens	Inhibition	%	3.32
	8131534	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	2.02	CHEMBL3906	Homo sapiens	Inhibition	%	2.02
	8131701	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	5.22	CHEMBL3906	Homo sapiens	Inhibition	%	5.22
	8132066	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	52.93	CHEMBL3906	Homo sapiens	Inhibition	%	52.93
	8132352	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	1.84	CHEMBL3906	Homo sapiens	Inhibition	%	1.84
	8132499	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	2.22	CHEMBL3906	Homo sapiens	Inhibition	%	2.22
	8132891	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	-1.02	CHEMBL3906	Homo sapiens	Inhibition	%	-1.02
	8133012	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.62	CHEMBL3906	Homo sapiens	Inhibition	%	0.62
	8133236	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.33	CHEMBL3906	Homo sapiens	Inhibition	%	0.33
	8133374	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	1.12	CHEMBL3906	Homo sapiens	Inhibition	%	1.12
	8133546	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.83	CHEMBL3906	Homo sapiens	Inhibition	%	0.83
	8133770	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-0.49	CHEMBL3906	Homo sapiens	Inhibition	%	-0.49
	8133950	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	4.07	CHEMBL3906	Homo sapiens	Inhibition	%	4.07
	8134098	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-0.65	CHEMBL3906	Homo sapiens	Inhibition	%	-0.65
	8134322	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	0.29	CHEMBL3906	Homo sapiens	Inhibition	%	0.29
	8134482	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	2.0	CHEMBL3906	Homo sapiens	Inhibition	%	2.0
	8134666	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	0.85	CHEMBL3906	Homo sapiens	Inhibition	%	0.85
	8134890	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	13.84	CHEMBL3906	Homo sapiens	Inhibition	%	13.84
	8135050	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	0.4	CHEMBL3906	Homo sapiens	Inhibition	%	0.4
	8135389	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	2.31	CHEMBL3906	Homo sapiens	Inhibition	%	2.31
	8135530	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	4.89	CHEMBL3906	Homo sapiens	Inhibition	%	4.89
	8135875	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	0.02	CHEMBL3906	Homo sapiens	Inhibition	%	0.02
	8136043	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.64	CHEMBL3906	Homo sapiens	Inhibition	%	1.64
	8136267	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	2.21	CHEMBL3906	Homo sapiens	Inhibition	%	2.21
	8136411	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	2.81	CHEMBL3906	Homo sapiens	Inhibition	%	2.81
	8136701	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	2.69	CHEMBL3906	Homo sapiens	Inhibition	%	2.69
	8136836	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	0.64	CHEMBL3906	Homo sapiens	Inhibition	%	0.64
	8137060	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	13.2	CHEMBL3906	Homo sapiens	Inhibition	%	13.2
	8137223	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	-0.01	CHEMBL3906	Homo sapiens	Inhibition	%	-0.01
	8137567	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	1.22	CHEMBL3906	Homo sapiens	Inhibition	%	1.22
	8137715	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	1.83	CHEMBL3906	Homo sapiens	Inhibition	%	1.83
	8138105	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	0.67	CHEMBL3906	Homo sapiens	Inhibition	%	0.67
	8138284	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	1.45	CHEMBL3906	Homo sapiens	Inhibition	%	1.45
	8138656	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-0.25	CHEMBL3906	Homo sapiens	Inhibition	%	-0.25
	8138814	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.72	CHEMBL3906	Homo sapiens	Inhibition	%	1.72
	8139223	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	2.5	CHEMBL3906	Homo sapiens	Inhibition	%	2.5
	8139382	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	1.84	CHEMBL3906	Homo sapiens	Inhibition	%	1.84
	8139720	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	2.74	CHEMBL3906	Homo sapiens	Inhibition	%	2.74
	8139861	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	3.09	CHEMBL3906	Homo sapiens	Inhibition	%	3.09
	8140085	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	3.37	CHEMBL3906	Homo sapiens	Inhibition	%	3.37
	8140208	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	0.19	CHEMBL3906	Homo sapiens	Inhibition	%	0.19
	8140591	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	2.73	CHEMBL3906	Homo sapiens	Inhibition	%	2.73
	8140734	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	4.39	CHEMBL3906	Homo sapiens	Inhibition	%	4.39
	8141036	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.86	CHEMBL3906	Homo sapiens	Inhibition	%	0.86
	8141390	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.54	CHEMBL3906	Homo sapiens	Inhibition	%	0.54
	8141550	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	2.43	CHEMBL3906	Homo sapiens	Inhibition	%	2.43
	8141893	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	0.63	CHEMBL3906	Homo sapiens	Inhibition	%	0.63
	8142054	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	1.27	CHEMBL3906	Homo sapiens	Inhibition	%	1.27
	8142278	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	0.17	CHEMBL3906	Homo sapiens	Inhibition	%	0.17
	8142446	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	3.14	CHEMBL3906	Homo sapiens	Inhibition	%	3.14
	8142622	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	2.09	CHEMBL3906	Homo sapiens	Inhibition	%	2.09
	8142846	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	2.99	CHEMBL3906	Homo sapiens	Inhibition	%	2.99
	8142995	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	0.47	CHEMBL3906	Homo sapiens	Inhibition	%	0.47
	8143150	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.56	CHEMBL3906	Homo sapiens	Inhibition	%	1.56
	8143374	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	3.21	CHEMBL3906	Homo sapiens	Inhibition	%	3.21
	8143561	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	3.82	CHEMBL3906	Homo sapiens	Inhibition	%	3.82
	8143720	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.58	CHEMBL3906	Homo sapiens	Inhibition	%	3.58
	8143944	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.98	CHEMBL3906	Homo sapiens	Inhibition	%	3.98
	8144058	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.5	CHEMBL3906	Homo sapiens	Inhibition	%	1.5
	8144421	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	1.55	CHEMBL3906	Homo sapiens	Inhibition	%	1.55
	8144551	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.1	CHEMBL3906	Homo sapiens	Inhibition	%	2.1
	8144775	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	3.21	CHEMBL3906	Homo sapiens	Inhibition	%	3.21
	8144928	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	2.91	CHEMBL3906	Homo sapiens	Inhibition	%	2.91
	8145065	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	1.16	CHEMBL3906	Homo sapiens	Inhibition	%	1.16
	8145289	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	2.98	CHEMBL3906	Homo sapiens	Inhibition	%	2.98
	8145378	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.48	CHEMBL3906	Homo sapiens	Inhibition	%	0.48
	8145726	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	1.46	CHEMBL3906	Homo sapiens	Inhibition	%	1.46
	8145887	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	-2.19	CHEMBL3906	Homo sapiens	Inhibition	%	-2.19
	8146111	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	1.78	CHEMBL3906	Homo sapiens	Inhibition	%	1.78
	8146231	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	47.74	CHEMBL3906	Homo sapiens	Inhibition	%	47.74
	8146615	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	0.29	CHEMBL3906	Homo sapiens	Inhibition	%	0.29
	8146782	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	30.91	CHEMBL3906	Homo sapiens	Inhibition	%	30.91
	8147175	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	6.17	CHEMBL3906	Homo sapiens	Inhibition	%	6.17
	8147317	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	1.39	CHEMBL3906	Homo sapiens	Inhibition	%	1.39
	8147694	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.64	CHEMBL3906	Homo sapiens	Inhibition	%	1.64
	8147881	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	3.99	CHEMBL3906	Homo sapiens	Inhibition	%	3.99
	8148263	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	3.77	CHEMBL3906	Homo sapiens	Inhibition	%	3.77
	8148377	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.01	CHEMBL3906	Homo sapiens	Inhibition	%	1.01
	8148601	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	-0.47	CHEMBL3906	Homo sapiens	Inhibition	%	-0.47
	8148740	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	2.44	CHEMBL3906	Homo sapiens	Inhibition	%	2.44
	8149102	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	4.43	CHEMBL3906	Homo sapiens	Inhibition	%	4.43
	8149261	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.79	CHEMBL3906	Homo sapiens	Inhibition	%	0.79
	8149619	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	25.38	CHEMBL3906	Homo sapiens	Inhibition	%	25.38
	8149717	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	1.4	CHEMBL3906	Homo sapiens	Inhibition	%	1.4
	8149941	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	3.44	CHEMBL3906	Homo sapiens	Inhibition	%	3.44
	8150066	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	5.27	CHEMBL3906	Homo sapiens	Inhibition	%	5.27
	8150450	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.63	CHEMBL3906	Homo sapiens	Inhibition	%	-0.63
	8150570	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	2.97	CHEMBL3906	Homo sapiens	Inhibition	%	2.97
	8150794	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.57	CHEMBL3906	Homo sapiens	Inhibition	%	0.57
	8150959	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	7.85	CHEMBL3906	Homo sapiens	Inhibition	%	7.85
	8151122	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-0.94	CHEMBL3906	Homo sapiens	Inhibition	%	-0.94
	8151346	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	0.23	CHEMBL3906	Homo sapiens	Inhibition	%	0.23
	8151523	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	3.18	CHEMBL3906	Homo sapiens	Inhibition	%	3.18
	8151661	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	2.04	CHEMBL3906	Homo sapiens	Inhibition	%	2.04
	8151885	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	1.09	CHEMBL3906	Homo sapiens	Inhibition	%	1.09
	8152039	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	2.11	CHEMBL3906	Homo sapiens	Inhibition	%	2.11
	8152227	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	6.79	CHEMBL3906	Homo sapiens	Inhibition	%	6.79
	8152609	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	3.41	CHEMBL3906	Homo sapiens	Inhibition	%	3.41
	8152947	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	1.56	CHEMBL3906	Homo sapiens	Inhibition	%	1.56
	8153086	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.32	CHEMBL3906	Homo sapiens	Inhibition	%	2.32
	8153447	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	3.17	CHEMBL3906	Homo sapiens	Inhibition	%	3.17
	8153604	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.34	CHEMBL3906	Homo sapiens	Inhibition	%	0.34
	8153961	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	73.84	CHEMBL3906	Homo sapiens	Inhibition	%	73.84
	8154282	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	19.15	CHEMBL3906	Homo sapiens	Inhibition	%	19.15
	8154408	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	35.69	CHEMBL3906	Homo sapiens	Inhibition	%	35.69
	8154632	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	-0.12	CHEMBL3906	Homo sapiens	Inhibition	%	-0.12
	8154791	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	0.72	CHEMBL3906	Homo sapiens	Inhibition	%	0.72
	8155135	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-0.16	CHEMBL3906	Homo sapiens	Inhibition	%	-0.16
	8155311	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.95	CHEMBL3906	Homo sapiens	Inhibition	%	0.95
	8155696	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	1.68	CHEMBL3906	Homo sapiens	Inhibition	%	1.68
	8155874	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.75	CHEMBL3906	Homo sapiens	Inhibition	%	2.75
	8156236	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.76	CHEMBL3906	Homo sapiens	Inhibition	%	0.76
	8156448	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	2.35	CHEMBL3906	Homo sapiens	Inhibition	%	2.35
	8156598	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	3.67	CHEMBL3906	Homo sapiens	Inhibition	%	3.67
	8156822	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	1.38	CHEMBL3906	Homo sapiens	Inhibition	%	1.38
	8156965	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	4.37	CHEMBL3906	Homo sapiens	Inhibition	%	4.37
	8157309	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	9.89	CHEMBL3906	Homo sapiens	Inhibition	%	9.89
	8157450	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	7.09	CHEMBL3906	Homo sapiens	Inhibition	%	7.09
	8157674	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	37.14	CHEMBL3906	Homo sapiens	Inhibition	%	37.14
	8157804	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	2.69	CHEMBL3906	Homo sapiens	Inhibition	%	2.69
	8157965	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-1.0	CHEMBL3906	Homo sapiens	Inhibition	%	-1.0
	8158189	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	0.97	CHEMBL3906	Homo sapiens	Inhibition	%	0.97
	8158439	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	18.26	CHEMBL3906	Homo sapiens	Inhibition	%	18.26
	8158597	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	5.23	CHEMBL3906	Homo sapiens	Inhibition	%	5.23
	8158990	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	3.43	CHEMBL3906	Homo sapiens	Inhibition	%	3.43
	8159125	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	2.72	CHEMBL3906	Homo sapiens	Inhibition	%	2.72
	8159469	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	2.43	CHEMBL3906	Homo sapiens	Inhibition	%	2.43
	8159824	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	9.15	CHEMBL3906	Homo sapiens	Inhibition	%	9.15
	8159965	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.35	CHEMBL3906	Homo sapiens	Inhibition	%	1.35
	8160326	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.68	CHEMBL3906	Homo sapiens	Inhibition	%	1.68
	8160476	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-0.62	CHEMBL3906	Homo sapiens	Inhibition	%	-0.62
	8160770	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	2.3	CHEMBL3906	Homo sapiens	Inhibition	%	2.3
	8161144	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	2.28	CHEMBL3906	Homo sapiens	Inhibition	%	2.28
	8161287	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	2.89	CHEMBL3906	Homo sapiens	Inhibition	%	2.89
	8161636	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	2.1	CHEMBL3906	Homo sapiens	Inhibition	%	2.1
	8161998	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	2.21	CHEMBL3906	Homo sapiens	Inhibition	%	2.21
	8162128	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	11.34	CHEMBL3906	Homo sapiens	Inhibition	%	11.34
	8162512	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	2.27	CHEMBL3906	Homo sapiens	Inhibition	%	2.27
	8162765	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	65.89	CHEMBL3906	Homo sapiens	Inhibition	%	65.89
	8162913	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	34.34	CHEMBL3906	Homo sapiens	Inhibition	%	34.34
	8163137	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	80.45	CHEMBL3906	Homo sapiens	Inhibition	%	80.45
	8163306	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	2.55	CHEMBL3906	Homo sapiens	Inhibition	%	2.55
	8163440	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	3.4	CHEMBL3906	Homo sapiens	Inhibition	%	3.4
	8163664	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	2.93	CHEMBL3906	Homo sapiens	Inhibition	%	2.93
	8163787	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	3.27	CHEMBL3906	Homo sapiens	Inhibition	%	3.27
	8164145	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	37.97	CHEMBL3906	Homo sapiens	Inhibition	%	37.97
	8164285	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.16	CHEMBL3906	Homo sapiens	Inhibition	%	1.16
	8164509	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.53	CHEMBL3906	Homo sapiens	Inhibition	%	1.53
	8164664	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	2.01	CHEMBL3906	Homo sapiens	Inhibition	%	2.01
	8164808	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	0.59	CHEMBL3906	Homo sapiens	Inhibition	%	0.59
	8165032	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	0.73	CHEMBL3906	Homo sapiens	Inhibition	%	0.73
	8165102	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	3.13	CHEMBL3906	Homo sapiens	Inhibition	%	3.13
	8165467	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	1.27	CHEMBL3906	Homo sapiens	Inhibition	%	1.27
	8165610	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	4.85	CHEMBL3906	Homo sapiens	Inhibition	%	4.85
	8165834	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	6.07	CHEMBL3906	Homo sapiens	Inhibition	%	6.07
	8165960	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	6.19	CHEMBL3906	Homo sapiens	Inhibition	%	6.19
	8166322	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	4.15	CHEMBL3906	Homo sapiens	Inhibition	%	4.15
	8166452	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	1.27	CHEMBL3906	Homo sapiens	Inhibition	%	1.27
	8166676	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	3.22	CHEMBL3906	Homo sapiens	Inhibition	%	3.22
	8166777	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	0.74	CHEMBL3906	Homo sapiens	Inhibition	%	0.74
	8167089	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	15.57	CHEMBL3906	Homo sapiens	Inhibition	%	15.57
	8167454	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	8.55	CHEMBL3906	Homo sapiens	Inhibition	%	8.55
	8167618	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	2.14	CHEMBL3906	Homo sapiens	Inhibition	%	2.14
	8167975	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	14.01	CHEMBL3906	Homo sapiens	Inhibition	%	14.01
	8168099	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	2.36	CHEMBL3906	Homo sapiens	Inhibition	%	2.36
	8168323	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	7.93	CHEMBL3906	Homo sapiens	Inhibition	%	7.93
	8168464	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	2.66	CHEMBL3906	Homo sapiens	Inhibition	%	2.66
	8168824	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-0.89	CHEMBL3906	Homo sapiens	Inhibition	%	-0.89
	8168988	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	4.16	CHEMBL3906	Homo sapiens	Inhibition	%	4.16
	8169354	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	3.79	CHEMBL3906	Homo sapiens	Inhibition	%	3.79
	8169434	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	7.32	CHEMBL3906	Homo sapiens	Inhibition	%	7.32
	8169658	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	5.36	CHEMBL3906	Homo sapiens	Inhibition	%	5.36
	8169792	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	2.74	CHEMBL3906	Homo sapiens	Inhibition	%	2.74
	8170161	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	38.75	CHEMBL3906	Homo sapiens	Inhibition	%	38.75
	8170286	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.69	CHEMBL3906	Homo sapiens	Inhibition	%	1.69
	8170510	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	2.49	CHEMBL3906	Homo sapiens	Inhibition	%	2.49
	8170650	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	2.47	CHEMBL3906	Homo sapiens	Inhibition	%	2.47
	8171009	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	0.12	CHEMBL3906	Homo sapiens	Inhibition	%	0.12
	8171206	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	0.87	CHEMBL3906	Homo sapiens	Inhibition	%	0.87
	8171423	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	60.95	CHEMBL3906	Homo sapiens	Inhibition	%	60.95
	8171788	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	34.37	CHEMBL3906	Homo sapiens	Inhibition	%	34.37
	8171941	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	2.85	CHEMBL3906	Homo sapiens	Inhibition	%	2.85
	8172297	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	4.19	CHEMBL3906	Homo sapiens	Inhibition	%	4.19
	8172649	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	1.32	CHEMBL3906	Homo sapiens	Inhibition	%	1.32
	8172791	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	3.1	CHEMBL3906	Homo sapiens	Inhibition	%	3.1
	8173151	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	0.27	CHEMBL3906	Homo sapiens	Inhibition	%	0.27
	8173316	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	2.35	CHEMBL3906	Homo sapiens	Inhibition	%	2.35
	8173681	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	1.03	CHEMBL3906	Homo sapiens	Inhibition	%	1.03
	8173992	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	23.5	CHEMBL3906	Homo sapiens	Inhibition	%	23.5
	8174124	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	2.03	CHEMBL3906	Homo sapiens	Inhibition	%	2.03
	8174348	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	2.47	CHEMBL3906	Homo sapiens	Inhibition	%	2.47
	8174496	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.67	CHEMBL3906	Homo sapiens	Inhibition	%	0.67
	8174842	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.63	CHEMBL3906	Homo sapiens	Inhibition	%	1.63
	8174985	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	7.78	CHEMBL3906	Homo sapiens	Inhibition	%	7.78
	8175345	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	2.76	CHEMBL3906	Homo sapiens	Inhibition	%	2.76
	8175601	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	14.23	CHEMBL3906	Homo sapiens	Inhibition	%	14.23
	8175764	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	2.93	CHEMBL3906	Homo sapiens	Inhibition	%	2.93
	8175988	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	4.46	CHEMBL3906	Homo sapiens	Inhibition	%	4.46
	8176141	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	55.51	CHEMBL3906	Homo sapiens	Inhibition	%	55.51
	8176290	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	3.5	CHEMBL3906	Homo sapiens	Inhibition	%	3.5
	8176514	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	5.18	CHEMBL3906	Homo sapiens	Inhibition	%	5.18
	8176646	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	20.49	CHEMBL3906	Homo sapiens	Inhibition	%	20.49
	8177000	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	1.36	CHEMBL3906	Homo sapiens	Inhibition	%	1.36
	8177142	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	3.53	CHEMBL3906	Homo sapiens	Inhibition	%	3.53
	8177366	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	3.85	CHEMBL3906	Homo sapiens	Inhibition	%	3.85
	8177504	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	73.45	CHEMBL3906	Homo sapiens	Inhibition	%	73.45
	8177668	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	4.92	CHEMBL3906	Homo sapiens	Inhibition	%	4.92
	8177892	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	1.93	CHEMBL3906	Homo sapiens	Inhibition	%	1.93
	8178032	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	3.66	CHEMBL3906	Homo sapiens	Inhibition	%	3.66
	8178344	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	0.37	CHEMBL3906	Homo sapiens	Inhibition	%	0.37
	8178695	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	0.94	CHEMBL3906	Homo sapiens	Inhibition	%	0.94
	8178844	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.58	CHEMBL3906	Homo sapiens	Inhibition	%	0.58
	8179191	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.86	CHEMBL3906	Homo sapiens	Inhibition	%	0.86
	8179335	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	1.92	CHEMBL3906	Homo sapiens	Inhibition	%	1.92
	8179559	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	7.63	CHEMBL3906	Homo sapiens	Inhibition	%	7.63
	8179696	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	1.59	CHEMBL3906	Homo sapiens	Inhibition	%	1.59
	8179953	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	2.42	CHEMBL3906	Homo sapiens	Inhibition	%	2.42
	8180331	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	1.77	CHEMBL3906	Homo sapiens	Inhibition	%	1.77
	8180487	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	91.36	CHEMBL3906	Homo sapiens	Inhibition	%	91.36
	8180859	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	25.92	CHEMBL3906	Homo sapiens	Inhibition	%	25.92
	8180992	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	3.52	CHEMBL3906	Homo sapiens	Inhibition	%	3.52
	8181216	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	3.02	CHEMBL3906	Homo sapiens	Inhibition	%	3.02
	8181347	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	2.22	CHEMBL3906	Homo sapiens	Inhibition	%	2.22
	8181711	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	3.06	CHEMBL3906	Homo sapiens	Inhibition	%	3.06
	8181850	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	92.39	CHEMBL3906	Homo sapiens	Inhibition	%	92.39
	8182237	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	3.03	CHEMBL3906	Homo sapiens	Inhibition	%	3.03
	8182377	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.11	CHEMBL3906	Homo sapiens	Inhibition	%	1.11
	8182601	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	2.41	CHEMBL3906	Homo sapiens	Inhibition	%	2.41
	8182693	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	3.74	CHEMBL3906	Homo sapiens	Inhibition	%	3.74
	8183039	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	3.3	CHEMBL3906	Homo sapiens	Inhibition	%	3.3
	8183188	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	1.33	CHEMBL3906	Homo sapiens	Inhibition	%	1.33
	8183412	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	4.86	CHEMBL3906	Homo sapiens	Inhibition	%	4.86
	8183541	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	-0.87	CHEMBL3906	Homo sapiens	Inhibition	%	-0.87
	8183907	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	1.83	CHEMBL3906	Homo sapiens	Inhibition	%	1.83
	8184043	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	1.46	CHEMBL3906	Homo sapiens	Inhibition	%	1.46
	8184309	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	3.15	CHEMBL3906	Homo sapiens	Inhibition	%	3.15
	8184680	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	2.41	CHEMBL3906	Homo sapiens	Inhibition	%	2.41
	8184837	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	2.3	CHEMBL3906	Homo sapiens	Inhibition	%	2.3
	8185061	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	4.22	CHEMBL3906	Homo sapiens	Inhibition	%	4.22
	8185210	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	1.51	CHEMBL3906	Homo sapiens	Inhibition	%	1.51
	8185565	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	3.31	CHEMBL3906	Homo sapiens	Inhibition	%	3.31
	8185696	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	23.45	CHEMBL3906	Homo sapiens	Inhibition	%	23.45
	8186059	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	3.36	CHEMBL3906	Homo sapiens	Inhibition	%	3.36
	8186200	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	2.96	CHEMBL3906	Homo sapiens	Inhibition	%	2.96
	8186424	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	2.69	CHEMBL3906	Homo sapiens	Inhibition	%	2.69
	8186588	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	2.16	CHEMBL3906	Homo sapiens	Inhibition	%	2.16
	8186951	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	2.14	CHEMBL3906	Homo sapiens	Inhibition	%	2.14
	8187049	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.1	CHEMBL3906	Homo sapiens	Inhibition	%	1.1
	8187273	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.48	CHEMBL3906	Homo sapiens	Inhibition	%	1.48
	8187397	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	1.43	CHEMBL3906	Homo sapiens	Inhibition	%	1.43
	8187769	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.51	CHEMBL3906	Homo sapiens	Inhibition	%	1.51
	8187898	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	0.6	CHEMBL3906	Homo sapiens	Inhibition	%	0.6
	8188265	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	2.94	CHEMBL3906	Homo sapiens	Inhibition	%	2.94
	8188400	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	1.87	CHEMBL3906	Homo sapiens	Inhibition	%	1.87
	8188624	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	4.48	CHEMBL3906	Homo sapiens	Inhibition	%	4.48
	8188674	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.76	CHEMBL3906	Homo sapiens	Inhibition	%	1.76
	8188898	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	4.93	CHEMBL3906	Homo sapiens	Inhibition	%	4.93
	8189046	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	1.98	CHEMBL3906	Homo sapiens	Inhibition	%	1.98
	8189426	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	5.57	CHEMBL3906	Homo sapiens	Inhibition	%	5.57
	8189575	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	1.36	CHEMBL3906	Homo sapiens	Inhibition	%	1.36
	8189931	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	4.55	CHEMBL3906	Homo sapiens	Inhibition	%	4.55
	8190063	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	1.52	CHEMBL3906	Homo sapiens	Inhibition	%	1.52
	8190287	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	3.85	CHEMBL3906	Homo sapiens	Inhibition	%	3.85
	8190427	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	3.07	CHEMBL3906	Homo sapiens	Inhibition	%	3.07
	8190788	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	3.09	CHEMBL3906	Homo sapiens	Inhibition	%	3.09
	8190952	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	3.86	CHEMBL3906	Homo sapiens	Inhibition	%	3.86
	8191314	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	4.06	CHEMBL3906	Homo sapiens	Inhibition	%	4.06
	8191634	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	1.05	CHEMBL3906	Homo sapiens	Inhibition	%	1.05
	8191756	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	2.43	CHEMBL3906	Homo sapiens	Inhibition	%	2.43
	8192129	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.74	CHEMBL3906	Homo sapiens	Inhibition	%	0.74
	8192258	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	0.39	CHEMBL3906	Homo sapiens	Inhibition	%	0.39
	8192482	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	0.4	CHEMBL3906	Homo sapiens	Inhibition	%	0.4
	8192626	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	0.87	CHEMBL3906	Homo sapiens	Inhibition	%	0.87
	8192986	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	0.44	CHEMBL3906	Homo sapiens	Inhibition	%	0.44
	8193258	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	1.82	CHEMBL3906	Homo sapiens	Inhibition	%	1.82
	8193403	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	2.99	CHEMBL3906	Homo sapiens	Inhibition	%	2.99
	8193627	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	1.46	CHEMBL3906	Homo sapiens	Inhibition	%	1.46
	8193784	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	26.18	CHEMBL3906	Homo sapiens	Inhibition	%	26.18
	8193933	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-0.11	CHEMBL3906	Homo sapiens	Inhibition	%	-0.11
	8194157	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	7.05	CHEMBL3906	Homo sapiens	Inhibition	%	7.05
	8194288	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	3.28	CHEMBL3906	Homo sapiens	Inhibition	%	3.28
	8194643	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	2.52	CHEMBL3906	Homo sapiens	Inhibition	%	2.52
	8194786	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	2.57	CHEMBL3906	Homo sapiens	Inhibition	%	2.57
	8195143	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	4.29	CHEMBL3906	Homo sapiens	Inhibition	%	4.29
	8195307	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.45	CHEMBL3906	Homo sapiens	Inhibition	%	1.45
	8195531	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	9.07	CHEMBL3906	Homo sapiens	Inhibition	%	9.07
	8195670	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.72	CHEMBL3906	Homo sapiens	Inhibition	%	2.72
	8195992	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	3.76	CHEMBL3906	Homo sapiens	Inhibition	%	3.76
	8196109	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	1.07	CHEMBL3906	Homo sapiens	Inhibition	%	1.07
	8196333	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	3.24	CHEMBL3906	Homo sapiens	Inhibition	%	3.24
	8196483	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	2.02	CHEMBL3906	Homo sapiens	Inhibition	%	2.02
	8196835	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	2.98	CHEMBL3906	Homo sapiens	Inhibition	%	2.98
	8196976	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	2.74	CHEMBL3906	Homo sapiens	Inhibition	%	2.74
	8197200	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.22	CHEMBL3906	Homo sapiens	Inhibition	%	0.22
	8197337	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	0.33	CHEMBL3906	Homo sapiens	Inhibition	%	0.33
	8197612	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	2.97	CHEMBL3906	Homo sapiens	Inhibition	%	2.97
	8197976	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	8.47	CHEMBL3906	Homo sapiens	Inhibition	%	8.47
	8198133	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	3.31	CHEMBL3906	Homo sapiens	Inhibition	%	3.31
	8198495	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	1.61	CHEMBL3906	Homo sapiens	Inhibition	%	1.61
	8198625	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	3.51	CHEMBL3906	Homo sapiens	Inhibition	%	3.51
	8198849	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	4.11	CHEMBL3906	Homo sapiens	Inhibition	%	4.11
	8198980	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	2.25	CHEMBL3906	Homo sapiens	Inhibition	%	2.25
	8199128	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	2.08	CHEMBL3906	Homo sapiens	Inhibition	%	2.08
	8199352	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	3.2	CHEMBL3906	Homo sapiens	Inhibition	%	3.2
	8199486	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	3.21	CHEMBL3906	Homo sapiens	Inhibition	%	3.21
	8199873	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	1.57	CHEMBL3906	Homo sapiens	Inhibition	%	1.57
	8200011	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	3.66	CHEMBL3906	Homo sapiens	Inhibition	%	3.66
	8200339	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	0.49	CHEMBL3906	Homo sapiens	Inhibition	%	0.49
	8200678	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	1.62	CHEMBL3906	Homo sapiens	Inhibition	%	1.62
	8200828	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	2.16	CHEMBL3906	Homo sapiens	Inhibition	%	2.16
	8201052	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	1.86	CHEMBL3906	Homo sapiens	Inhibition	%	1.86
	8201182	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	9.31	CHEMBL3906	Homo sapiens	Inhibition	%	9.31
	8201541	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	2.19	CHEMBL3906	Homo sapiens	Inhibition	%	2.19
	8201674	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.02	CHEMBL3906	Homo sapiens	Inhibition	%	0.02
	8201953	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	2.39	CHEMBL3906	Homo sapiens	Inhibition	%	2.39
	8202317	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-0.77	CHEMBL3906	Homo sapiens	Inhibition	%	-0.77
	8202484	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	4.36	CHEMBL3906	Homo sapiens	Inhibition	%	4.36
	8202833	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	2.64	CHEMBL3906	Homo sapiens	Inhibition	%	2.64
	8203187	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	9.99	CHEMBL3906	Homo sapiens	Inhibition	%	9.99
	8203318	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	3.56	CHEMBL3906	Homo sapiens	Inhibition	%	3.56
	8203688	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	1.93	CHEMBL3906	Homo sapiens	Inhibition	%	1.93
	8203822	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	2.81	CHEMBL3906	Homo sapiens	Inhibition	%	2.81
	8204046	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	2.82	CHEMBL3906	Homo sapiens	Inhibition	%	2.82
	8204212	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	1.41	CHEMBL3906	Homo sapiens	Inhibition	%	1.41
	8204349	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.68	CHEMBL3906	Homo sapiens	Inhibition	%	1.68
	8204573	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	2.66	CHEMBL3906	Homo sapiens	Inhibition	%	2.66
	8204678	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.37	CHEMBL3906	Homo sapiens	Inhibition	%	1.37
	8205017	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	9.77	CHEMBL3906	Homo sapiens	Inhibition	%	9.77
	8205390	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	5.06	CHEMBL3906	Homo sapiens	Inhibition	%	5.06
	8205526	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	5.7	CHEMBL3906	Homo sapiens	Inhibition	%	5.7
	8205889	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	1.88	CHEMBL3906	Homo sapiens	Inhibition	%	1.88
	8206021	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.67	CHEMBL3906	Homo sapiens	Inhibition	%	-0.67
	8206245	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-1.79	CHEMBL3906	Homo sapiens	Inhibition	%	-1.79
	8206297	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	2.88	CHEMBL3906	Homo sapiens	Inhibition	%	2.88
	8206521	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	3.07	CHEMBL3906	Homo sapiens	Inhibition	%	3.07
	8206664	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	1.44	CHEMBL3906	Homo sapiens	Inhibition	%	1.44
	8206844	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	4.55	CHEMBL3906	Homo sapiens	Inhibition	%	4.55
	8207068	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	16.45	CHEMBL3906	Homo sapiens	Inhibition	%	16.45
	8207194	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	3.04	CHEMBL3906	Homo sapiens	Inhibition	%	3.04
	8207548	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	22.4	CHEMBL3906	Homo sapiens	Inhibition	%	22.4
	8207680	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	5.15	CHEMBL3906	Homo sapiens	Inhibition	%	5.15
	8207904	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.81	CHEMBL3906	Homo sapiens	Inhibition	%	2.81
	8208049	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	3.97	CHEMBL3906	Homo sapiens	Inhibition	%	3.97
	8208405	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	4.07	CHEMBL3906	Homo sapiens	Inhibition	%	4.07
	8208571	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	2.26	CHEMBL3906	Homo sapiens	Inhibition	%	2.26
	8208928	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	67.04	CHEMBL3906	Homo sapiens	Inhibition	%	67.04
	8209033	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	0.3	CHEMBL3906	Homo sapiens	Inhibition	%	0.3
	8209257	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	2.3	CHEMBL3906	Homo sapiens	Inhibition	%	2.3
	8209373	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	1.71	CHEMBL3906	Homo sapiens	Inhibition	%	1.71
	8209747	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	0.45	CHEMBL3906	Homo sapiens	Inhibition	%	0.45
	8209883	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	27.85	CHEMBL3906	Homo sapiens	Inhibition	%	27.85
	8210107	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	2.9	CHEMBL3906	Homo sapiens	Inhibition	%	2.9
	8210248	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	2.04	CHEMBL3906	Homo sapiens	Inhibition	%	2.04
	8210608	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	0.38	CHEMBL3906	Homo sapiens	Inhibition	%	0.38
	8210867	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	3.77	CHEMBL3906	Homo sapiens	Inhibition	%	3.77
	8211011	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	1.77	CHEMBL3906	Homo sapiens	Inhibition	%	1.77
	8211405	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	3.56	CHEMBL3906	Homo sapiens	Inhibition	%	3.56
	8211528	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	2.74	CHEMBL3906	Homo sapiens	Inhibition	%	2.74
	8211752	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	3.45	CHEMBL3906	Homo sapiens	Inhibition	%	3.45
	8211881	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	70.56	CHEMBL3906	Homo sapiens	Inhibition	%	70.56
	8212237	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.38	CHEMBL3906	Homo sapiens	Inhibition	%	2.38
	8212378	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	3.68	CHEMBL3906	Homo sapiens	Inhibition	%	3.68
	8212735	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	3.01	CHEMBL3906	Homo sapiens	Inhibition	%	3.01
	8212905	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	13.69	CHEMBL3906	Homo sapiens	Inhibition	%	13.69
	8213129	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.83	CHEMBL3906	Homo sapiens	Inhibition	%	0.83
	8213258	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	90.86	CHEMBL3906	Homo sapiens	Inhibition	%	90.86
	8213586	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-1.33	CHEMBL3906	Homo sapiens	Inhibition	%	-1.33
	8213699	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	1.96	CHEMBL3906	Homo sapiens	Inhibition	%	1.96
	8213923	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	1.9	CHEMBL3906	Homo sapiens	Inhibition	%	1.9
	8214070	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	2.46	CHEMBL3906	Homo sapiens	Inhibition	%	2.46
	8214431	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	10.61	CHEMBL3906	Homo sapiens	Inhibition	%	10.61
	8214565	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	1.81	CHEMBL3906	Homo sapiens	Inhibition	%	1.81
	8214941	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-0.89	CHEMBL3906	Homo sapiens	Inhibition	%	-0.89
	8215192	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	3.04	CHEMBL3906	Homo sapiens	Inhibition	%	3.04
	8215345	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	4.5	CHEMBL3906	Homo sapiens	Inhibition	%	4.5
	8215569	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	2.4	CHEMBL3906	Homo sapiens	Inhibition	%	2.4
	8215733	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	2.57	CHEMBL3906	Homo sapiens	Inhibition	%	2.57
	8216076	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	5.13	CHEMBL3906	Homo sapiens	Inhibition	%	5.13
	8216195	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	0.97	CHEMBL3906	Homo sapiens	Inhibition	%	0.97
	8216555	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	9.8	CHEMBL3906	Homo sapiens	Inhibition	%	9.8
	8216693	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	6.96	CHEMBL3906	Homo sapiens	Inhibition	%	6.96
	8216917	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	69.45	CHEMBL3906	Homo sapiens	Inhibition	%	69.45
	8217051	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	2.85	CHEMBL3906	Homo sapiens	Inhibition	%	2.85
	8217449	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	1.55	CHEMBL3906	Homo sapiens	Inhibition	%	1.55
	8217580	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	3.37	CHEMBL3906	Homo sapiens	Inhibition	%	3.37
	8217905	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-1.11	CHEMBL3906	Homo sapiens	Inhibition	%	-1.11
	8218244	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	2.18	CHEMBL3906	Homo sapiens	Inhibition	%	2.18
	8218371	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	1.89	CHEMBL3906	Homo sapiens	Inhibition	%	1.89
	8218738	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	1.67	CHEMBL3906	Homo sapiens	Inhibition	%	1.67
	8218869	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	3.37	CHEMBL3906	Homo sapiens	Inhibition	%	3.37
	8219093	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	3.12	CHEMBL3906	Homo sapiens	Inhibition	%	3.12
	8219253	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-0.56	CHEMBL3906	Homo sapiens	Inhibition	%	-0.56
	8219503	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	2.27	CHEMBL3906	Homo sapiens	Inhibition	%	2.27
	8219888	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	2.21	CHEMBL3906	Homo sapiens	Inhibition	%	2.21
	8220057	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	2.32	CHEMBL3906	Homo sapiens	Inhibition	%	2.32
	8220410	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.99	CHEMBL3906	Homo sapiens	Inhibition	%	2.99
	8220524	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	3.47	CHEMBL3906	Homo sapiens	Inhibition	%	3.47
	8220748	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	13.11	CHEMBL3906	Homo sapiens	Inhibition	%	13.11
	8220886	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	42.14	CHEMBL3906	Homo sapiens	Inhibition	%	42.14
	8221246	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	91.2	CHEMBL3906	Homo sapiens	Inhibition	%	91.2
	8221379	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	0.99	CHEMBL3906	Homo sapiens	Inhibition	%	0.99
	8221768	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.37	CHEMBL3906	Homo sapiens	Inhibition	%	0.37
	8221899	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	10.16	CHEMBL3906	Homo sapiens	Inhibition	%	10.16
	8222123	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.21	CHEMBL3906	Homo sapiens	Inhibition	%	2.21
	8222221	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	0.6	CHEMBL3906	Homo sapiens	Inhibition	%	0.6
	8222579	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	2.5	CHEMBL3906	Homo sapiens	Inhibition	%	2.5
	8222697	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	8.18	CHEMBL3906	Homo sapiens	Inhibition	%	8.18
	8222921	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	1.77	CHEMBL3906	Homo sapiens	Inhibition	%	1.77
	8223065	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	34.09	CHEMBL3906	Homo sapiens	Inhibition	%	34.09
	8223418	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	20.49	CHEMBL3906	Homo sapiens	Inhibition	%	20.49
	8223579	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	0.01	CHEMBL3906	Homo sapiens	Inhibition	%	0.01
	8223829	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	3.42	CHEMBL3906	Homo sapiens	Inhibition	%	3.42
	8224053	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	3.72	CHEMBL3906	Homo sapiens	Inhibition	%	3.72
	8224215	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	3.89	CHEMBL3906	Homo sapiens	Inhibition	%	3.89
	8224385	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	3.24	CHEMBL3906	Homo sapiens	Inhibition	%	3.24
	8224609	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	1.04	CHEMBL3906	Homo sapiens	Inhibition	%	1.04
	8224744	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.17	CHEMBL3906	Homo sapiens	Inhibition	%	2.17
	8225082	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	53.37	CHEMBL3906	Homo sapiens	Inhibition	%	53.37
	8225216	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	1.18	CHEMBL3906	Homo sapiens	Inhibition	%	1.18
	8225440	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	5.39	CHEMBL3906	Homo sapiens	Inhibition	%	5.39
	8225578	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.95	CHEMBL3906	Homo sapiens	Inhibition	%	1.95
	8225713	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	5.21	CHEMBL3906	Homo sapiens	Inhibition	%	5.21
	8225937	CHEMBL1961932	GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.89	CHEMBL3906	Homo sapiens	Inhibition	%	1.89
	8226095	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.92	CHEMBL3906	Homo sapiens	Inhibition	%	1.92
	8226444	CHEMBL1961933	GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.85	CHEMBL3906	Homo sapiens	Inhibition	%	2.85
	10839480	CHEMBL2015511	Inhibition of RSK3 N-terminal at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	36.0	CHEMBL3906	Homo sapiens	INH	%	36.0
	10867546	CHEMBL2027436	Inhibition of Rsk3 at 2 uM	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	=	Inhibition	%	0.0	CHEMBL3906	Homo sapiens	INH	%	0.0
	10921402	CHEMBL2044784	Inhibition of RPS6KA2 at 1 uM	B	CCN1C(=O)CCCc2c1ccc(Nc1ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n1)c2OC		CHEMBL2042829	=	Inhibition	%	100.0	CHEMBL3906	Homo sapiens	INH	%	100.0
	10921403	CHEMBL2044932	Inhibition of RPS6KA2 at 0.1 uM	B	CCN1C(=O)CCCc2c1ccc(Nc1ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n1)c2OC		CHEMBL2042829	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	10981533	CHEMBL2066387	Inhibition of human Rsk3 at 1 uM	B	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2		CHEMBL2064666	>=	Inhibition	%	90.0	CHEMBL3906	Homo sapiens	INH	%	90.0
	10981548	CHEMBL2067598	Inhibition of human Rsk3	B	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2		CHEMBL2064666	=	IC50	nM	7.0	CHEMBL3906	Homo sapiens	IC50	nM	7.0
	12047344	CHEMBL2157697	Inhibition of Rsk3 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	2.8	CHEMBL3906	Homo sapiens	INH	%	2.8
	12068074	CHEMBL2162583	Inhibition of RSK3 at 0.1 uM	B	Cc1nc2cnc3[nH]ccc3c2n1[C@@H]1CCC[C@@H](O)C1		CHEMBL2159210	=	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	12074702	CHEMBL2161423	Inhibition of Rsk3 at 1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	12145287	CHEMBL2186668	Inhibition of RSK3 using fluorescent labelled substrate at 5 uM by caliper method	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1		CHEMBL2177819	>	Inhibition	%	25.0	CHEMBL3906	Homo sapiens	INH	%	25.0
	12145288	CHEMBL2186668	Inhibition of RSK3 using fluorescent labelled substrate at 5 uM by caliper method	B	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1		CHEMBL2177818	>	Inhibition	%	25.0	CHEMBL3906	Homo sapiens	INH	%	25.0
	12172214	CHEMBL2211994	Inhibition of RSK3 C-terminal domain 2 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	78.0	CHEMBL3906	Homo sapiens	Activity	%	78.0
	12172215	CHEMBL2211995	Inhibition of RSK3 N-terminal domain 1 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	12257856	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	106.0	CHEMBL3906	Homo sapiens	Residual Activity	%	106.0
	12257857	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	5.0	CHEMBL3906	Homo sapiens	Residual Activity	%	5.0
	12257858	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12257859	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	102.0	CHEMBL3906	Homo sapiens	Residual Activity	%	102.0
	12257860	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	87.0	CHEMBL3906	Homo sapiens	Residual Activity	%	87.0
	12257861	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	103.0	CHEMBL3906	Homo sapiens	Residual Activity	%	103.0
	12257862	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	4.0	CHEMBL3906	Homo sapiens	Residual Activity	%	4.0
	12257863	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	87.0	CHEMBL3906	Homo sapiens	Residual Activity	%	87.0
	12257864	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	107.0	CHEMBL3906	Homo sapiens	Residual Activity	%	107.0
	12257865	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12257866	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12257867	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	98.0	CHEMBL3906	Homo sapiens	Residual Activity	%	98.0
	12257868	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12257869	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12257870	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	82.0	CHEMBL3906	Homo sapiens	Residual Activity	%	82.0
	12257871	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	72.0	CHEMBL3906	Homo sapiens	Residual Activity	%	72.0
	12257872	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	117.0	CHEMBL3906	Homo sapiens	Residual Activity	%	117.0
	12257873	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	104.0	CHEMBL3906	Homo sapiens	Residual Activity	%	104.0
	12257874	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	94.0	CHEMBL3906	Homo sapiens	Residual Activity	%	94.0
	12257875	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	25.0	CHEMBL3906	Homo sapiens	Residual Activity	%	25.0
	12257876	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	102.0	CHEMBL3906	Homo sapiens	Residual Activity	%	102.0
	12257877	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	103.0	CHEMBL3906	Homo sapiens	Residual Activity	%	103.0
	12257878	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	105.0	CHEMBL3906	Homo sapiens	Residual Activity	%	105.0
	12257879	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	108.0	CHEMBL3906	Homo sapiens	Residual Activity	%	108.0
	12257880	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	109.0	CHEMBL3906	Homo sapiens	Residual Activity	%	109.0
	12257881	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12257882	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	13.0	CHEMBL3906	Homo sapiens	Residual Activity	%	13.0
	12257883	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	44.0	CHEMBL3906	Homo sapiens	Residual Activity	%	44.0
	12257884	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12257885	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	0.0	CHEMBL3906	Homo sapiens	Residual Activity	%	0.0
	12257886	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	108.0	CHEMBL3906	Homo sapiens	Residual Activity	%	108.0
	12257887	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	106.0	CHEMBL3906	Homo sapiens	Residual Activity	%	106.0
	12257888	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	108.0	CHEMBL3906	Homo sapiens	Residual Activity	%	108.0
	12257889	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	109.0	CHEMBL3906	Homo sapiens	Residual Activity	%	109.0
	12257890	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	94.0	CHEMBL3906	Homo sapiens	Residual Activity	%	94.0
	12257891	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	103.0	CHEMBL3906	Homo sapiens	Residual Activity	%	103.0
	12257892	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	93.0	CHEMBL3906	Homo sapiens	Residual Activity	%	93.0
	12257893	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	102.0	CHEMBL3906	Homo sapiens	Residual Activity	%	102.0
	12257894	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12257895	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	79.0	CHEMBL3906	Homo sapiens	Residual Activity	%	79.0
	12257896	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	109.0	CHEMBL3906	Homo sapiens	Residual Activity	%	109.0
	12257897	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	105.0	CHEMBL3906	Homo sapiens	Residual Activity	%	105.0
	12257898	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	0.0	CHEMBL3906	Homo sapiens	Residual Activity	%	0.0
	12257899	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	3.0	CHEMBL3906	Homo sapiens	Residual Activity	%	3.0
	12257900	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	103.0	CHEMBL3906	Homo sapiens	Residual Activity	%	103.0
	12257901	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	98.0	CHEMBL3906	Homo sapiens	Residual Activity	%	98.0
	12257902	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	116.0	CHEMBL3906	Homo sapiens	Residual Activity	%	116.0
	12257903	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	27.0	CHEMBL3906	Homo sapiens	Residual Activity	%	27.0
	12257904	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	120.0	CHEMBL3906	Homo sapiens	Residual Activity	%	120.0
	12257905	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	108.0	CHEMBL3906	Homo sapiens	Residual Activity	%	108.0
	12257906	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	0.0	CHEMBL3906	Homo sapiens	Residual Activity	%	0.0
	12257907	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	106.0	CHEMBL3906	Homo sapiens	Residual Activity	%	106.0
	12257908	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	5.0	CHEMBL3906	Homo sapiens	Residual Activity	%	5.0
	12257909	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12257910	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	122.0	CHEMBL3906	Homo sapiens	Residual Activity	%	122.0
	12257911	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	108.0	CHEMBL3906	Homo sapiens	Residual Activity	%	108.0
	12257912	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	109.0	CHEMBL3906	Homo sapiens	Residual Activity	%	109.0
	12257913	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	119.0	CHEMBL3906	Homo sapiens	Residual Activity	%	119.0
	12257914	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	92.0	CHEMBL3906	Homo sapiens	Residual Activity	%	92.0
	12257915	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12257916	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	88.0	CHEMBL3906	Homo sapiens	Residual Activity	%	88.0
	12257917	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	1.0
	12257918	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	108.0	CHEMBL3906	Homo sapiens	Residual Activity	%	108.0
	12257919	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	107.0	CHEMBL3906	Homo sapiens	Residual Activity	%	107.0
	12257920	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	106.0	CHEMBL3906	Homo sapiens	Residual Activity	%	106.0
	12257921	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	74.0	CHEMBL3906	Homo sapiens	Residual Activity	%	74.0
	12257922	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	93.0	CHEMBL3906	Homo sapiens	Residual Activity	%	93.0
	12257923	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	115.0	CHEMBL3906	Homo sapiens	Residual Activity	%	115.0
	12257924	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	114.0	CHEMBL3906	Homo sapiens	Residual Activity	%	114.0
	12257925	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	100.0	CHEMBL3906	Homo sapiens	Residual Activity	%	100.0
	12257926	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	110.0	CHEMBL3906	Homo sapiens	Residual Activity	%	110.0
	12257927	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	106.0	CHEMBL3906	Homo sapiens	Residual Activity	%	106.0
	12257928	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	1.0
	12257929	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	110.0	CHEMBL3906	Homo sapiens	Residual Activity	%	110.0
	12257930	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12257931	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	95.0	CHEMBL3906	Homo sapiens	Residual Activity	%	95.0
	12257932	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	117.0	CHEMBL3906	Homo sapiens	Residual Activity	%	117.0
	12257933	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	9.0	CHEMBL3906	Homo sapiens	Residual Activity	%	9.0
	12257934	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	100.0	CHEMBL3906	Homo sapiens	Residual Activity	%	100.0
	12257935	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	1.0
	12257936	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12257937	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	19.0	CHEMBL3906	Homo sapiens	Residual Activity	%	19.0
	12257938	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	44.0	CHEMBL3906	Homo sapiens	Residual Activity	%	44.0
	12257939	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	62.0	CHEMBL3906	Homo sapiens	Residual Activity	%	62.0
	12257940	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	36.0	CHEMBL3906	Homo sapiens	Residual Activity	%	36.0
	12257941	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	97.0	CHEMBL3906	Homo sapiens	Residual Activity	%	97.0
	12257942	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	40.0	CHEMBL3906	Homo sapiens	Residual Activity	%	40.0
	12257943	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	107.0	CHEMBL3906	Homo sapiens	Residual Activity	%	107.0
	12257944	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	98.0	CHEMBL3906	Homo sapiens	Residual Activity	%	98.0
	12257945	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	19.0	CHEMBL3906	Homo sapiens	Residual Activity	%	19.0
	12257946	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12257947	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12257948	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	29.0	CHEMBL3906	Homo sapiens	Residual Activity	%	29.0
	12257949	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12257950	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	93.0	CHEMBL3906	Homo sapiens	Residual Activity	%	93.0
	12257951	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	76.0	CHEMBL3906	Homo sapiens	Residual Activity	%	76.0
	12257952	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	108.0	CHEMBL3906	Homo sapiens	Residual Activity	%	108.0
	12257953	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	102.0	CHEMBL3906	Homo sapiens	Residual Activity	%	102.0
	12257954	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12257955	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12257956	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	33.0	CHEMBL3906	Homo sapiens	Residual Activity	%	33.0
	12257957	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	0.0	CHEMBL3906	Homo sapiens	Residual Activity	%	0.0
	12257958	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	102.0	CHEMBL3906	Homo sapiens	Residual Activity	%	102.0
	12257959	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	8.0	CHEMBL3906	Homo sapiens	Residual Activity	%	8.0
	12257960	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	38.0	CHEMBL3906	Homo sapiens	Residual Activity	%	38.0
	12257961	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12257962	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	77.0	CHEMBL3906	Homo sapiens	Residual Activity	%	77.0
	12257963	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12257964	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	96.0	CHEMBL3906	Homo sapiens	Residual Activity	%	96.0
	12257965	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	12.0	CHEMBL3906	Homo sapiens	Residual Activity	%	12.0
	12259372	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	103.0	CHEMBL3906	Homo sapiens	Residual Activity	%	103.0
	12259373	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	100.0	CHEMBL3906	Homo sapiens	Residual Activity	%	100.0
	12259374	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	8.0	CHEMBL3906	Homo sapiens	Residual Activity	%	8.0
	12259375	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	91.0	CHEMBL3906	Homo sapiens	Residual Activity	%	91.0
	12259376	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	18.0	CHEMBL3906	Homo sapiens	Residual Activity	%	18.0
	12259377	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12259378	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	30.0	CHEMBL3906	Homo sapiens	Residual Activity	%	30.0
	12259379	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	106.0	CHEMBL3906	Homo sapiens	Residual Activity	%	106.0
	12259380	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	83.0	CHEMBL3906	Homo sapiens	Residual Activity	%	83.0
	12259381	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	106.0	CHEMBL3906	Homo sapiens	Residual Activity	%	106.0
	12259382	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	68.0	CHEMBL3906	Homo sapiens	Residual Activity	%	68.0
	12259383	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	30.0	CHEMBL3906	Homo sapiens	Residual Activity	%	30.0
	12259384	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	6.0	CHEMBL3906	Homo sapiens	Residual Activity	%	6.0
	12259385	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	30.0	CHEMBL3906	Homo sapiens	Residual Activity	%	30.0
	12259386	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	11.0	CHEMBL3906	Homo sapiens	Residual Activity	%	11.0
	12259387	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	107.0	CHEMBL3906	Homo sapiens	Residual Activity	%	107.0
	12259388	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	75.0	CHEMBL3906	Homo sapiens	Residual Activity	%	75.0
	12259389	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	91.0	CHEMBL3906	Homo sapiens	Residual Activity	%	91.0
	12259390	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	70.0	CHEMBL3906	Homo sapiens	Residual Activity	%	70.0
	12259391	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	0.0	CHEMBL3906	Homo sapiens	Residual Activity	%	0.0
	12259392	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	11.0	CHEMBL3906	Homo sapiens	Residual Activity	%	11.0
	12259393	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	92.0	CHEMBL3906	Homo sapiens	Residual Activity	%	92.0
	12259394	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	58.0	CHEMBL3906	Homo sapiens	Residual Activity	%	58.0
	12259395	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	100.0	CHEMBL3906	Homo sapiens	Residual Activity	%	100.0
	12259396	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	76.0	CHEMBL3906	Homo sapiens	Residual Activity	%	76.0
	12259397	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	22.0	CHEMBL3906	Homo sapiens	Residual Activity	%	22.0
	12259398	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	93.0	CHEMBL3906	Homo sapiens	Residual Activity	%	93.0
	12259399	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	18.0	CHEMBL3906	Homo sapiens	Residual Activity	%	18.0
	12259400	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	17.0	CHEMBL3906	Homo sapiens	Residual Activity	%	17.0
	12259401	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12259402	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	53.0	CHEMBL3906	Homo sapiens	Residual Activity	%	53.0
	12259403	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	70.0	CHEMBL3906	Homo sapiens	Residual Activity	%	70.0
	12259404	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12259405	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	95.0	CHEMBL3906	Homo sapiens	Residual Activity	%	95.0
	12259406	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	116.0	CHEMBL3906	Homo sapiens	Residual Activity	%	116.0
	12259407	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	88.0	CHEMBL3906	Homo sapiens	Residual Activity	%	88.0
	12259408	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	71.0	CHEMBL3906	Homo sapiens	Residual Activity	%	71.0
	12259409	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	93.0	CHEMBL3906	Homo sapiens	Residual Activity	%	93.0
	12259410	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	59.0	CHEMBL3906	Homo sapiens	Residual Activity	%	59.0
	12259411	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	108.0	CHEMBL3906	Homo sapiens	Residual Activity	%	108.0
	12259412	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	30.0	CHEMBL3906	Homo sapiens	Residual Activity	%	30.0
	12259413	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	111.0	CHEMBL3906	Homo sapiens	Residual Activity	%	111.0
	12259414	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	104.0	CHEMBL3906	Homo sapiens	Residual Activity	%	104.0
	12259415	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	63.0	CHEMBL3906	Homo sapiens	Residual Activity	%	63.0
	12259416	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	98.0	CHEMBL3906	Homo sapiens	Residual Activity	%	98.0
	12259417	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	89.0	CHEMBL3906	Homo sapiens	Residual Activity	%	89.0
	12259418	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	105.0	CHEMBL3906	Homo sapiens	Residual Activity	%	105.0
	12259419	CHEMBL2219167	Millipore: Percentage of residual kinase activity of RPS6KA2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	0.0	CHEMBL3906	Homo sapiens	Residual Activity	%	0.0
	12259420	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	82.0	CHEMBL3906	Homo sapiens	Residual Activity	%	82.0
	12259421	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	0.0	CHEMBL3906	Homo sapiens	Residual Activity	%	0.0
	12259422	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	55.0	CHEMBL3906	Homo sapiens	Residual Activity	%	55.0
	12259423	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	95.0	CHEMBL3906	Homo sapiens	Residual Activity	%	95.0
	12259424	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	38.0	CHEMBL3906	Homo sapiens	Residual Activity	%	38.0
	12259425	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	84.0	CHEMBL3906	Homo sapiens	Residual Activity	%	84.0
	12259426	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	0.0	CHEMBL3906	Homo sapiens	Residual Activity	%	0.0
	12259427	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	47.0	CHEMBL3906	Homo sapiens	Residual Activity	%	47.0
	12259428	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	83.0	CHEMBL3906	Homo sapiens	Residual Activity	%	83.0
	12259429	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	70.0	CHEMBL3906	Homo sapiens	Residual Activity	%	70.0
	12259430	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	96.0	CHEMBL3906	Homo sapiens	Residual Activity	%	96.0
	12259431	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	85.0	CHEMBL3906	Homo sapiens	Residual Activity	%	85.0
	12259432	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	71.0	CHEMBL3906	Homo sapiens	Residual Activity	%	71.0
	12259433	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	85.0	CHEMBL3906	Homo sapiens	Residual Activity	%	85.0
	12259434	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	29.0	CHEMBL3906	Homo sapiens	Residual Activity	%	29.0
	12259435	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	77.0	CHEMBL3906	Homo sapiens	Residual Activity	%	77.0
	12259436	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	97.0	CHEMBL3906	Homo sapiens	Residual Activity	%	97.0
	12259437	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	93.0	CHEMBL3906	Homo sapiens	Residual Activity	%	93.0
	12259438	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	97.0	CHEMBL3906	Homo sapiens	Residual Activity	%	97.0
	12259439	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	7.0	CHEMBL3906	Homo sapiens	Residual Activity	%	7.0
	12259440	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12259441	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	78.0	CHEMBL3906	Homo sapiens	Residual Activity	%	78.0
	12259442	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	94.0	CHEMBL3906	Homo sapiens	Residual Activity	%	94.0
	12259443	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	105.0	CHEMBL3906	Homo sapiens	Residual Activity	%	105.0
	12259444	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	88.0	CHEMBL3906	Homo sapiens	Residual Activity	%	88.0
	12259445	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	48.0	CHEMBL3906	Homo sapiens	Residual Activity	%	48.0
	12259446	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	2.0	CHEMBL3906	Homo sapiens	Residual Activity	%	2.0
	12259447	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	7.0	CHEMBL3906	Homo sapiens	Residual Activity	%	7.0
	12259448	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	71.0	CHEMBL3906	Homo sapiens	Residual Activity	%	71.0
	12259449	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	-1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	-1.0
	12259450	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	95.0	CHEMBL3906	Homo sapiens	Residual Activity	%	95.0
	12259451	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	95.0	CHEMBL3906	Homo sapiens	Residual Activity	%	95.0
	12259452	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	93.0	CHEMBL3906	Homo sapiens	Residual Activity	%	93.0
	12259453	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12259454	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	71.0	CHEMBL3906	Homo sapiens	Residual Activity	%	71.0
	12259455	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12259456	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	63.0	CHEMBL3906	Homo sapiens	Residual Activity	%	63.0
	12259457	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12259458	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	97.0	CHEMBL3906	Homo sapiens	Residual Activity	%	97.0
	12259459	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	76.0	CHEMBL3906	Homo sapiens	Residual Activity	%	76.0
	12259460	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12259461	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	107.0	CHEMBL3906	Homo sapiens	Residual Activity	%	107.0
	12259462	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	-1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	-1.0
	12259463	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	1.0
	12259464	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	82.0	CHEMBL3906	Homo sapiens	Residual Activity	%	82.0
	12259465	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	48.0	CHEMBL3906	Homo sapiens	Residual Activity	%	48.0
	12259466	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12259467	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	4.0	CHEMBL3906	Homo sapiens	Residual Activity	%	4.0
	12259468	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	106.0	CHEMBL3906	Homo sapiens	Residual Activity	%	106.0
	12259469	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12259470	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	-2.0	CHEMBL3906	Homo sapiens	Residual Activity	%	-2.0
	12259471	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	69.0	CHEMBL3906	Homo sapiens	Residual Activity	%	69.0
	12259472	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	-1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	-1.0
	12259473	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	43.0	CHEMBL3906	Homo sapiens	Residual Activity	%	43.0
	12259474	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	93.0	CHEMBL3906	Homo sapiens	Residual Activity	%	93.0
	12259475	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	100.0	CHEMBL3906	Homo sapiens	Residual Activity	%	100.0
	12259476	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	69.0	CHEMBL3906	Homo sapiens	Residual Activity	%	69.0
	12259477	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	100.0	CHEMBL3906	Homo sapiens	Residual Activity	%	100.0
	12259478	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	64.0	CHEMBL3906	Homo sapiens	Residual Activity	%	64.0
	12259479	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	89.0	CHEMBL3906	Homo sapiens	Residual Activity	%	89.0
	12259480	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	36.0	CHEMBL3906	Homo sapiens	Residual Activity	%	36.0
	12259481	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	0.0	CHEMBL3906	Homo sapiens	Residual Activity	%	0.0
	12259482	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	70.0	CHEMBL3906	Homo sapiens	Residual Activity	%	70.0
	12259483	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	103.0	CHEMBL3906	Homo sapiens	Residual Activity	%	103.0
	12259484	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	70.0	CHEMBL3906	Homo sapiens	Residual Activity	%	70.0
	12259485	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	25.0	CHEMBL3906	Homo sapiens	Residual Activity	%	25.0
	12259486	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	104.0	CHEMBL3906	Homo sapiens	Residual Activity	%	104.0
	12259487	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	104.0	CHEMBL3906	Homo sapiens	Residual Activity	%	104.0
	12259488	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	78.0	CHEMBL3906	Homo sapiens	Residual Activity	%	78.0
	12259489	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	73.0	CHEMBL3906	Homo sapiens	Residual Activity	%	73.0
	12259490	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12259491	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	62.0	CHEMBL3906	Homo sapiens	Residual Activity	%	62.0
	12259492	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	-1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	-1.0
	12259493	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	72.0	CHEMBL3906	Homo sapiens	Residual Activity	%	72.0
	12259494	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	69.0	CHEMBL3906	Homo sapiens	Residual Activity	%	69.0
	12259495	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	46.0	CHEMBL3906	Homo sapiens	Residual Activity	%	46.0
	12259496	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12259497	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	1.0
	12259498	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	68.0	CHEMBL3906	Homo sapiens	Residual Activity	%	68.0
	12259499	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	-1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	-1.0
	12259500	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12259501	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	4.0	CHEMBL3906	Homo sapiens	Residual Activity	%	4.0
	12259502	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	32.0	CHEMBL3906	Homo sapiens	Residual Activity	%	32.0
	12259503	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	11.0	CHEMBL3906	Homo sapiens	Residual Activity	%	11.0
	12259504	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	17.0	CHEMBL3906	Homo sapiens	Residual Activity	%	17.0
	12259505	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	86.0	CHEMBL3906	Homo sapiens	Residual Activity	%	86.0
	12259506	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	42.0	CHEMBL3906	Homo sapiens	Residual Activity	%	42.0
	12259507	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	96.0	CHEMBL3906	Homo sapiens	Residual Activity	%	96.0
	12259508	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	99.0	CHEMBL3906	Homo sapiens	Residual Activity	%	99.0
	12259509	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	4.0	CHEMBL3906	Homo sapiens	Residual Activity	%	4.0
	12259510	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	88.0	CHEMBL3906	Homo sapiens	Residual Activity	%	88.0
	12259511	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	68.0	CHEMBL3906	Homo sapiens	Residual Activity	%	68.0
	12259512	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	6.0	CHEMBL3906	Homo sapiens	Residual Activity	%	6.0
	12259513	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	71.0	CHEMBL3906	Homo sapiens	Residual Activity	%	71.0
	12259514	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	93.0	CHEMBL3906	Homo sapiens	Residual Activity	%	93.0
	12259515	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	34.0	CHEMBL3906	Homo sapiens	Residual Activity	%	34.0
	12259516	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	112.0	CHEMBL3906	Homo sapiens	Residual Activity	%	112.0
	12259517	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	109.0	CHEMBL3906	Homo sapiens	Residual Activity	%	109.0
	12259518	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	102.0	CHEMBL3906	Homo sapiens	Residual Activity	%	102.0
	12259519	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	78.0	CHEMBL3906	Homo sapiens	Residual Activity	%	78.0
	12259520	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	15.0	CHEMBL3906	Homo sapiens	Residual Activity	%	15.0
	12259521	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	1.0
	12259522	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12259523	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	8.0	CHEMBL3906	Homo sapiens	Residual Activity	%	8.0
	12259524	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	22.0	CHEMBL3906	Homo sapiens	Residual Activity	%	22.0
	12259525	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	72.0	CHEMBL3906	Homo sapiens	Residual Activity	%	72.0
	12259526	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	57.0	CHEMBL3906	Homo sapiens	Residual Activity	%	57.0
	12259527	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	90.0	CHEMBL3906	Homo sapiens	Residual Activity	%	90.0
	12259528	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	97.0	CHEMBL3906	Homo sapiens	Residual Activity	%	97.0
	12259529	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	9.0	CHEMBL3906	Homo sapiens	Residual Activity	%	9.0
	12259530	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	97.0	CHEMBL3906	Homo sapiens	Residual Activity	%	97.0
	12259531	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	92.0	CHEMBL3906	Homo sapiens	Residual Activity	%	92.0
	12259532	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	1.0
	12259533	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	44.0	CHEMBL3906	Homo sapiens	Residual Activity	%	44.0
	12259534	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	5.0	CHEMBL3906	Homo sapiens	Residual Activity	%	5.0
	12259535	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	97.0	CHEMBL3906	Homo sapiens	Residual Activity	%	97.0
	12259536	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	7.0	CHEMBL3906	Homo sapiens	Residual Activity	%	7.0
	12259537	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	92.0	CHEMBL3906	Homo sapiens	Residual Activity	%	92.0
	12259538	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	50.0	CHEMBL3906	Homo sapiens	Residual Activity	%	50.0
	12259539	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	104.0	CHEMBL3906	Homo sapiens	Residual Activity	%	104.0
	12259540	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	44.0	CHEMBL3906	Homo sapiens	Residual Activity	%	44.0
	12259541	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	5.0	CHEMBL3906	Homo sapiens	Residual Activity	%	5.0
	12259542	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	2.0	CHEMBL3906	Homo sapiens	Residual Activity	%	2.0
	12259543	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	24.0	CHEMBL3906	Homo sapiens	Residual Activity	%	24.0
	12259544	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	2.0	CHEMBL3906	Homo sapiens	Residual Activity	%	2.0
	12259545	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	101.0	CHEMBL3906	Homo sapiens	Residual Activity	%	101.0
	12259546	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	21.0	CHEMBL3906	Homo sapiens	Residual Activity	%	21.0
	12259547	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	80.0	CHEMBL3906	Homo sapiens	Residual Activity	%	80.0
	12259548	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	70.0	CHEMBL3906	Homo sapiens	Residual Activity	%	70.0
	12259549	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	-1.0	CHEMBL3906	Homo sapiens	Residual Activity	%	-1.0
	12259550	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	5.0	CHEMBL3906	Homo sapiens	Residual Activity	%	5.0
	12259551	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	94.0	CHEMBL3906	Homo sapiens	Residual Activity	%	94.0
	12259552	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	22.0	CHEMBL3906	Homo sapiens	Residual Activity	%	22.0
	12259553	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	112.0	CHEMBL3906	Homo sapiens	Residual Activity	%	112.0
	12259554	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	27.0	CHEMBL3906	Homo sapiens	Residual Activity	%	27.0
	12259555	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	4.0	CHEMBL3906	Homo sapiens	Residual Activity	%	4.0
	12259556	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	77.0	CHEMBL3906	Homo sapiens	Residual Activity	%	77.0
	12259557	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	2.0	CHEMBL3906	Homo sapiens	Residual Activity	%	2.0
	12259558	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	28.0	CHEMBL3906	Homo sapiens	Residual Activity	%	28.0
	12259559	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	63.0	CHEMBL3906	Homo sapiens	Residual Activity	%	63.0
	12259560	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	48.0	CHEMBL3906	Homo sapiens	Residual Activity	%	48.0
	12259561	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	13.0	CHEMBL3906	Homo sapiens	Residual Activity	%	13.0
	12259562	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	55.0	CHEMBL3906	Homo sapiens	Residual Activity	%	55.0
	12259563	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	50.0	CHEMBL3906	Homo sapiens	Residual Activity	%	50.0
	12259564	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	103.0	CHEMBL3906	Homo sapiens	Residual Activity	%	103.0
	12259565	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	47.0	CHEMBL3906	Homo sapiens	Residual Activity	%	47.0
	12259566	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	34.0	CHEMBL3906	Homo sapiens	Residual Activity	%	34.0
	12259567	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	51.0	CHEMBL3906	Homo sapiens	Residual Activity	%	51.0
	12259568	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	17.0	CHEMBL3906	Homo sapiens	Residual Activity	%	17.0
	12259569	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	93.0	CHEMBL3906	Homo sapiens	Residual Activity	%	93.0
	12259570	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	4.0	CHEMBL3906	Homo sapiens	Residual Activity	%	4.0
	12259571	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	107.0	CHEMBL3906	Homo sapiens	Residual Activity	%	107.0
	12259572	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	102.0	CHEMBL3906	Homo sapiens	Residual Activity	%	102.0
	12259573	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	55.0	CHEMBL3906	Homo sapiens	Residual Activity	%	55.0
	12259574	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	111.0	CHEMBL3906	Homo sapiens	Residual Activity	%	111.0
	12259575	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	65.0	CHEMBL3906	Homo sapiens	Residual Activity	%	65.0
	12259576	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	68.0	CHEMBL3906	Homo sapiens	Residual Activity	%	68.0
	12259577	CHEMBL2219168	Millipore: Percentage of residual kinase activity of RPS6KA2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	0.0	CHEMBL3906	Homo sapiens	Residual Activity	%	0.0
	12660668	CHEMBL2330655	Inhibition of RSK3 (unknown origin) at 1 uM	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Inhibition	%	75.0	CHEMBL3906	Homo sapiens	INH	%	75.0
	12693169	CHEMBL2345772	Inhibition of RSK3 (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	10000.0	CHEMBL3906	Homo sapiens	IC50	nM	10000.0
	12727654	CHEMBL2351118	Inhibition of RSK3 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	88.0	CHEMBL3906	Homo sapiens	Activity	%	88.0
	12728940	CHEMBL2352839	Inhibition of RSK3 (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	104.0	CHEMBL3906	Homo sapiens	Activity	%	104.0
	12729827	CHEMBL2352160	Inhibition of RSK3 (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	97.0	CHEMBL3906	Homo sapiens	Activity	%	97.0
	12730083	CHEMBL2351118	Inhibition of RSK3 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	94.0	CHEMBL3906	Homo sapiens	Activity	%	94.0
	13315789	CHEMBL2389254	Inhibition of RSK3 (unknown origin) at 100 x Ki relative to control	B	N#Cc1cc(F)c(C(=O)Nc2ccnc(NC(=O)[C@H]3C[C@H]3F)c2)c(Cl)c1		CHEMBL2387223	>	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	13315802	CHEMBL2389263	Inhibition of RSK3 (unknown origin) at 180 nM relative to control	B	N#Cc1cc(Cl)c(C(=O)Nc2ccnc(NC(=O)C3CC3)c2)c(Cl)c1		CHEMBL2387124	=	Inhibition	%	80.0	CHEMBL3906	Homo sapiens	INH	%	80.0
	13374356	CHEMBL2406301	Inhibition of RSK3 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	1.0	CHEMBL3906	Homo sapiens	INH	%	1.0
	13419769	CHEMBL2422289	Inhibition of RSK3 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCC3(CCN(c4ncnc5[nH]cnc45)CC3)NC2)cc1		CHEMBL2420901	=	Inhibition	%	57.0	CHEMBL3906	Homo sapiens	INH	%	57.0
	13419770	CHEMBL2422289	Inhibition of RSK3 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(CC2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420900	=	Inhibition	%	91.0	CHEMBL3906	Homo sapiens	INH	%	91.0
	13419771	CHEMBL2422289	Inhibition of RSK3 (unknown origin) at 30 uM by microfluidic mobility shift assay relative to control	B	c1ccc(C2CCNC3(CCN(c4ncnc5[nH]cnc45)CC3)C2)cc1		CHEMBL2420899	=	Inhibition	%	81.0	CHEMBL3906	Homo sapiens	INH	%	81.0
	13439758	CHEMBL2428999	Competitive binding affinity to RPS6KA2 kinase domain 2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	13439929	CHEMBL2429472	Competitive binding affinity to RPS6KA2 kinase domain 1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	13445439	CHEMBL2429472	Competitive binding affinity to RPS6KA2 kinase domain 1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	=	Inhibition	%	99.0	CHEMBL3906	Homo sapiens	INH	%	99.0
	13445591	CHEMBL2428999	Competitive binding affinity to RPS6KA2 kinase domain 2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	13448494	CHEMBL2429472	Competitive binding affinity to RPS6KA2 kinase domain 1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	=	Inhibition	%	73.0	CHEMBL3906	Homo sapiens	INH	%	73.0
	13448630	CHEMBL2429472	Competitive binding affinity to RPS6KA2 kinase domain 1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O=C([C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1)N1CCOCC1		CHEMBL2425649	=	Inhibition	%	100.0	CHEMBL3906	Homo sapiens	INH	%	100.0
	13451425	CHEMBL2429472	Competitive binding affinity to RPS6KA2 kinase domain 1 (unknown origin) at 10 uM in presence of ATP relative to control	B	N[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425652	=	Inhibition	%	91.0	CHEMBL3906	Homo sapiens	INH	%	91.0
	13451578	CHEMBL2428999	Competitive binding affinity to RPS6KA2 kinase domain 2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	=	Inhibition	%	87.0	CHEMBL3906	Homo sapiens	INH	%	87.0
	13454610	CHEMBL2429472	Competitive binding affinity to RPS6KA2 kinase domain 1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	=	Inhibition	%	95.0	CHEMBL3906	Homo sapiens	INH	%	95.0
	13871751	CHEMBL3100916	Inhibition of human Rsk3 assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	72.0	CHEMBL3906	Homo sapiens	Activity	%	72.0
	13928579	CHEMBL3124204	Inhibition of RSK3 (unknown origin) at 0.1 uM relative to control	B	CNc1nc(Nc2cn(C(C)(C)C#N)nc2C)ncc1C(F)(F)F		CHEMBL3122113	=	Inhibition	%	68.0	CHEMBL3906	Homo sapiens	INH	%	68.0
	13966051	CHEMBL3136667	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 1000 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1cnc2[nH]ccc2c1		CHEMBL389685	=	Inhibition	%	71.0	CHEMBL3906	Homo sapiens	INH	%	71.0
	13973326	CHEMBL3135064	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.1 uM after 90 mins by microfluidic peptide phosphorylation assay	B	C[C@H](CN(C)C)Oc1nc(Nc2cc3cccc(Cl)c3cn2)cnc1C#N		CHEMBL1928705	=	Inhibition	%	60.5	CHEMBL3906	Homo sapiens	INH	%	60.5
	13974044	CHEMBL3136636	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.35 uM after 90 mins by microfluidic peptide phosphorylation assay	B	COC(=O)c1cnc(Nc2cnc(C#N)cn2)cc1NCC1CCNCC1		CHEMBL1928692	=	Inhibition	%	44.0	CHEMBL3906	Homo sapiens	INH	%	44.0
	13974135	CHEMBL3136349	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 9 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]c4cnccc4c23)CCO1		CHEMBL1928677	=	Inhibition	%	95.5	CHEMBL3906	Homo sapiens	INH	%	95.5
	13974226	CHEMBL3135451	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 90 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CN(c2ncnc3[nH]cnc23)CCO1		CHEMBL560373	=	Inhibition	%	100.0	CHEMBL3906	Homo sapiens	INH	%	100.0
	13974964	CHEMBL3136986	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 420 uM after 90 mins by microfluidic peptide phosphorylation assay	B	c1nc(N2CCOCC2)c2nc[nH]c2n1		CHEMBL271138	=	Inhibition	%	98.0	CHEMBL3906	Homo sapiens	INH	%	98.0
	13975055	CHEMBL3136133	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.02 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	Inhibition	%	2.5	CHEMBL3906	Homo sapiens	INH	%	2.5
	13975146	CHEMBL3134751	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.06 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	Inhibition	%	0.0	CHEMBL3906	Homo sapiens	INH	%	0.0
	13975237	CHEMBL3136518	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL259141	=	Inhibition	%	0.0	CHEMBL3906	Homo sapiens	INH	%	0.0
	13975880	CHEMBL3135651	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 8 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCC1CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL261249	=	Inhibition	%	28.0	CHEMBL3906	Homo sapiens	INH	%	28.0
	13975973	CHEMBL3136170	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 0.2 uM after 90 mins by microfluidic peptide phosphorylation assay	B	Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1		CHEMBL228133	=	Inhibition	%	40.0	CHEMBL3906	Homo sapiens	INH	%	40.0
	13976064	CHEMBL3136048	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 95 uM after 90 mins by microfluidic peptide phosphorylation assay	B	NCCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL227727	=	Inhibition	%	89.0	CHEMBL3906	Homo sapiens	INH	%	89.0
	13976155	CHEMBL3135092	Inhibition of human full length RSK3 expressed in baculovirus assessed as substrate phosphorylation using fluorescence-labelled peptides as substrate at 70 uM after 90 mins by microfluidic peptide phosphorylation assay	B	CNCc1ccc(-c2ncnc3[nH]cnc23)cc1		CHEMBL376388	=	Inhibition	%	81.0	CHEMBL3906	Homo sapiens	INH	%	81.0
	14585326	CHEMBL3241842	Inhibition of human Rsk3 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	87.0	CHEMBL3906	Homo sapiens	Activity	%	87.0
	14664314	CHEMBL3271264	Inhibition of RPS6KA5 (unknown origin) at 1 uM relative to control	B	CCOC(=O)c1sc(-c2ccncc2)nc1O		CHEMBL3261228	=	Inhibition	%	100.0	CHEMBL3906	Homo sapiens	INH	%	100.0
	14664315	CHEMBL3271264	Inhibition of RPS6KA5 (unknown origin) at 1 uM relative to control	B	NC(=O)c1sc(-c2ccnc(N)n2)nc1-c1ccc(Cl)cc1Cl		CHEMBL3261514	=	Inhibition	%	100.0	CHEMBL3906	Homo sapiens	INH	%	100.0
	14664316	CHEMBL3271264	Inhibition of RPS6KA5 (unknown origin) at 1 uM relative to control	B	COc1ccc(-c2nc(-c3ccnc(N)n3)sc2C(N)=O)c(Cl)c1		CHEMBL3261517	=	Inhibition	%	100.0	CHEMBL3906	Homo sapiens	INH	%	100.0
	15018692	CHEMBL3369192	Inhibition of RSK3 (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	11.2	CHEMBL3906	Homo sapiens	INH	%	11.2
	15035050	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(Nc2nc3cccc(-c4cccc5[nH]cnc45)c3o2)cc(OC)c1OC		CHEMBL3298194	=	IC50	nM	4.0	CHEMBL3906	Homo sapiens	IC50	uM	0.004
	15035051	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1ccc(Nc2nc3cccc(-c4c(F)cccc4OC)c3o2)cc1O[C@H]1CCNC1		CHEMBL3297951	=	IC50	nM	10.0	CHEMBL3906	Homo sapiens	IC50	uM	0.01
	15035052	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(Nc2nc3cccc(-c4c(F)cccc4OC)c3o2)cc(OC)c1OC		CHEMBL3297945	=	IC50	nM	20.0	CHEMBL3906	Homo sapiens	IC50	uM	0.02
	15035053	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1ccccc1-c1cccc2nc(Nc3cc(OC)c(OC)c(OC)c3)oc12		CHEMBL3298039	=	IC50	nM	20.0	CHEMBL3906	Homo sapiens	IC50	uM	0.02
	15035054	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1ccc(F)cc1-c1cccc2nc(Nc3cc(OC)c(OC)c(OC)c3)oc12		CHEMBL3298045	=	IC50	nM	40.0	CHEMBL3906	Homo sapiens	IC50	uM	0.04
	15035055	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(C)ccc1-c1cccc2nc(Nc3cc(OC)c(OC)c(OC)c3)oc12		CHEMBL3298046	=	IC50	nM	40.0	CHEMBL3906	Homo sapiens	IC50	uM	0.04
	15035056	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(Nc2nc3cccc(-c4cccc5cn[nH]c45)c3o2)cc(OC)c1OC		CHEMBL3298193	=	IC50	nM	50.0	CHEMBL3906	Homo sapiens	IC50	uM	0.05
	15035057	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1ccc(Nc2nc3cccc(-c4c(F)cccc4OC)c3o2)cc1OC		CHEMBL3297948	=	IC50	nM	70.0	CHEMBL3906	Homo sapiens	IC50	uM	0.07
	15035058	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(Nc2nc3cccc(-c4c(F)cccc4OC)c3o2)cc(OC)c1		CHEMBL3297947	=	IC50	nM	210.0	CHEMBL3906	Homo sapiens	IC50	uM	0.21
	15035059	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1ccc(Nc2nc3cccc(-c4c(F)cccc4OC)c3o2)cc1N		CHEMBL3297950	=	IC50	nM	220.0	CHEMBL3906	Homo sapiens	IC50	uM	0.22
	15035060	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(Nc2nc3cccc(-c4ccccc4F)c3o2)cc(OC)c1OC		CHEMBL3298040	=	IC50	nM	220.0	CHEMBL3906	Homo sapiens	IC50	uM	0.22
	15035061	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cccc(F)c1-c1cccc2nc(Nc3cccc(S(N)(=O)=O)c3)oc12		CHEMBL3297949	=	IC50	nM	340.0	CHEMBL3906	Homo sapiens	IC50	uM	0.34
	15035062	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cccc(Nc2nc3cccc(-c4c(F)cccc4OC)c3o2)c1		CHEMBL3297840	=	IC50	nM	410.0	CHEMBL3906	Homo sapiens	IC50	uM	0.41
	15035064	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	CCOc1cccc(F)c1-c1cccc2nc(Nc3cc(OC)c(OC)c(OC)c3)oc12		CHEMBL3298042	=	IC50	nM	490.0	CHEMBL3906	Homo sapiens	IC50	uM	0.49
	15035065	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(Nc2nc3cccc(-c4nc(C)[nH]c4C)c3o2)cc(OC)c1OC		CHEMBL3298192	=	IC50	nM	560.0	CHEMBL3906	Homo sapiens	IC50	uM	0.56
	15035068	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cccc(F)c1-c1cccc2nc(NC3CCCCC3)oc12		CHEMBL3297843	=	IC50	nM	620.0	CHEMBL3906	Homo sapiens	IC50	uM	0.62
	15035069	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cccc(Nc2nc3cccc(-c4c(F)cccc4OC)c3o2)n1		CHEMBL3297845	=	IC50	nM	620.0	CHEMBL3906	Homo sapiens	IC50	uM	0.62
	15035070	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	CCOc1cccc(Nc2nc3cccc(-c4c(F)cccc4OC)c3o2)c1		CHEMBL3297846	=	IC50	nM	730.0	CHEMBL3906	Homo sapiens	IC50	uM	0.73
	15035072	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(Nc2nc3cccc(-c4c(F)cccc4OC(C)C)c3o2)cc(OC)c1OC		CHEMBL3298043	=	IC50	nM	970.0	CHEMBL3906	Homo sapiens	IC50	uM	0.97
	15035073	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cccc(F)c1-c1cccc2nc(Nc3ccccc3)oc12		CHEMBL3297842	=	IC50	nM	1000.0	CHEMBL3906	Homo sapiens	IC50	uM	1.0
	15035074	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1ccc(C)cc1-c1cccc2nc(Nc3cc(OC)c(OC)c(OC)c3)oc12		CHEMBL3298047	=	IC50	nM	1100.0	CHEMBL3906	Homo sapiens	IC50	uM	1.1
	15035075	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(Nc2nc3cccc(-c4c(OC)cccc4OC)c3o2)cc(OC)c1OC		CHEMBL3298044	=	IC50	nM	1200.0	CHEMBL3906	Homo sapiens	IC50	uM	1.2
	15035076	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1ccc(Nc2nc3cccc(-c4c(F)cccc4OC)c3o2)cc1		CHEMBL3297946	=	IC50	nM	1400.0	CHEMBL3906	Homo sapiens	IC50	uM	1.4
	15035078	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cccc(F)c1-c1cccc2nc(N)oc12		CHEMBL3297841	=	IC50	nM	2800.0	CHEMBL3906	Homo sapiens	IC50	uM	2.8
	15035079	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cccc(F)c1-c1cccc2nc(NC3CCOCC3)oc12		CHEMBL3297844	=	IC50	nM	3200.0	CHEMBL3906	Homo sapiens	IC50	uM	3.2
	15035081	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(Nc2nc3cccc(-c4ccccc4OC(F)(F)F)c3o2)cc(OC)c1OC		CHEMBL3298041	=	IC50	nM	4000.0	CHEMBL3906	Homo sapiens	IC50	uM	4.0
	15035086	CHEMBL3368764	Inhibition of recombinant full length RSK2 (unknown origin) using biotin-AGAGRSRHSSYPAGT-OH as substrate after 150 mins	B	COc1cc(Nc2nc3cccc(-c4ccccc4-c4cn[nH]c4)c3o2)cc(OC)c1OC		CHEMBL3298191	=	IC50	nM	9300.0	CHEMBL3906	Homo sapiens	IC50	uM	9.3
	15058838	CHEMBL3371392	Inhibition of RPS6KA2 (unknown origin) assessed as residual activity at 1 uM by radiometric protein kinase assay	B	COc1cc(-c2c[nH]c(=O)c(-c3cc(OC)c(OC)c(OC)c3)n2)ccc1O		CHEMBL3358999	=	Activity	%	33.0	CHEMBL3906	Homo sapiens	Activity	%	33.0
	15104858	CHEMBL3386816	Inhibition of RSK3 (KD 1-N-terminal domain) (unknown origin) assessed as residual enzyme activity at 10 uM	B	O=C(Nc1nc2cc3c(cc2[nH]1)OC(F)(F)O3)c1csc(NC(=O)c2ccccc2OC(F)(F)F)n1		CHEMBL3337845	=	Activity	%	26.0	CHEMBL3906	Homo sapiens	Activity	%	26.0
	15650166	CHEMBL3595486	Inhibition of human RSK3 at 0.1 uM relative to control	B	CCc1cc(NC(=O)Nc2ccc(-c3cnc(Nc4cc(N5CCN(CC)CC5)nc(C)n4)s3)cc2)no1		CHEMBL3593290	=	Inhibition	%	7.0	CHEMBL3906	Homo sapiens	INH	%	7.0
	15651990	CHEMBL3595331	Inhibition of recombinant human RSK3 at 1 uM relative to control	B	C[C@H]1CN(C)C(=O)[C@@H]1c1cc(Nc2ccnc(N(C)C[C@H]3CC[C@H](N)CC3)n2)n[nH]1		CHEMBL3594181	<	Inhibition	%	75.0	CHEMBL3906	Homo sapiens	INH	%	75.0
	15684366	CHEMBL3607888	Binding affinity to DNA-tagged RSK3 N-terminal kinase domain (unknown origin) assessed as level of protein captured on solid support at 10 uM by qPCR analysis relative to control	B	Oc1c(F)cc(-c2cnccc2-c2ccc(N3CCOCC3)cc2)cc1F		CHEMBL3604794	=	Activity	%	0.05	CHEMBL3906	Homo sapiens	Activity	%	0.05
	15756821	CHEMBL3631465	Inhibition of RSK3 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	53.39	CHEMBL3906	Homo sapiens	INH	%	53.39
	15757902	CHEMBL3631465	Inhibition of RSK3 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	67.55	CHEMBL3906	Homo sapiens	INH	%	67.55
	15758881	CHEMBL3631465	Inhibition of RSK3 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	11.15	CHEMBL3906	Homo sapiens	INH	%	11.15
	16425275	CHEMBL3751109	Inhibition of Rsk3 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	-0.6	CHEMBL3906	Homo sapiens	INH	%	-0.6
	16431997	CHEMBL3750036	Inhibition of human RSK3 using [KKLNRTLSVA] as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL3906	Homo sapiens	IC50	uM	10.0
	16451601	CHEMBL3761182	Inhibition of RSK3 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	7.4	CHEMBL3906	Homo sapiens	INH	%	7.4
	16495217	CHEMBL3777759	Inhibition of N-terminal His6-tagged recombinant human RSK3 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	-5.0	CHEMBL3906	Homo sapiens	Activity	%	-5.0
	16496136	CHEMBL3777759	Inhibition of N-terminal His6-tagged recombinant human RSK3 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	2.0	CHEMBL3906	Homo sapiens	Activity	%	2.0
	16508926	CHEMBL3777759	Inhibition of N-terminal His6-tagged recombinant human RSK3 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	-5.0	CHEMBL3906	Homo sapiens	Activity	%	-5.0
Not Active	16515654	CHEMBL3782395	Inhibition of N-terminal partial length human RSK2 kinase domain 1 expressed in mammalian system at 1 uM	B	Cc1cnc(N)nc1OCC(C)(C)CO		CHEMBL3780032		Inhibition	%		CHEMBL3906	Homo sapiens	INH		
	16518889	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3ccc(NC(=O)c4ccccc4)cc3C2=O)cc1		CHEMBL3780464	=	Inhibition	%	82.0	CHEMBL3906	Homo sapiens	INH	%	82.0
	16518890	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3cccc(NC(=O)c4ccccc4)c3C2=O)cc1		CHEMBL3780363	=	Inhibition	%	99.51	CHEMBL3906	Homo sapiens	INH	%	99.51
	16518891	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3ccc(N)cc3C2=O)cc1		CHEMBL3780594	=	Inhibition	%	109.1	CHEMBL3906	Homo sapiens	INH	%	109.1
	16518892	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3cccc(N)c3C2=O)cc1		CHEMBL3780920	=	Inhibition	%	95.64	CHEMBL3906	Homo sapiens	INH	%	95.64
	16518893	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	CCOc1ccc(NCN2C(=O)c3ccc([N+](=O)[O-])cc3C2=O)cc1		CHEMBL3780942	=	Inhibition	%	86.96	CHEMBL3906	Homo sapiens	INH	%	86.96
	16518894	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	Cc1ccc(NCN2C(=O)c3ccc([N+](=O)[O-])cc3C2=O)cc1		CHEMBL3781591	=	Inhibition	%	35.69	CHEMBL3906	Homo sapiens	INH	%	35.69
	16518895	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(N(CN2C(=O)c3ccccc3C2=O)C(C)=O)cc1		CHEMBL3781611	=	Inhibition	%	17.17	CHEMBL3906	Homo sapiens	INH	%	17.17
	16518896	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(N(C)CN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3780055	=	Inhibition	%	86.99	CHEMBL3906	Homo sapiens	INH	%	86.99
	16518897	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccc(N2CCOCC2)cc1		CHEMBL1775068	=	Inhibition	%	101.43	CHEMBL3906	Homo sapiens	INH	%	101.43
	16518898	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	CCN(CC)c1ccc(NCN2C(=O)c3ccccc3C2=O)c(C)c1		CHEMBL3781117	=	Inhibition	%	81.04	CHEMBL3906	Homo sapiens	INH	%	81.04
	16518899	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	CCOc1ccc(NCN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3780949	=	Inhibition	%	100.12	CHEMBL3906	Homo sapiens	INH	%	100.12
	16518900	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccc(O)cc1		CHEMBL3779994	=	Inhibition	%	100.92	CHEMBL3906	Homo sapiens	INH	%	100.92
	16518901	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccc(OC(F)(F)F)cc1		CHEMBL3780433	=	Inhibition	%	28.05	CHEMBL3906	Homo sapiens	INH	%	28.05
	16518902	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3781731	=	Inhibition	%	97.19	CHEMBL3906	Homo sapiens	INH	%	97.19
	16518903	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	CC(C)c1ccc(NCN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3780859	=	Inhibition	%	46.54	CHEMBL3906	Homo sapiens	INH	%	46.54
	16518904	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	CCc1ccc(NCN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3781064	=	Inhibition	%	62.99	CHEMBL3906	Homo sapiens	INH	%	62.99
	16518905	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	Cc1ccc(NCN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3781760	=	Inhibition	%	54.0	CHEMBL3906	Homo sapiens	INH	%	54.0
	16518906	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccc(Cl)cc1		CHEMBL3781291	=	Inhibition	%	8.52	CHEMBL3906	Homo sapiens	INH	%	8.52
	16518907	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccc(F)cc1		CHEMBL3780781	=	Inhibition	%	56.66	CHEMBL3906	Homo sapiens	INH	%	56.66
	16518908	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccccc1		CHEMBL38326	=	Inhibition	%	43.57	CHEMBL3906	Homo sapiens	INH	%	43.57
	16518909	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL6291	=	IC50	nM	10.0	CHEMBL3906	Homo sapiens	IC50	uM	0.01
Not Determined	16518910	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3ccc(NC(=O)Nc4ccccc4)cc3C2=O)cc1		CHEMBL3780618		IC50			CHEMBL3906	Homo sapiens	IC50		
	16518911	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	O=C(Nc1ccc2c(c1)C(=O)N(CNc1ccc(N3CCOCC3)cc1)C2=O)c1ccccc1		CHEMBL3781068	=	IC50	nM	1010.0	CHEMBL3906	Homo sapiens	IC50	uM	1.01
	16518912	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	CCOc1ccc(NCN2C(=O)c3ccc(NC(=O)c4ccccc4)cc3C2=O)cc1		CHEMBL3781690	=	IC50	nM	4580.0	CHEMBL3906	Homo sapiens	IC50	uM	4.58
	16518913	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	CCOc1ccc(NCN2C(=O)c3cccc(NC(=O)c4ccccc4)c3C2=O)cc1		CHEMBL3781355	=	IC50	nM	1340.0	CHEMBL3906	Homo sapiens	IC50	uM	1.34
	16518914	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3ccc(NC(=O)c4ccccc4)cc3C2=O)cc1		CHEMBL3780464	=	IC50	nM	2160.0	CHEMBL3906	Homo sapiens	IC50	uM	2.16
	16518915	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3cccc(NC(=O)c4ccccc4)c3C2=O)cc1		CHEMBL3780363	=	IC50	nM	990.0	CHEMBL3906	Homo sapiens	IC50	uM	0.99
	16518916	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3ccc(N)cc3C2=O)cc1		CHEMBL3780594	=	IC50	nM	590.0	CHEMBL3906	Homo sapiens	IC50	uM	0.59
	16518917	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3cccc(N)c3C2=O)cc1		CHEMBL3780920	=	IC50	nM	3530.0	CHEMBL3906	Homo sapiens	IC50	uM	3.53
	16518918	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	CCOc1ccc(NCN2C(=O)c3ccc([N+](=O)[O-])cc3C2=O)cc1		CHEMBL3780942	=	IC50	nM	2830.0	CHEMBL3906	Homo sapiens	IC50	uM	2.83
Not Determined	16518919	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	Cc1ccc(NCN2C(=O)c3ccc([N+](=O)[O-])cc3C2=O)cc1		CHEMBL3781591		IC50			CHEMBL3906	Homo sapiens	IC50		
Not Determined	16518920	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(N(CN2C(=O)c3ccccc3C2=O)C(C)=O)cc1		CHEMBL3781611		IC50			CHEMBL3906	Homo sapiens	IC50		
	16518921	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(N(C)CN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3780055	=	IC50	nM	3500.0	CHEMBL3906	Homo sapiens	IC50	uM	3.5
	16518922	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccc(N2CCOCC2)cc1		CHEMBL1775068	=	IC50	nM	790.0	CHEMBL3906	Homo sapiens	IC50	uM	0.79
	16518923	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	CCN(CC)c1ccc(NCN2C(=O)c3ccccc3C2=O)c(C)c1		CHEMBL3781117	=	IC50	nM	860.0	CHEMBL3906	Homo sapiens	IC50	uM	0.86
	16518924	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	CCOc1ccc(NCN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3780949	=	IC50	nM	590.0	CHEMBL3906	Homo sapiens	IC50	uM	0.59
	16518925	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccc(O)cc1		CHEMBL3779994	=	IC50	nM	520.0	CHEMBL3906	Homo sapiens	IC50	uM	0.52
Not Determined	16518926	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccc(OC(F)(F)F)cc1		CHEMBL3780433		IC50			CHEMBL3906	Homo sapiens	IC50		
	16518927	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3781731	=	IC50	nM	470.0	CHEMBL3906	Homo sapiens	IC50	uM	0.47
Not Determined	16518928	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	CC(C)c1ccc(NCN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3780859		IC50			CHEMBL3906	Homo sapiens	IC50		
	16518929	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	CCc1ccc(NCN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3781064	=	IC50	nM	4310.0	CHEMBL3906	Homo sapiens	IC50	uM	4.31
	16518930	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	Cc1ccc(NCN2C(=O)c3ccccc3C2=O)cc1		CHEMBL3781760	=	IC50	nM	4300.0	CHEMBL3906	Homo sapiens	IC50	uM	4.3
Not Determined	16518931	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccc(Cl)cc1		CHEMBL3781291		IC50			CHEMBL3906	Homo sapiens	IC50		
	16518932	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccc(F)cc1		CHEMBL3780781	=	IC50	nM	8740.0	CHEMBL3906	Homo sapiens	IC50	uM	8.74
Not Determined	16518933	CHEMBL3783584	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 using S6 peptide after 20 mins by fluorescence assay	B	O=C1c2ccccc2C(=O)N1CNc1ccccc1		CHEMBL38326		IC50			CHEMBL3906	Homo sapiens	IC50		
	16518934	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	Cn1cc(C2=C(c3cn(CCCSC(=N)N)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL6291	=	Inhibition	%	98.21	CHEMBL3906	Homo sapiens	INH	%	98.21
	16518935	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	COc1ccc(NCN2C(=O)c3ccc(NC(=O)Nc4ccccc4)cc3C2=O)cc1		CHEMBL3780618	=	Inhibition	%	34.79	CHEMBL3906	Homo sapiens	INH	%	34.79
	16518936	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	O=C(Nc1ccc2c(c1)C(=O)N(CNc1ccc(N3CCOCC3)cc1)C2=O)c1ccccc1		CHEMBL3781068	=	Inhibition	%	102.51	CHEMBL3906	Homo sapiens	INH	%	102.51
	16518937	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	CCOc1ccc(NCN2C(=O)c3ccc(NC(=O)c4ccccc4)cc3C2=O)cc1		CHEMBL3781690	=	Inhibition	%	69.47	CHEMBL3906	Homo sapiens	INH	%	69.47
	16518938	CHEMBL3783583	Inhibition of N-terminal His6 tagged full-length human recombinant active RSK2 at 10 uM using S6 peptide after 20 mins by fluorescence assay	B	CCOc1ccc(NCN2C(=O)c3cccc(NC(=O)c4ccccc4)c3C2=O)cc1		CHEMBL3781355	=	Inhibition	%	105.41	CHEMBL3906	Homo sapiens	INH	%	105.41
	16518939	CHEMBL3783586	Inhibition of His6-tagged RSK2 c-terminal domain (415 to 740 residues) (unknown origin) expressed in Escherichia coli using CTD-tide as substrate after 20 mins by standard disk phosphocellulose assay	B	Cc1ccc(-c2c(C(=O)CF)n(CCCO)c3ncnc(N(C)C)c23)cc1		CHEMBL3779984	=	IC50	nM	15.0	CHEMBL3906	Homo sapiens	IC50	nM	15.0
	16594840	CHEMBL3812897	Inhibition of human RSK2 Kin.Dom.1-N-terminal (1 to 394 amino acid residues) assessed as enzyme activity at 10 uM by KINOMEScan assay	B	O=C1C2=C(C(=O)c3c(O)ccc(O)c31)[C@@H](O)[C@@H](O)[C@@H](O)C2		CHEMBL1987813	=	Activity	%	53.0	CHEMBL3906	Homo sapiens	Activity	%	53.0
	16618649	CHEMBL3816526	Inhibition of full length recombinant human His-tagged RSK2 expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	16619695	CHEMBL3820362	Inhibition of recombinant human full length His-tagged RSK2 expressed in Baculovirus at 1 uM relative to control	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Inhibition	%	75.0	CHEMBL3906	Homo sapiens	INH	%	75.0
	16627574	CHEMBL3820504	Inhibition of full length recombinant human N-terminal His6-tagged RSK2 expressed in baculovirus infected Sf21 cells at 1 uM by radiometric assay relative to control	B	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Oc4ccccc4)nc23)ccc1C(=O)NC1CC1	Outside typical range	CHEMBL3819210	=	Inhibition	%	-18.0	CHEMBL3906	Homo sapiens	INH	%	-18.0
	16627575	CHEMBL3820504	Inhibition of full length recombinant human N-terminal His6-tagged RSK2 expressed in baculovirus infected Sf21 cells at 1 uM by radiometric assay relative to control	B	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4CC(O)C5)cc3)c2c1		CHEMBL3818239	=	Inhibition	%	15.0	CHEMBL3906	Homo sapiens	INH	%	15.0
	16654175	CHEMBL3830960	Inhibition of human RSK2 assessed as remaining enzyme activity at 50 uM after 30 mins by 33P-ATP filter-binding assay	B	Cc1cc(=O)c2c(O)cc(O)c([C@H]3CCN(C)C[C@H]3O)c2o1		CHEMBL1077604	=	Activity	%	45.0	CHEMBL3906	Homo sapiens	Activity	%	45.0
332391	17710739	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cccc(Cl)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938783	=	IC50	nM	270.0	CHEMBL3906	Homo sapiens	IC50	nM	270.0
332392	17710740	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)no1		CHEMBL3985216	=	IC50	nM	30.0	CHEMBL3906	Homo sapiens	IC50	nM	30.0
332393	17710741	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(C)c1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)sn1		CHEMBL3912005	=	IC50	nM	240.0	CHEMBL3906	Homo sapiens	IC50	nM	240.0
332394	17710742	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ccc(Cl)cc1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938782	=	IC50	nM	190.0	CHEMBL3906	Homo sapiens	IC50	nM	190.0
332395	17710743	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ccc2ccccc2n1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938800	=	IC50	nM	70.0	CHEMBL3906	Homo sapiens	IC50	nM	70.0
332396	17710744	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	N#Cc1cccc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)c1		CHEMBL3905379	=	IC50	nM	140.0	CHEMBL3906	Homo sapiens	IC50	nM	140.0
332397	17710745	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cccc(N2CCOCC2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3966940	=	IC50	nM	60.0	CHEMBL3906	Homo sapiens	IC50	nM	60.0
332398	17710746	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cccc(Oc2ccccc2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3948994	=	IC50	nM	900.0	CHEMBL3906	Homo sapiens	IC50	nM	900.0
332399	17710747	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1(C)CNC(=O)c2cc3ccc(C(=O)Nc4cccnc4)cc3n2C1		CHEMBL1938768	=	IC50	nM	4600.0	CHEMBL3906	Homo sapiens	IC50	nM	4600.0
332400	17710748	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CCNC(=O)c2cc3ccc(C(=O)Nc4cccnc4)cc3n21		CHEMBL1938765	=	IC50	nM	41.0	CHEMBL3906	Homo sapiens	IC50	nM	41.0
332401	17710749	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1ccc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)n1		CHEMBL1938795	=	IC50	nM	540.0	CHEMBL3906	Homo sapiens	IC50	nM	540.0
332402	17710750	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ccn(Cc2ccc(F)cc2)n1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3952432	=	IC50	nM	220.0	CHEMBL3906	Homo sapiens	IC50	nM	220.0
332403	17710751	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1ccc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)n1		CHEMBL3916424	=	IC50	nM	1600.0	CHEMBL3906	Homo sapiens	IC50	nM	1600.0
332404	17710752	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ccn(-c2ccccc2)n1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3943709	=	IC50	nM	108.0	CHEMBL3906	Homo sapiens	IC50	nM	108.0
332405	17710753	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cn[nH]c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938794	=	IC50	nM	43.0	CHEMBL3906	Homo sapiens	IC50	nM	43.0
332406	17710754	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1(C)CNC(=O)c2cc3ccc(C(=O)Nc4cn[nH]c4)cc3n2C1		CHEMBL3967861	=	IC50	nM	2500.0	CHEMBL3906	Homo sapiens	IC50	nM	2500.0
332407	17710755	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CNC(=O)c2cc3ccc(C(=O)Nc4cn[nH]c4)cc3n2C1		CHEMBL3938307	=	IC50	nM	145.0	CHEMBL3906	Homo sapiens	IC50	nM	145.0
332408	17710756	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1ncc2cc(NC(=O)c3ccc4cc5n(c4c3)[C@@H](C)[C@@H](C)NC5=O)cnc21		CHEMBL4110640	=	IC50	nM	8.1	CHEMBL3906	Homo sapiens	IC50	nM	8.1
332409	17710757	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1ncc2cc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)cnc21		CHEMBL1938799	=	IC50	nM	53.0	CHEMBL3906	Homo sapiens	IC50	nM	53.0
332410	17710758	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1ncc2cc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)cnc21		CHEMBL3974341	=	IC50	nM	87.0	CHEMBL3906	Homo sapiens	IC50	nM	87.0
332411	17710759	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1[C@@H](C)NC(=O)c2cc3ccc(C(=O)Nc4cnn(C)c4)cc3n21		CHEMBL4108963	=	IC50	nM	4.3	CHEMBL3906	Homo sapiens	IC50	nM	4.3
332412	17710760	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CNC(=O)c2cc3ccc(C(=O)Nc4cnn(C)c4)cc3n21		CHEMBL3981684	=	IC50	nM	5.1	CHEMBL3906	Homo sapiens	IC50	nM	5.1
332413	17710761	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cn1		CHEMBL1933148	=	IC50	nM	11.0	CHEMBL3906	Homo sapiens	IC50	nM	11.0
332414	17710762	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1cc(NC(=O)c2ccc3cc4n(c3c2)CC2(CCC2)CNC4=O)cn1		CHEMBL3958165	=	IC50	nM	320.0	CHEMBL3906	Homo sapiens	IC50	nM	320.0
332415	17710763	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cn1		CHEMBL3892648	=	IC50	nM	14.0	CHEMBL3906	Homo sapiens	IC50	nM	14.0
332416	17710764	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(C2CCOC2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3969237	=	IC50	nM	27.0	CHEMBL3906	Homo sapiens	IC50	nM	27.0
332417	17710765	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(C2CCOCC2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3898040	=	IC50	nM	46.0	CHEMBL3906	Homo sapiens	IC50	nM	46.0
332418	17710766	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(C)cc(Cn2cc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)cn2)c1		CHEMBL3980724	=	IC50	nM	1.9	CHEMBL3906	Homo sapiens	IC50	nM	1.9
332419	17710767	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1[C@@H](C)NC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n21		CHEMBL4113926	=	IC50	nM	1.9	CHEMBL3906	Homo sapiens	IC50	nM	1.9
332420	17710768	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@@H]1NC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n2[C@H]1C		CHEMBL3891520	=	IC50	nM	10.0	CHEMBL3906	Homo sapiens	IC50	nM	10.0
332421	17710769	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(Cc2ccccc2)c1)c1ccc2cc3n(c2c1)CC1(CCOCC1)CNC3=O		CHEMBL3973806	=	IC50	nM	900.0	CHEMBL3906	Homo sapiens	IC50	nM	900.0
332422	17710770	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(Cc2ccccc2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3921354	=	IC50	nM	4.0	CHEMBL3906	Homo sapiens	IC50	nM	4.0
332423	17710771	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(CC2CCCCC2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1933149	=	IC50	nM	7.4	CHEMBL3906	Homo sapiens	IC50	nM	7.4
332424	17710772	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1ccccc1Cn1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cn1		CHEMBL3893357	=	IC50	nM	7.9	CHEMBL3906	Homo sapiens	IC50	nM	7.9
332425	17710773	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)CCn1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cn1		CHEMBL3923698	=	IC50	nM	11.0	CHEMBL3906	Homo sapiens	IC50	nM	11.0
332426	17710774	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cn1		CHEMBL3945349	=	IC50	nM	84.0	CHEMBL3906	Homo sapiens	IC50	nM	84.0
332427	17710775	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(CCN2CCOCC2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3965166	=	IC50	nM	84.0	CHEMBL3906	Homo sapiens	IC50	nM	84.0
332428	17710776	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	COCCn1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cn1		CHEMBL3978178	=	IC50	nM	19.0	CHEMBL3906	Homo sapiens	IC50	nM	19.0
332429	17710777	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1ccc2[nH]c(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)nc2c1		CHEMBL3916626	=	IC50	nM	3.0	CHEMBL3906	Homo sapiens	IC50	nM	3.0
332430	17710778	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2cc(C)ccc21		CHEMBL3941501	=	IC50	nM	4.8	CHEMBL3906	Homo sapiens	IC50	nM	4.8
332431	17710779	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	N#Cc1ccc2[nH]c(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)nc2c1		CHEMBL3912033	=	IC50	nM	4.9	CHEMBL3906	Homo sapiens	IC50	nM	4.9
332432	17710780	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)c1ccc2[nH]c(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)nc2c1		CHEMBL3954642	=	IC50	nM	6.2	CHEMBL3906	Homo sapiens	IC50	nM	6.2
332433	17710781	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2cc(C(F)(F)F)ccc2[nH]1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3937497	=	IC50	nM	24.0	CHEMBL3906	Homo sapiens	IC50	nM	24.0
332434	17710782	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN1CCN(c2ccc3[nH]c(NC(=O)c4ccc5cc6n(c5c4)CCCNC6=O)nc3c2)CC1		CHEMBL3917125	=	IC50	nM	2.6	CHEMBL3906	Homo sapiens	IC50	nM	2.6
332435	17710783	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCCS(=O)(=O)c1ccc2[nH]c(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)nc2c1		CHEMBL4110776	=	IC50	nM	3.6	CHEMBL3906	Homo sapiens	IC50	nM	3.6
332436	17710784	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2cc(Cl)cc(CN3CCOCC3)c2[nH]1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3936241	=	IC50	nM	8.7	CHEMBL3906	Homo sapiens	IC50	nM	8.7
332437	17710785	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2cc(Cl)ccc2[nH]1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3907067	=	IC50	nM	8.0	CHEMBL3906	Homo sapiens	IC50	nM	8.0
332438	17710786	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CCNC(=O)c2cc3ccc(C(=O)Nc4nc5cc(Cl)ccc5[nH]4)cc3n21		CHEMBL3946668	=	IC50	nM	2.5	CHEMBL3906	Homo sapiens	IC50	nM	2.5
332439	17710787	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2cc(Cl)ccc21		CHEMBL3920136	=	IC50	nM	26.0	CHEMBL3906	Homo sapiens	IC50	nM	26.0
332440	17710788	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1c(NC(=O)c2ccc3cc4n(c3c2)CC(C)(C)CNC4=O)nc2cc(Cl)ccc21		CHEMBL3922600	=	IC50	nM	34.0	CHEMBL3906	Homo sapiens	IC50	nM	34.0
332441	17710789	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2cc(F)ccc2[nH]1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3917267	=	IC50	nM	5.2	CHEMBL3906	Homo sapiens	IC50	nM	5.2
332442	17710790	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccc(Cl)cc21		CHEMBL3909410	=	IC50	nM	170.0	CHEMBL3906	Homo sapiens	IC50	nM	170.0
332443	17710791	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccc(Cl)cc21		CHEMBL1933285	=	IC50	nM	12.0	CHEMBL3906	Homo sapiens	IC50	nM	12.0
332444	17710792	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccc(Cl)cc21		CHEMBL1933286	=	IC50	nM	20.0	CHEMBL3906	Homo sapiens	IC50	nM	20.0
332445	17710793	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2ccccc2[nH]1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938803	=	IC50	nM	4.4	CHEMBL3906	Homo sapiens	IC50	nM	4.4
332446	17710794	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1(C)CNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5[nH]4)cc3n21		CHEMBL3985027	=	IC50	nM	0.89	CHEMBL3906	Homo sapiens	IC50	nM	0.89
332447	17710795	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5[nH]4)cc3n21		CHEMBL3959915	=	IC50	nM	0.59	CHEMBL3906	Homo sapiens	IC50	nM	0.59
332448	17710796	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CCNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5[nH]4)cc3n21		CHEMBL3951802	=	IC50	nM	0.77	CHEMBL3906	Homo sapiens	IC50	nM	0.77
332449	17710797	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1c(NC(=O)c2ccc3cc4n(c3c2)C(C)(C)CNC4=O)nc2ccccc21		CHEMBL3908561	=	IC50	nM	0.62	CHEMBL3906	Homo sapiens	IC50	nM	0.62
332450	17710798	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1c(NC(=O)c2ccc3cc4n(c3c2)CC(C)(C)CNC4=O)nc2ccccc21		CHEMBL3912727	=	IC50	nM	20.0	CHEMBL3906	Homo sapiens	IC50	nM	20.0
332451	17710799	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4C)cc3n21		CHEMBL3969149	=	IC50	nM	2.2	CHEMBL3906	Homo sapiens	IC50	nM	2.2
332452	17710800	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4C)cc3n2C1		CHEMBL3950889	=	IC50	nM	8.2	CHEMBL3906	Homo sapiens	IC50	nM	8.2
332453	17710801	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CCNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4C)cc3n21		CHEMBL3918100	=	IC50	nM	1.6	CHEMBL3906	Homo sapiens	IC50	nM	1.6
332454	17710802	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccccc21		CHEMBL1933279	=	IC50	nM	9.0	CHEMBL3906	Homo sapiens	IC50	nM	9.0
332455	17710803	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(C)n1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccccc21		CHEMBL3962101	=	IC50	nM	19.0	CHEMBL3906	Homo sapiens	IC50	nM	19.0
332456	17710804	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(CO)n1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccccc21		CHEMBL3896578	=	IC50	nM	610.0	CHEMBL3906	Homo sapiens	IC50	nM	610.0
332457	17710805	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1c(NC(=O)c2ccc3cc4n(c3c2)[C@@H](C)[C@@H](C)NC4=O)nc2ccccc21		CHEMBL4107750	=	IC50	nM	3.4	CHEMBL3906	Homo sapiens	IC50	nM	3.4
332458	17710806	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1c(NC(=O)c2ccc3cc4n(c3c2)[C@H](C)CNC4=O)nc2ccccc21		CHEMBL4109800	=	IC50	nM	1.9	CHEMBL3906	Homo sapiens	IC50	nM	1.9
332459	17710807	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1c(NC(=O)c2ccc3cc4n(c3c2)[C@@H](C)CNC4=O)nc2ccccc21		CHEMBL3898985	=	IC50	nM	21.0	CHEMBL3906	Homo sapiens	IC50	nM	21.0
332460	17710808	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1c(NC(=O)c2ccc3cc4n(c3c2)[C@@H](C)[C@@H](C)CNC4=O)nc2ccccc21		CHEMBL3904474	=	IC50	nM	1.8	CHEMBL3906	Homo sapiens	IC50	nM	1.8
332461	17710809	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1c(NC(=O)c2ccc3cc4n(c3c2)[C@H](C)CCNC4=O)nc2ccccc21		CHEMBL4112559	=	IC50	nM	1.4	CHEMBL3906	Homo sapiens	IC50	nM	1.4
332462	17710810	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccccc21		CHEMBL1933281	=	IC50	nM	20.0	CHEMBL3906	Homo sapiens	IC50	nM	20.0
332463	17710811	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1c(NC(=O)c2ccc3cc4n(c3c2)C(C)(C)CCNC4=O)nc2ccccc21		CHEMBL3965519	=	IC50	nM	2.0	CHEMBL3906	Homo sapiens	IC50	nM	2.0
332464	17710812	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1c(NC(=O)c2ccc3cc4n(c3c2)C(C)CNC4=O)nc2ccccc21		CHEMBL3909595	=	IC50	nM	7.3	CHEMBL3906	Homo sapiens	IC50	nM	7.3
332465	17710813	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2ccccc2n1C1CCCC1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3942582	=	IC50	nM	25.0	CHEMBL3906	Homo sapiens	IC50	nM	25.0
332466	17710814	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2ccccc2n1-c1ccccc1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1933282	=	IC50	nM	61.0	CHEMBL3906	Homo sapiens	IC50	nM	61.0
332467	17710815	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN1CCC(n2c(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)nc3ccccc32)CC1		CHEMBL3919317	=	IC50	nM	14.0	CHEMBL3906	Homo sapiens	IC50	nM	14.0
332468	17710816	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(=O)N1CCC(n2c(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)nc3ccccc32)CC1		CHEMBL3891232	=	IC50	nM	58.0	CHEMBL3906	Homo sapiens	IC50	nM	58.0
332469	17710817	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCn1c(NC(=O)c2ccc3cc4n(c3c2)[C@@H](C)[C@@H](C)NC4=O)nc2ccccc21		CHEMBL4108521	=	IC50	nM	0.64	CHEMBL3906	Homo sapiens	IC50	nM	0.64
332470	17710818	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCn1c(NC(=O)c2ccc3cc4n(c3c2)[C@@H](C)[C@H](C)NC4=O)nc2ccccc21		CHEMBL3961025	=	IC50	nM	5.0	CHEMBL3906	Homo sapiens	IC50	nM	5.0
332471	17710819	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccccc21		CHEMBL1933280	=	IC50	nM	1.1	CHEMBL3906	Homo sapiens	IC50	nM	1.1
332472	17710820	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCn1c(NC(=O)c2ccc3cc4n(c3c2)C(C)(C)CNC4=O)nc2ccccc21		CHEMBL3945993	=	IC50	nM	0.25	CHEMBL3906	Homo sapiens	IC50	nM	0.25
332473	17710821	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCn1c(NC(=O)c2ccc3cc4n(c3c2)C(C)CNC4=O)nc2ccccc21		CHEMBL3972132	=	IC50	nM	0.63	CHEMBL3906	Homo sapiens	IC50	nM	0.63
332474	17710822	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CC(C)(C)Cn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccccc21		CHEMBL3919214	=	IC50	nM	30.0	CHEMBL3906	Homo sapiens	IC50	nM	30.0
332475	17710823	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(O)Cn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccccc21		CHEMBL3947009	=	IC50	nM	5.4	CHEMBL3906	Homo sapiens	IC50	nM	5.4
332476	17710824	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(O)Cn1c(NC(=O)c2ccc3cc4n(c3c2)CC(C)(C)CNC4=O)nc2ccccc21		CHEMBL3924643	=	IC50	nM	5.9	CHEMBL3906	Homo sapiens	IC50	nM	5.9
332477	17710825	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2ccccc2n1CC(F)(F)F)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3955733	=	IC50	nM	4.8	CHEMBL3906	Homo sapiens	IC50	nM	4.8
332478	17710826	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN1CCC(Cn2c(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)nc3ccccc32)CC1		CHEMBL3925887	=	IC50	nM	21.0	CHEMBL3906	Homo sapiens	IC50	nM	21.0
332479	17710827	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2ccccc2n1CCc1ccccn1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3953520	=	IC50	nM	22.0	CHEMBL3906	Homo sapiens	IC50	nM	22.0
332480	17710828	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1[C@@H](C)NC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21		CHEMBL4111985	=	IC50	nM	2.1	CHEMBL3906	Homo sapiens	IC50	nM	2.1
332481	17710829	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@@H]1NC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n2[C@H]1C		CHEMBL3964098	=	IC50	nM	8.5	CHEMBL3906	Homo sapiens	IC50	nM	8.5
332482	17710830	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1CNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n2[C@H]1C		CHEMBL3910099	=	IC50	nM	2.0	CHEMBL3906	Homo sapiens	IC50	nM	2.0
332483	17710831	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@@H]1CCNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21		CHEMBL1933288	=	IC50	nM	1.1	CHEMBL3906	Homo sapiens	IC50	nM	1.1
332484	17710832	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1CCNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21		CHEMBL1933289	=	IC50	nM	14.0	CHEMBL3906	Homo sapiens	IC50	nM	14.0
332485	17710833	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1c(NC(=O)c2ccc3cc4n(c3c2)CC2(CCOCC2)CNC4=O)nc2ccccc21		CHEMBL3937135	=	IC50	nM	16.0	CHEMBL3906	Homo sapiens	IC50	nM	16.0
332486	17710834	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccccc21		CHEMBL1933283	=	IC50	nM	21.0	CHEMBL3906	Homo sapiens	IC50	nM	21.0
332487	17710835	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1c(NC(=O)c2ccc3cc4n(c3c2)CC2(CCC2)CNC4=O)nc2ccccc21		CHEMBL3952605	=	IC50	nM	11.0	CHEMBL3906	Homo sapiens	IC50	nM	11.0
332488	17710836	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1c(NC(=O)c2ccc3cc4n(c3c2)C(C)(C)CNC4=O)nc2ccccc21		CHEMBL3903528	=	IC50	nM	0.38	CHEMBL3906	Homo sapiens	IC50	nM	0.38
332489	17710837	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1c(NC(=O)c2ccc3cc4n(c3c2)CC(C)(C)CNC4=O)nc2ccccc21		CHEMBL1933290	=	IC50	nM	27.0	CHEMBL3906	Homo sapiens	IC50	nM	27.0
332490	17710838	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21		CHEMBL3939884	=	IC50	nM	1.3	CHEMBL3906	Homo sapiens	IC50	nM	1.3
332491	17710839	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n2C1		CHEMBL3911905	=	IC50	nM	13.0	CHEMBL3906	Homo sapiens	IC50	nM	13.0
332492	17710840	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CCNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21		CHEMBL3942136	=	IC50	nM	1.3	CHEMBL3906	Homo sapiens	IC50	nM	1.3
332493	17710841	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2ccccc21		CHEMBL3938752	=	IC50	nM	23.0	CHEMBL3906	Homo sapiens	IC50	nM	23.0
332494	17710842	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3931581	=	IC50	nM	54.0	CHEMBL3906	Homo sapiens	IC50	nM	54.0
332495	17710843	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCn1c(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc2cccnc21		CHEMBL1933287	=	IC50	nM	4.4	CHEMBL3906	Homo sapiens	IC50	nM	4.4
332496	17710844	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cnc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)s1		CHEMBL3955674	=	IC50	nM	300.0	CHEMBL3906	Homo sapiens	IC50	nM	300.0
332497	17710845	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1c(-c2ccccc2)cnc1NC(=O)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3919152	=	IC50	nM	500.0	CHEMBL3906	Homo sapiens	IC50	nM	500.0
332498	17710846	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ncc[nH]1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938792	=	IC50	nM	25.5	CHEMBL3906	Homo sapiens	IC50	nM	25.5
332499	17710847	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1ccnc1NC(=O)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938793	=	IC50	nM	2200.0	CHEMBL3906	Homo sapiens	IC50	nM	2200.0
332500	17710848	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(C)c1nnc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)s1		CHEMBL3946956	=	IC50	nM	96.0	CHEMBL3906	Homo sapiens	IC50	nM	96.0
332501	17710849	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(C)c1cnc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)o1		CHEMBL3910239	=	IC50	nM	1800.0	CHEMBL3906	Homo sapiens	IC50	nM	1800.0
332502	17710850	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nc2ccccc2o1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938802	=	IC50	nM	370.0	CHEMBL3906	Homo sapiens	IC50	nM	370.0
332503	17710851	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(CCc2ccccc2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3941636	=	IC50	nM	17.0	CHEMBL3906	Homo sapiens	IC50	nM	17.0
332504	17710852	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(Cc2ccncc2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1933278	=	IC50	nM	1.9	CHEMBL3906	Homo sapiens	IC50	nM	1.9
332505	17710853	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(Cc2ccccc2)c1)c1ccc2cc3n(c2c1)CC(F)(F)CNC3=O		CHEMBL3904664	=	IC50	nM	32.0	CHEMBL3906	Homo sapiens	IC50	nM	32.0
332506	17710854	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)ccc1=O		CHEMBL3932659	=	IC50	nM	110.0	CHEMBL3906	Homo sapiens	IC50	nM	110.0
332507	17710855	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1nnc(Cc2ccccc2)s1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3939391	=	IC50	nM	98.0	CHEMBL3906	Homo sapiens	IC50	nM	98.0
332508	17710856	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CS(=O)(=O)c1ccc2c(c1)nc(NC(=O)c1ccc3cc4n(c3c1)CCCNC4=O)n2CC(F)(F)F		CHEMBL3908897	=	IC50	nM	18.0	CHEMBL3906	Homo sapiens	IC50	nM	18.0
332509	17710857	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCn1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cn1		CHEMBL3966001	=	IC50	nM	120.0	CHEMBL3906	Homo sapiens	IC50	nM	120.0
332510	17710858	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)c1cccc(Cn2cc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)cn2)c1		CHEMBL3936149	=	IC50	nM	3.8	CHEMBL3906	Homo sapiens	IC50	nM	3.8
332511	17710859	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1c(NC(=O)c2ccc3cc4n(c3c2)CC(F)(F)CNC4=O)nc2ccccc21		CHEMBL3974499	=	IC50	nM	23.0	CHEMBL3906	Homo sapiens	IC50	nM	23.0
332512	17710860	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1(C)CNC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n2C1		CHEMBL3948495	=	IC50	nM	110.0	CHEMBL3906	Homo sapiens	IC50	nM	110.0
332513	17710861	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cccnc1)c1ccc2cc3n(c2c1)CC1(CC1)CNC3=O		CHEMBL1938770	=	IC50	nM	430.0	CHEMBL3906	Homo sapiens	IC50	nM	430.0
332514	17710862	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1c(NC(=O)c2ccc3cc4n(c3c2)CC2(CC2)CNC4=O)nc2ccccc21		CHEMBL3949573	=	IC50	nM	9.25	CHEMBL3906	Homo sapiens	IC50	nM	9.25
332515	17710863	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(Cc2ccccc2)c1)c1ccc2cc3n(c2c1)CC1(CC1)CNC3=O		CHEMBL3921790	=	IC50	nM	11.0	CHEMBL3906	Homo sapiens	IC50	nM	11.0
332516	17710864	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)C(C)(C)CNC4=O)no1		CHEMBL3958213	=	IC50	nM	36.0	CHEMBL3906	Homo sapiens	IC50	nM	36.0
332517	17710865	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)CC2(CC2)CNC4=O)no1		CHEMBL3927200	=	IC50	nM	145.0	CHEMBL3906	Homo sapiens	IC50	nM	145.0
332518	17710866	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)[C@H](C)CNC4=O)no1		CHEMBL4112688	=	IC50	nM	6.6	CHEMBL3906	Homo sapiens	IC50	nM	6.6
332519	17710867	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@@H]1CNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21		CHEMBL4113357	=	IC50	nM	0.7	CHEMBL3906	Homo sapiens	IC50	nM	0.7
332520	17710868	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@@H]1CNC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n21		CHEMBL4109143	=	IC50	nM	0.6	CHEMBL3906	Homo sapiens	IC50	nM	0.6
332521	17710869	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1CNC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21		CHEMBL3923687	=	IC50	nM	15.0	CHEMBL3906	Homo sapiens	IC50	nM	15.0
332522	17710870	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)[C@@H](C)CNC4=O)no1		CHEMBL3971944	=	IC50	nM	495.0	CHEMBL3906	Homo sapiens	IC50	nM	495.0
332523	17710871	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1CNC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n21		CHEMBL3907405	=	IC50	nM	17.5	CHEMBL3906	Homo sapiens	IC50	nM	17.5
332524	17710872	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1(C)CNC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n21		CHEMBL3963988	=	IC50	nM	1.8	CHEMBL3906	Homo sapiens	IC50	nM	1.8
332525	17710873	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CNC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n2C1		CHEMBL3979890	=	IC50	nM	7.6	CHEMBL3906	Homo sapiens	IC50	nM	7.6
332526	17710874	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1CNC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n2[C@H]1C		CHEMBL3944581	=	IC50	nM	9.3	CHEMBL3906	Homo sapiens	IC50	nM	9.3
332527	17710875	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1[C@H](C)CNC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n21		CHEMBL4111610	=	IC50	nM	43.5	CHEMBL3906	Homo sapiens	IC50	nM	43.5
332528	17710876	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(Cc2ccccc2)c1)c1ccc2cc3n(c2c1)CC1(CCC1)CNC3=O		CHEMBL3928994	=	IC50	nM	26.5	CHEMBL3906	Homo sapiens	IC50	nM	26.5
332529	17710877	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@@H]1NC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n2[C@@H]1C		CHEMBL3956539	=	IC50	nM	0.18	CHEMBL3906	Homo sapiens	IC50	nM	0.18
332530	17710878	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@@H]1NC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n2[C@@H]1C		CHEMBL3900064	=	IC50	nM	0.42	CHEMBL3906	Homo sapiens	IC50	nM	0.42
332531	17710879	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1[C@@H](C)NC(=O)c2cc3ccc(C(=O)Nc4nc5ccccc5n4CCCN(C)C)cc3n21		CHEMBL4111985	=	IC50	nM	13.7	CHEMBL3906	Homo sapiens	IC50	nM	13.7
332532	17710880	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1[C@@H](C)NC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n21		CHEMBL4113926	=	IC50	nM	65.5	CHEMBL3906	Homo sapiens	IC50	nM	65.5
332533	17710881	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@@H]1CCNC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n21		CHEMBL4111661	=	IC50	nM	0.71	CHEMBL3906	Homo sapiens	IC50	nM	0.71
332534	17710882	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1CCNC(=O)c2cc3ccc(C(=O)Nc4cnn(Cc5ccccc5)c4)cc3n21		CHEMBL3960147	=	IC50	nM	80.0	CHEMBL3906	Homo sapiens	IC50	nM	80.0
332535	17710883	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)c1cccc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)c1		CHEMBL3980455	=	IC50	nM	140.0	CHEMBL3906	Homo sapiens	IC50	nM	140.0
332536	17710884	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)c1ccc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cc1		CHEMBL3964720	=	IC50	nM	89.0	CHEMBL3906	Homo sapiens	IC50	nM	89.0
332537	17710885	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	COc1ccccc1NC(=O)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938785	=	IC50	nM	400.0	CHEMBL3906	Homo sapiens	IC50	nM	400.0
332538	17710886	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	COc1cccc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)c1		CHEMBL3975596	=	IC50	nM	190.0	CHEMBL3906	Homo sapiens	IC50	nM	190.0
332539	17710887	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	COc1ccc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cc1		CHEMBL3892337	=	IC50	nM	110.0	CHEMBL3906	Homo sapiens	IC50	nM	110.0
332540	17710888	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1CNC(=O)c2cc3ccc(C(=O)Nc4cccnc4)cc3n2[C@H]1C		CHEMBL3967109	=	IC50	nM	240.0	CHEMBL3906	Homo sapiens	IC50	nM	240.0
332541	17710889	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1[C@H](C)CNC(=O)c2cc3ccc(C(=O)Nc4cccnc4)cc3n21		CHEMBL1938767	=	IC50	nM	1100.0	CHEMBL3906	Homo sapiens	IC50	nM	1100.0
332542	17710890	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cccnc1)c1ccc2cc3n(c2c1)CC(F)(F)CNC3=O		CHEMBL1938769	=	IC50	nM	1700.0	CHEMBL3906	Homo sapiens	IC50	nM	1700.0
332543	17710891	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cccnc1)c1ccc2cc3n(c2c1)CC1(CCC1)CNC3=O		CHEMBL1938771	=	IC50	nM	3300.0	CHEMBL3906	Homo sapiens	IC50	nM	3300.0
332544	17710892	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ccccn1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938788	=	IC50	nM	220.0	CHEMBL3906	Homo sapiens	IC50	nM	220.0
332545	17710893	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1CNC(=O)c2cc3ccc(C(=O)Nc4cccnc4)cc3n21		CHEMBL3902177	=	IC50	nM	2300.0	CHEMBL3906	Homo sapiens	IC50	nM	2300.0
332546	17710894	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ccncc1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938787	=	IC50	nM	39.0	CHEMBL3906	Homo sapiens	IC50	nM	39.0
332547	17710895	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)CC(C)(C)CNC4=O)no1		CHEMBL3959103	=	IC50	nM	1800.0	CHEMBL3906	Homo sapiens	IC50	nM	1800.0
332548	17710896	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1ccnc(NC(=O)c2ccc3cc4n(c3c2)C(C)CCNC4=O)c1		CHEMBL3932915	=	IC50	nM	39.0	CHEMBL3906	Homo sapiens	IC50	nM	39.0
332549	17710897	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)C(C)CCNC4=O)no1		CHEMBL3905749	=	IC50	nM	12.0	CHEMBL3906	Homo sapiens	IC50	nM	12.0
332550	17710898	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CCNC(=O)c2cc3ccc(C(=O)Nc4cc(C(C)(C)C)on4)cc3n21		CHEMBL3923642	=	IC50	nM	32.0	CHEMBL3906	Homo sapiens	IC50	nM	32.0
332551	17710899	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CCNC(=O)c2cc3ccc(C(=O)Nc4cccc(F)c4)cc3n21		CHEMBL3947938	=	IC50	nM	21.0	CHEMBL3906	Homo sapiens	IC50	nM	21.0
332552	17710900	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1ncc2cc(NC(=O)c3ccc4cc5n(c4c3)C(C)CCNC5=O)cnc21		CHEMBL3951696	=	IC50	nM	19.0	CHEMBL3906	Homo sapiens	IC50	nM	19.0
332553	17710901	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1cc(NC(=O)c2ccc3cc4n(c3c2)CC(C)(C)CNC4=O)cn1		CHEMBL3939161	=	IC50	nM	335.0	CHEMBL3906	Homo sapiens	IC50	nM	335.0
332554	17710902	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CCNC(=O)c2cc3ccc(C(=O)Nc4cnn(C)c4)cc3n21		CHEMBL3938082	=	IC50	nM	10.0	CHEMBL3906	Homo sapiens	IC50	nM	10.0
332555	17710903	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)n1c(NC(=O)c2ccc3cc4n(c3c2)C(C)CCNC4=O)nc2ccccc21		CHEMBL3900130	=	IC50	nM	1.8	CHEMBL3906	Homo sapiens	IC50	nM	1.8
332556	17710904	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCn1c(NC(=O)c2ccc3cc4n(c3c2)C(C)CCNC4=O)nc2ccccc21		CHEMBL3955947	=	IC50	nM	0.6	CHEMBL3906	Homo sapiens	IC50	nM	0.6
332557	17710905	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)CC(F)(F)CNC4=O)no1		CHEMBL3927732	=	IC50	nM	670.0	CHEMBL3906	Homo sapiens	IC50	nM	670.0
332558	17710906	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)[C@@H](C)[C@H](C)NC4=O)no1		CHEMBL3954110	=	IC50	nM	160.0	CHEMBL3906	Homo sapiens	IC50	nM	160.0
332559	17710907	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)[C@@H](C)[C@H](C)CNC4=O)no1		CHEMBL4108195	=	IC50	nM	570.0	CHEMBL3906	Homo sapiens	IC50	nM	570.0
332560	17710908	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)CC2(CCC2)CNC4=O)no1		CHEMBL3972364	=	IC50	nM	1300.0	CHEMBL3906	Homo sapiens	IC50	nM	1300.0
332561	17710909	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)[C@H](C)[C@H](C)NC4=O)no1		CHEMBL3916789	=	IC50	nM	4.0	CHEMBL3906	Homo sapiens	IC50	nM	4.0
332562	17710910	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)[C@@H](C)[C@@H](C)NC4=O)no1		CHEMBL4111144	=	IC50	nM	1100.0	CHEMBL3906	Homo sapiens	IC50	nM	1100.0
332563	17710911	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)[C@@H](C)CCNC4=O)no1		CHEMBL3954908	=	IC50	nM	1200.0	CHEMBL3906	Homo sapiens	IC50	nM	1200.0
332564	17710912	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)C(C)CNC4=O)no1		CHEMBL3894714	=	IC50	nM	34.0	CHEMBL3906	Homo sapiens	IC50	nM	34.0
332565	17710913	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(C)c1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)no1		CHEMBL3966062	=	IC50	nM	150.0	CHEMBL3906	Homo sapiens	IC50	nM	150.0
332566	17710914	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CNC(=O)c2cc3ccc(C(=O)Nc4cc(C(C)(C)C)on4)cc3n21		CHEMBL3906539	=	IC50	nM	25.0	CHEMBL3906	Homo sapiens	IC50	nM	25.0
332567	17710915	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CNC(=O)c2cc3ccc(C(=O)Nc4cc5ccccc5[nH]4)cc3n21		CHEMBL3973993	=	IC50	nM	8.0	CHEMBL3906	Homo sapiens	IC50	nM	8.0
332568	17710916	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ccccc1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938781	=	IC50	nM	290.0	CHEMBL3906	Homo sapiens	IC50	nM	290.0
332569	17710917	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@H]1[C@@H](C)NC(=O)c2cc3ccc(C(=O)Nc4cccnc4)cc3n21		CHEMBL4111535	=	IC50	nM	45.0	CHEMBL3906	Homo sapiens	IC50	nM	45.0
332570	17710918	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	C[C@@H]1NC(=O)c2cc3ccc(C(=O)Nc4cccnc4)cc3n2[C@H]1C		CHEMBL3968696	=	IC50	nM	895.0	CHEMBL3906	Homo sapiens	IC50	nM	895.0
332571	17710919	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCc1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)no1		CHEMBL3920993	=	IC50	nM	34.5	CHEMBL3906	Homo sapiens	IC50	nM	34.5
332572	17710920	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)CC(C)CNC4=O)no1		CHEMBL3896482	=	IC50	nM	150.0	CHEMBL3906	Homo sapiens	IC50	nM	150.0
332573	17710921	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc(C2CC2)on1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3912056	=	IC50	nM	26.0	CHEMBL3906	Homo sapiens	IC50	nM	26.0
332574	17710922	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc(-c2ccc(F)cc2)on1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3981997	=	IC50	nM	155.0	CHEMBL3906	Homo sapiens	IC50	nM	155.0
332575	17710923	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	N#Cc1ccc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cc1		CHEMBL3914275	=	IC50	nM	106.0	CHEMBL3906	Homo sapiens	IC50	nM	106.0
332576	17710924	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1nc2cc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)ccc2s1		CHEMBL3910980	=	IC50	nM	270.0	CHEMBL3906	Homo sapiens	IC50	nM	270.0
332577	17710925	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(=O)c1cccc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)c1		CHEMBL3983605	=	IC50	nM	160.0	CHEMBL3906	Homo sapiens	IC50	nM	160.0
332578	17710926	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cn[nH]c1-c1ccccc1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3949208	=	IC50	nM	7700.0	CHEMBL3906	Homo sapiens	IC50	nM	7700.0
332579	17710927	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1nn(C)c2ncc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)cc12		CHEMBL3933821	=	IC50	nM	1300.0	CHEMBL3906	Homo sapiens	IC50	nM	1300.0
332580	17710928	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnc2ccccc2c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938798	=	IC50	nM	34.0	CHEMBL3906	Homo sapiens	IC50	nM	34.0
332581	17710929	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(C)n1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)cn1		CHEMBL3957848	=	IC50	nM	48.0	CHEMBL3906	Homo sapiens	IC50	nM	48.0
332582	17710930	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(-c2ccccc2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3906949	=	IC50	nM	18.0	CHEMBL3906	Homo sapiens	IC50	nM	18.0
332583	17710931	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)on1		CHEMBL1933143	=	IC50	nM	19.0	CHEMBL3906	Homo sapiens	IC50	nM	19.0
332584	17710932	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1noc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)c1Cl		CHEMBL3934894	=	IC50	nM	3300.0	CHEMBL3906	Homo sapiens	IC50	nM	3300.0
332585	17710933	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(C)c1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)on1		CHEMBL3912437	=	IC50	nM	44.0	CHEMBL3906	Homo sapiens	IC50	nM	44.0
332586	17710934	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)c1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)on1		CHEMBL1933145	=	IC50	nM	26.0	CHEMBL3906	Homo sapiens	IC50	nM	26.0
332587	17710935	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1(c2cc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)on2)CC1		CHEMBL3943871	=	IC50	nM	27.0	CHEMBL3906	Homo sapiens	IC50	nM	27.0
332588	17710936	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc(C2CC2)no1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1933068	=	IC50	nM	18.0	CHEMBL3906	Homo sapiens	IC50	nM	18.0
332589	17710937	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1ccc(-c2cc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)on2)cc1		CHEMBL3913615	=	IC50	nM	115.0	CHEMBL3906	Homo sapiens	IC50	nM	115.0
332590	17710938	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cccc(-c2cc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)on2)c1		CHEMBL3941595	=	IC50	nM	160.0	CHEMBL3906	Homo sapiens	IC50	nM	160.0
332591	17710939	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1(C)CNC(=O)c2cc3ccc(C(=O)Nc4cc(-c5ccccc5)no4)cc3n21		CHEMBL3938374	=	IC50	nM	15.0	CHEMBL3906	Homo sapiens	IC50	nM	15.0
332592	17710940	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCCc1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)on1		CHEMBL3910435	=	IC50	nM	16.0	CHEMBL3906	Homo sapiens	IC50	nM	16.0
332593	17710941	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ccc2scnc2c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3947149	=	IC50	nM	180.0	CHEMBL3906	Homo sapiens	IC50	nM	180.0
332594	17710942	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	COc1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)ccn1		CHEMBL3915806	=	IC50	nM	17.0	CHEMBL3906	Homo sapiens	IC50	nM	17.0
332595	17710943	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1nc2ccc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)cc2s1		CHEMBL3952504	=	IC50	nM	10.0	CHEMBL3906	Homo sapiens	IC50	nM	10.0
332596	17710944	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	COc1ccnc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)c1		CHEMBL3924810	=	IC50	nM	96.0	CHEMBL3906	Homo sapiens	IC50	nM	96.0
332597	17710945	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc(C(F)(F)F)no1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3961193	=	IC50	nM	85.0	CHEMBL3906	Homo sapiens	IC50	nM	85.0
332598	17710946	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)(CO)c1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)on1		CHEMBL3937261	=	IC50	nM	96.0	CHEMBL3906	Homo sapiens	IC50	nM	96.0
332599	17710947	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc(C2CCCCC2)no1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3930593	=	IC50	nM	39.0	CHEMBL3906	Homo sapiens	IC50	nM	39.0
332600	17710948	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc(-c2cccnc2)no1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3902606	=	IC50	nM	30.0	CHEMBL3906	Homo sapiens	IC50	nM	30.0
332601	17710949	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc(-c2ccccc2)on1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3897006	=	IC50	nM	290.0	CHEMBL3906	Homo sapiens	IC50	nM	290.0
332602	17710950	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc(Cc2ccccc2)on1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3972558	=	IC50	nM	30.0	CHEMBL3906	Homo sapiens	IC50	nM	30.0
332603	17710951	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC(C)c1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)no1		CHEMBL3933995	=	IC50	nM	66.0	CHEMBL3906	Homo sapiens	IC50	nM	66.0
332604	17710952	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc(-c2ccccc2)no1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1933146	=	IC50	nM	87.0	CHEMBL3906	Homo sapiens	IC50	nM	87.0
332605	17710953	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	NC(=O)c1ccccc1NC(=O)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938786	=	IC50	nM	21.0	CHEMBL3906	Homo sapiens	IC50	nM	21.0
332606	17710954	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ccccc1Cl)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938784	=	IC50	nM	6000.0	CHEMBL3906	Homo sapiens	IC50	nM	6000.0
332607	17710955	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	N#Cc1ccccc1NC(=O)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3910706	=	IC50	nM	7000.0	CHEMBL3906	Homo sapiens	IC50	nM	7000.0
332608	17710956	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc(-c2ccccc2)[nH]n1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3960426	=	IC50	nM	40.0	CHEMBL3906	Homo sapiens	IC50	nM	40.0
332609	17710957	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)n[nH]1		CHEMBL3985647	=	IC50	nM	68.0	CHEMBL3906	Homo sapiens	IC50	nM	68.0
332610	17710958	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cc[nH]n1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938796	=	IC50	nM	93.0	CHEMBL3906	Homo sapiens	IC50	nM	93.0
332611	17710959	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1(C)CNC(=O)c2cc3ccc(C(=O)Nc4ccccc4C(N)=O)cc3n21		CHEMBL3977541	=	IC50	nM	8.2	CHEMBL3906	Homo sapiens	IC50	nM	8.2
332612	17710960	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CCNC(=O)c2cc3ccc(C(=O)Nc4ccccc4C(N)=O)cc3n21		CHEMBL3931737	=	IC50	nM	11.0	CHEMBL3906	Homo sapiens	IC50	nM	11.0
332613	17710961	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1ccncn1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3962701	=	IC50	nM	76.0	CHEMBL3906	Homo sapiens	IC50	nM	76.0
332614	17710962	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	COc1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)ncn1		CHEMBL3899642	=	IC50	nM	9.1	CHEMBL3906	Homo sapiens	IC50	nM	9.1
332615	17710963	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)[C@H](C)CCNC4=O)no1		CHEMBL4110939	=	IC50	nM	12.0	CHEMBL3906	Homo sapiens	IC50	nM	12.0
332616	17710964	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cccc(-c2c[nH]cn2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL1938791	=	IC50	nM	52.0	CHEMBL3906	Homo sapiens	IC50	nM	52.0
332617	17710965	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cccc(-c2cc[nH]n2)c1)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3890669	=	IC50	nM	41.0	CHEMBL3906	Homo sapiens	IC50	nM	41.0
332618	17710966	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1ccc(-c2cccc(NC(=O)c3ccc4cc5n(c4c3)CCCNC5=O)c2)s1		CHEMBL3965433	=	IC50	nM	4100.0	CHEMBL3906	Homo sapiens	IC50	nM	4100.0
332619	17710967	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CNC(=O)c1ccccc1NC(=O)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3983084	=	IC50	nM	154.0	CHEMBL3906	Homo sapiens	IC50	nM	154.0
332620	17710968	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCNC(=O)c1ccccc1NC(=O)c1ccc2cc3n(c2c1)CCCNC3=O		CHEMBL3980088	=	IC50	nM	125.0	CHEMBL3906	Homo sapiens	IC50	nM	125.0
332621	17710969	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1cc(NC(=O)c2ccc3cc4n(c3c2)C(C)(C)CNC4=O)nc1C(=O)NC(C)(C)C		CHEMBL3904372	=	IC50	nM	6.0	CHEMBL3906	Homo sapiens	IC50	nM	6.0
332622	17710970	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1cc(NC(=O)c2ccc3cc4n(c3c2)CCCNC4=O)nc1C(=O)NC1CCCC1		CHEMBL3893525	=	IC50	nM	9.0	CHEMBL3906	Homo sapiens	IC50	nM	9.0
332623	17710971	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cn1cc(NC(=O)c2ccc3cc4n(c3c2)C(C)(C)CNC4=O)nc1C(=O)NC1CCCC1		CHEMBL1933142	=	IC50	nM	3.7	CHEMBL3906	Homo sapiens	IC50	nM	3.7
332624	17710972	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CC1CCNC(=O)c2cc3ccc(C(=O)Nc4cn(C)c(C(=O)NC5CCCC5)n4)cc3n21		CHEMBL3966733	=	IC50	nM	2.1	CHEMBL3906	Homo sapiens	IC50	nM	2.1
332625	17710973	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CCCNC(=O)c1nc(NC(=O)c2ccc3cc4n(c3c2)C(C)CNC4=O)sc1C(C)C		CHEMBL3968264	=	IC50	nM	10.9	CHEMBL3906	Homo sapiens	IC50	nM	10.9
332626	17710974	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CN(C)CCCn1c(NC(=O)c2ccc3cc4n(c3c2)CC2(CCNCC2)CNC4=O)nc2ccccc21		CHEMBL3897126	=	IC50	nM	540.0	CHEMBL3906	Homo sapiens	IC50	nM	540.0
332627	17710975	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	Cc1cc(NC(=O)c2ccc3cc4n(c3c2)CC2(CCNCC2)CNC4=O)no1		CHEMBL3973596	=	IC50	nM	6300.0	CHEMBL3906	Homo sapiens	IC50	nM	6300.0
332628	17710976	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	O=C(Nc1cnn(Cc2ccccc2)c1)c1ccc2cc3n(c2c1)CC1(CCNCC1)CNC3=O		CHEMBL3976641	=	IC50	nM	350.0	CHEMBL3906	Homo sapiens	IC50	nM	350.0
332629	17710977	CHEMBL3887327	Kinase Glo Plus Assay: Human RSK2 protein, purchased from Invitrogen, is used to measure kinase activity utilizing Kinase Glo Plus (Promega) a homogeneous assay technology, which uses a luciferin-luciferase based ATP detection reagent to quantify residual ATP. The assay is performed using 0.75 nM His-RSK2, 0.75 .mu.M ATP and 1.0 uM S6 Kinase/RSK Substrate Peptide 1 (Upstate, catalog #12-124), in assay buffer consisting of 25 mM HEPES, pH 7.5, 10 mM MgCl2, 5 mM MnCl2, 50 mM KCl, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4, 0.5 mM DTT, and 1% DMSO. Solutions of test compounds at various concentrations are prepared by 1:3 fold serial dilution of a 1 mM solution of compound in DMSO. The DMSO solutions are further diluted with assay buffer to a final concentration of DMSO of 5%. The assay is performed in a 384 well, white, non-binding plate (Corning, catalogue #3574). Solutions of test compounds (10 uL) are transferred to a dry assay plate, followed by addition of 20 uL kinase.	B	CS(=O)(=O)c1ccc2c(c1)nc(NC(=O)c1ccc3cc4n(c3c1)CC1(CCNCC1)CNC4=O)n2CC(F)(F)F		CHEMBL3952734	=	IC50	nM	51.0	CHEMBL3906	Homo sapiens	IC50	nM	51.0
	18052930	CHEMBL4011942	Inhibition of RSK3 (unknown origin) at 0.1 uM pretreated for 30 mins followed by substrate addition measured after 5 hrs in presence of 1 mM ATP relative to control	B	COC(=O)C1=C(Nc2ccccc2Cl)O/C(=C\c2c[nH]c3ncccc23)C1=O		CHEMBL4089159	=	Inhibition	%	-8.1	CHEMBL3906	Homo sapiens	INH	%	-8.1
	18114846	CHEMBL4025376	Inhibition of wild-type human partial length N-terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	92.0	CHEMBL3906	Homo sapiens	Activity	%	92.0
	18114847	CHEMBL4025377	Inhibition of wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	83.0	CHEMBL3906	Homo sapiens	Activity	%	83.0
	18153225	CHEMBL4034485	Inhibition of RSK3 domain 1 Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	11.2	CHEMBL3906	Homo sapiens	INH	%	11.2
	18203898	CHEMBL4044185	Inhibition of wild-type human partial length N-terminal RSK2 kinase domain 1 (M1 to D394 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	89.0	CHEMBL3906	Homo sapiens	Activity	%	89.0
	18203899	CHEMBL4044186	Inhibition of wild-type human partial length C-terminal RSK2 kinase domain 2 (V402 to S715 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	96.0	CHEMBL3906	Homo sapiens	Activity	%	96.0
	18211727	CHEMBL4045823	Inhibition of RSK3 domain1 conserved Lys2 (DLKPENILLDEEGHIK) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	10.2	CHEMBL3906	Homo sapiens	INH	%	10.2
	18211732	CHEMBL4045828	Inhibition of RSK3 domain1 conserved Lys2 (DLKPENILLDEEGHIKITDFGLSK) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	20.3	CHEMBL3906	Homo sapiens	INH	%	20.3
	18211968	CHEMBL4046064	Inhibition of RSK3 domain1 conserved Lys2 (DLKPENILLDEEGHIK) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	11.8	CHEMBL3906	Homo sapiens	INH	%	11.8
	18211973	CHEMBL4046069	Inhibition of RSK3 domain1 conserved Lys2 (DLKPENILLDEEGHIKITDFGLSK) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	13.0	CHEMBL3906	Homo sapiens	INH	%	13.0
	18212130	CHEMBL4046148	Inhibition of RSK2 (unknown origin) at 1 uM relative to control	B	Cc1c(-c2ccncc2)c[nH]c1C(N)=O		CHEMBL4100387	<	Inhibition	%	20.0	CHEMBL3906	Homo sapiens	INH	%	20.0
	18265799	CHEMBL4057249	Inhibition of RSK3 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	42.7	CHEMBL3906	Homo sapiens	INH	%	42.7
	18265997	CHEMBL4057447	Inhibition of RSK3 (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	2.0	CHEMBL3906	Homo sapiens	INH	%	2.0
	18275268	CHEMBL4118468	Inhibition of RSK3 domain1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPENILLDEEGHIK probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl		CHEMBL3883384	=	Inhibition	%	42.5	CHEMBL3906	Homo sapiens	INH	%	42.5
	18275269	CHEMBL4118468	Inhibition of RSK3 domain1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPENILLDEEGHIK probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl		CHEMBL3884839	=	Inhibition	%	13.0	CHEMBL3906	Homo sapiens	INH	%	13.0
	18275270	CHEMBL4118468	Inhibition of RSK3 domain1 in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled DLKPENILLDEEGHIK probe by mass-spectrometric analysis relative to control	B	COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O		CHEMBL1077979	=	Inhibition	%	65.4	CHEMBL3906	Homo sapiens	INH	%	65.4
	18282199	CHEMBL4120154	Inhibition of recombinant full length GST-tagged human RSK3 expressed in insect cells at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	3.6	CHEMBL3906	Homo sapiens	INH	%	3.6
	18282518	CHEMBL4120154	Inhibition of recombinant full length GST-tagged human RSK3 expressed in insect cells at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	3.5	CHEMBL3906	Homo sapiens	INH	%	3.5
	18282737	CHEMBL4120322	Inhibition of RSK3 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	42.7	CHEMBL3906	Homo sapiens	INH	%	42.7
	18282914	CHEMBL4120499	Inhibition of RSK3 (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	-2.3	CHEMBL3906	Homo sapiens	INH	%	-2.3
	18283134	CHEMBL4120719	Inhibition of RSK3 (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	4.7	CHEMBL3906	Homo sapiens	INH	%	4.7
	18286351	CHEMBL4121601	Inhibition of recombinant full length GST-tagged human RSK3 expressed in insect cells at 10 uM in presence of ATP relative to control	B	CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12		CHEMBL4128926	=	Inhibition	%	-4.0	CHEMBL3906	Homo sapiens	INH	%	-4.0
	18440440	CHEMBL4157264	Binding affinity to wild-type human partial length N-termianl RSK2 kinase domain 1 (M1 to D394 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	18440441	CHEMBL4157265	Binding affinity to wild-type human partial length C-terminal RSK2 kinase domain 2 (V402 to S715 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	96.0	CHEMBL3906	Homo sapiens	Activity	%	96.0
	18463805	CHEMBL4181221	Inhibition of recombinant human full length N-terminal His6-tagged RSK3 expressed in Sf21 insect cells at 10 uM by filter binding radioactive ATP transferase assay relative to control	B	C=C(C)n1c(=O)n(C(C)=O)c2cc(Br)cnc21		CHEMBL4212680	=	Inhibition	%	2.0	CHEMBL3906	Homo sapiens	INH	%	2.0
	18484396	CHEMBL4186043	Binding affinity to wild-type human partial length N-terminal RSK2 kinase domain 1 (M1 to D394 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	82.0	CHEMBL3906	Homo sapiens	Activity	%	82.0
	18484397	CHEMBL4186044	Binding affinity to wild-type human partial length C-terminal RSK2 kinase domain 2 (V402 to S715 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	18484880	CHEMBL4186043	Binding affinity to wild-type human partial length N-terminal RSK2 kinase domain 1 (M1 to D394 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	66.0	CHEMBL3906	Homo sapiens	Activity	%	66.0
	18484881	CHEMBL4186044	Binding affinity to wild-type human partial length C-terminal RSK2 kinase domain 2 (V402 to S715 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	18507614	CHEMBL4191165	Inhibition of recombinant full-length human Rsk3 at 1 uM using KKKNRTLSVA as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	-8.0	CHEMBL3906	Homo sapiens	INH	%	-8.0
	18653375	CHEMBL4230218	Inhibition of RSK3 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	10.0	CHEMBL3906	Homo sapiens	INH	%	10.0
	18653376	CHEMBL4230218	Inhibition of RSK3 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	2.0	CHEMBL3906	Homo sapiens	INH	%	2.0
	18655289	CHEMBL4230946	Binding affinity to wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	88.0	CHEMBL3906	Homo sapiens	Activity	%	88.0
	18655290	CHEMBL4230945	Binding affinity to wild-type human partial length N-terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	94.0	CHEMBL3906	Homo sapiens	Activity	%	94.0
	18665529	CHEMBL4233405	Inhibition of RSK3 (unknown origin)	B	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL4245507	>	IC50	nM	10000.0	CHEMBL3906	Homo sapiens	IC50	nM	10000.0
	18674892	CHEMBL4235433	Inhibition of RSK3 (unknown origin)	B	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1		CHEMBL4249925	=	Ki	nM	940.0	CHEMBL3906	Homo sapiens	Ki	nM	940.0
	18674893	CHEMBL4235433	Inhibition of RSK3 (unknown origin)	B	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1		CHEMBL4245242	>	Ki	nM	2000.0	CHEMBL3906	Homo sapiens	Ki	nM	2000.0
	18674894	CHEMBL4235433	Inhibition of RSK3 (unknown origin)	B	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1		CHEMBL4248525	>	Ki	nM	2000.0	CHEMBL3906	Homo sapiens	Ki	nM	2000.0
	18751232	CHEMBL4263941	Inhibition of RSK3 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	5.0	CHEMBL3906	Homo sapiens	INH	%	5.0
	18752197	CHEMBL4264534	Binding affinity to wild-type human partial length N-terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	90.0	CHEMBL3906	Homo sapiens	Activity	%	90.0
	18752198	CHEMBL4264535	Binding affinity to wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	92.0	CHEMBL3906	Homo sapiens	Activity	%	92.0
	18858197	CHEMBL4308043	Binding affinity to wild-type human partial length N- terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	18858198	CHEMBL4308044	Binding affinity to wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	18892707	CHEMBL4314542	Inhibition of recombinant full-length human Rsk3 assessed as residual activity at 10 uM using KKKNRTLSVA as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	114.0	CHEMBL3906	Homo sapiens	Activity	%	114.0
	18919558	CHEMBL4322914	Binding affinity to recombinant human full length N-terminal GST-tagged RPS6KA2 expressed in baculovirus expression system using S6K peptide as substrate incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	8.0	CHEMBL3906	Homo sapiens	Kd	nM	8.0
	18919746	CHEMBL4322914	Binding affinity to recombinant human full length N-terminal GST-tagged RPS6KA2 expressed in baculovirus expression system using S6K peptide as substrate incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	4.0	CHEMBL3906	Homo sapiens	Kd	nM	4.0
	18938285	CHEMBL4327869	Inhibition of human RSK3 assessed as residual activity at 1 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	100.01	CHEMBL3906	Homo sapiens	Activity	%	100.01
	18938286	CHEMBL4327869	Inhibition of human RSK3 assessed as residual activity at 1 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	93.44	CHEMBL3906	Homo sapiens	Activity	%	93.44
	18938714	CHEMBL4328233	Inhibition of human RSK3 assessed as residual activity at 100 uM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL3906	Homo sapiens	Activity	%	65.0
	18939100	CHEMBL4328597	Inhibition of human RSK3 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.227	CHEMBL3906	Homo sapiens	IC50	10'-10M	2.27
	18958563	CHEMBL4333628	Binding affinity to wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	98.0	CHEMBL3906	Homo sapiens	Activity	%	98.0
	18958564	CHEMBL4333627	Binding affinity to wild-type human partial length N-terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	54.0	CHEMBL3906	Homo sapiens	Activity	%	54.0
	18964670	CHEMBL4335276	Inhibition of recombinant full length human Rsk3 assessed as residual activity at 1 uM using KKKNRTLSVA as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	96.0	CHEMBL3906	Homo sapiens	Activity	%	96.0
	18964671	CHEMBL4335276	Inhibition of recombinant full length human Rsk3 assessed as residual activity at 1 uM using KKKNRTLSVA as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	112.0	CHEMBL3906	Homo sapiens	Activity	%	112.0
	18972091	CHEMBL4337101	Inhibition of recombinant full length human Rsk3 assessed as residual activity at 10 uM using KKKNRTLSVA as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	93.0	CHEMBL3906	Homo sapiens	Activity	%	93.0
Not Active	19040149	CHEMBL4352050	Inhibition of recombinant full-length human Rsk3 at 10 uM using KKKNRTLSVA as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL3906	Homo sapiens	INH		
Active	19041275	CHEMBL4352536	Inhibition of human RSK3 at 10 uM using KKLNRTLSVA as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL3906	Homo sapiens	INH		
	19059822	CHEMBL4358123	Binding affinity to wild-type human partial length N- terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	19059823	CHEMBL4358124	Binding affinity to wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	19090386	CHEMBL4365960	Inhibition of wild-type human partial length N-terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	69.0	CHEMBL3906	Homo sapiens	Activity	%	69.0
	19090387	CHEMBL4365961	Inhibition of wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	19092108	CHEMBL4366582	Inhibition of human RSK3 at 100 nM using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1	Outside typical range	CHEMBL4528675	=	Inhibition	%	-72.49	CHEMBL3906	Homo sapiens	INH	%	-72.49
	19121970	CHEMBL4373028	Inhibition of RSK3 (unknown origin) at 0.1 uM relative to control	B	COCCC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1		CHEMBL4540910	=	Inhibition	%	20.0	CHEMBL3906	Homo sapiens	INH	%	20.0
	19121978	CHEMBL4373036	Inhibition of RSK3 (unknown origin) at 1 uM relative to control	B	COCCC#Cc1c(Cl)c2c(Cl)cc(C(N)=O)nc2n1[C@H]1CCCNC1		CHEMBL4540910	=	Inhibition	%	54.0	CHEMBL3906	Homo sapiens	INH	%	54.0
	19144835	CHEMBL4377851	Inhibition of human Rsk2 (2 to end residues) at 1 uM using KKKNRTLSVA as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	19.0	CHEMBL3906	Homo sapiens	INH	%	19.0
	19146971	CHEMBL4378821	Inhibition of full length recombinant human Rsk3 at 10 uM using KKKNRTLSVA as substrate after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	9.0	CHEMBL3906	Homo sapiens	INH	%	9.0
	19148029	CHEMBL4379425	Inhibition of recombinant full length human Rsk3 using KKKNRTLSVA as substrate incubated for 40 mins in presence of [gamma33P]ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL3906	Homo sapiens	IC50	uM	10.0
	19159650	CHEMBL4382754	Binding affinity to wild-type human partial length N-terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	5.6	CHEMBL3906	Homo sapiens	Activity	%	5.6
	19159651	CHEMBL4382755	Binding affinity to wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	27.0	CHEMBL3906	Homo sapiens	Activity	%	27.0
	19181136	CHEMBL4387347	Inhibition of recombinant full length human GST-tagged RSK3 expressed in insect expression system at 0.1 uM using serine/threonine-6 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	19.5	CHEMBL3906	Homo sapiens	INH	%	19.5
	19181361	CHEMBL4387347	Inhibition of recombinant full length human GST-tagged RSK3 expressed in insect expression system at 0.1 uM using serine/threonine-6 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	58.5	CHEMBL3906	Homo sapiens	INH	%	58.5
	19191356	CHEMBL4389474	Inhibition of wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	66.0	CHEMBL3906	Homo sapiens	INH	%	66.0
	19191357	CHEMBL4389473	Inhibition of wild-type human partial length N-terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	78.0	CHEMBL3906	Homo sapiens	INH	%	78.0
	19192136	CHEMBL4389950	Inhibition of wild-type human partial length N-terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	88.0	CHEMBL3906	Homo sapiens	INH	%	88.0
	19192137	CHEMBL4389951	Inhibition of wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	97.0	CHEMBL3906	Homo sapiens	INH	%	97.0
	19200392	CHEMBL4391576	Binding affinity to wild-type human partial length N-terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	7.1	CHEMBL3906	Homo sapiens	Activity	%	7.1
	19200393	CHEMBL4391577	Binding affinity to wild-type human partial length C-terminal RSK3 kinase domain 2 (V403 to K700 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	74.0	CHEMBL3906	Homo sapiens	Activity	%	74.0
	19266605	CHEMBL4405555	Inhibition of wild-type human partial length N-terminal RSK3 kinase domain 1 (M1 to Q385 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	19266606	CHEMBL4405556	Inhibition of wild-type human partial length N-terminal RSK3 kinase domain 2 (M1 to Q385 residues) expressed in B6bacterial expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	19276121	CHEMBL4408124	Inhibition of recombinant human full length RSK3 at 1 uM using KKKNRTLSVA as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	26.0	CHEMBL3906	Homo sapiens	INH	%	26.0
	20600663	CHEMBL4603615	Inhibition of recombinant full length human GST-tagged RPS6KA2 expressed in insect expression system using Ser/Thr 06 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL3906	Homo sapiens	IC50	uM	100.0
	20680693	CHEMBL4623003	Inhibition of RSK3 (unknown origin) using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK a substrate by [32P] gammaATP assay	B	CC(C)CCN1c2nc(Nc3cc(F)c(O)c(F)c3)ncc2N(C)C(=O)C1C		CHEMBL573107	=	IC50	nM	18.0	CHEMBL3906	Homo sapiens	IC50	nM	18.0
	20680699	CHEMBL4623000	Inhibition of RSK3 (unknown origin)	B	CC(C)CCN1c2nc(Nc3cc(F)c(O)c(F)c3)ncc2N(C)C(=O)C1C		CHEMBL573107	=	IC50	nM	13.0	CHEMBL3906	Homo sapiens	IC50	nM	13.0
	20680700	CHEMBL4623000	Inhibition of RSK3 (unknown origin)	B	Oc1c(F)cc(-c2cnccc2-c2ccc(N3CCOCC3)cc2)cc1F		CHEMBL3604794	=	IC50	nM	4.0	CHEMBL3906	Homo sapiens	IC50	nM	4.0
	22392157	CHEMBL4667252	Inhibition of recombinant human GST-tagged full length RSK3 expressed in insect expression system using Ser/Thr 06 as substrate at 10 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	-4.5	CHEMBL3906	Homo sapiens	INH	%	-4.5
	22423257	CHEMBL4674204	Inhibition of human RSK3 using KKLNRTLSVA as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	103.09	CHEMBL3906	Homo sapiens	Activity	%	103.09
	22423258	CHEMBL4674204	Inhibition of human RSK3 using KKLNRTLSVA as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	54.64	CHEMBL3906	Homo sapiens	Activity	%	54.64
	22770396	CHEMBL4704293	Inhibition of RSK3 (unknown origin) at 1 uM relative to control	B	Cc1cn([C@@H](C)[C@]2(F)CCNC2)c2nc(C(N)=O)cc(Cl)c12		CHEMBL4778578	=	Inhibition	%	87.0	CHEMBL3906	Homo sapiens	INH	%	87.0
	22818132	CHEMBL4715355	Inhibition of recombinant human N-terminal full-length His6-tagged RSK3 (1883 to end residues) expressed in Sf21 insect cells at 2 uM using MAPKAP Kinase 2 as substrate relative to control	B	C[C@@H](c1ccc2ncccc2c1)c1nnc2sc(-c3cnn(C)c3)nn12		CHEMBL4791034	<	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	22843244	CHEMBL4720258	Inhibition of RSK3 (unknown origin)	B	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1		CHEMBL4755698	>	IC50	nM	10000.0	CHEMBL3906	Homo sapiens	IC50	nM	10000.0
	22843577	CHEMBL4720563	Inhibition of human RSK3 using KKLNRTLSVA as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.14	CHEMBL3906	Homo sapiens	IC50	10^-10M	1.4
	22843919	CHEMBL4720905	Inhibition of human RSK3 assessed as residual activity using KKLNRTLSVA as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	101.61	CHEMBL3906	Homo sapiens	Activity	%	101.61
	22844859	CHEMBL4721534	Inhibition of human RSK3 expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	80.28	CHEMBL3906	Homo sapiens	Activity	%	80.28
	22883477	CHEMBL4727562	Inhibition of recombinant human full-length GST-tagged RSK3 expressed in insect cells	B	CC(C)n1cnnc1-c1cccc(NC(=O)[C@H]2CN(c3ccc(C4CC4)nc3)CCO2)n1		CHEMBL4744428	<=	IC50	nM	500.0	CHEMBL3906	Homo sapiens	IC50	nM	500.0
	22952990	CHEMBL4766927	Inhibition of recombinant full length human Rsk3 assessed as residual activity at 10 uM using KKKNRTLSVA as substrate incubated for 40 mins in presence of [gamma33P]ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	45.0	CHEMBL3906	Homo sapiens	Activity	%	45.0
	23121010	CHEMBL4804488	Inhibition of RSK3 domain 1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	IC50	nM	3300.0	CHEMBL3906	Homo sapiens	IC50	uM	3.3
	23121011	CHEMBL4804488	Inhibition of RSK3 domain 1 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	IC50	nM	13300.0	CHEMBL3906	Homo sapiens	IC50	uM	13.3
	23121012	CHEMBL4804488	Inhibition of RSK3 domain 1 in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	IC50	nM	1000.0	CHEMBL3906	Homo sapiens	IC50	uM	1.0
	23121013	CHEMBL4804488	Inhibition of RSK3 domain 1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	IC50	nM	25800.0	CHEMBL3906	Homo sapiens	IC50	uM	25.8
	23121014	CHEMBL4804488	Inhibition of RSK3 domain 1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	IC50	nM	68400.0	CHEMBL3906	Homo sapiens	IC50	uM	68.4
	23121015	CHEMBL4804488	Inhibition of RSK3 domain 1 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	IC50	nM	58700.0	CHEMBL3906	Homo sapiens	IC50	uM	58.7
	23122049	CHEMBL4804670	Inhibition of RSK3 domain 1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL3906	Homo sapiens	INH	%	0.0
	23122050	CHEMBL4804670	Inhibition of RSK3 domain 1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL3906	Homo sapiens	INH	%	0.0
	23122051	CHEMBL4804670	Inhibition of RSK3 domain 1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	0.0	CHEMBL3906	Homo sapiens	INH	%	0.0
	23122052	CHEMBL4804670	Inhibition of RSK3 domain 1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	0.0	CHEMBL3906	Homo sapiens	INH	%	0.0
	23122053	CHEMBL4804670	Inhibition of RSK3 domain 1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	23122054	CHEMBL4804670	Inhibition of RSK3 domain 1 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	50.0	CHEMBL3906	Homo sapiens	INH	%	50.0
	23122807	CHEMBL4805158	Inhibition of human N-terminal RSK3 kinase domain 1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	23122808	CHEMBL4805159	Inhibition of human C-terminal RSK3 kinase domain 2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	91.0	CHEMBL3906	Homo sapiens	Activity	%	91.0
	23123502	CHEMBL4805746	Inhibition of human N-terminal RSK3 kinase domain 1 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	93.0	CHEMBL3906	Homo sapiens	Activity	%	93.0
	23123503	CHEMBL4805747	Inhibition of human C-terminal RSK3 kinase domain 2 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	81.0	CHEMBL3906	Homo sapiens	Activity	%	81.0
	23123956	CHEMBL4806200	Inhibition of DNA-tagged human N-terminal RSK3 kinase domain 1 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	23123957	CHEMBL4806201	Inhibition of DNA-tagged human C-terminal RSK3 kinase domain 2 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	92.0	CHEMBL3906	Homo sapiens	Activity	%	92.0
	23125094	CHEMBL4806763	Inhibition of human N-terminal RSK3 kinase domain 1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	99.0	CHEMBL3906	Homo sapiens	Activity	%	99.0
	23125095	CHEMBL4806763	Inhibition of human N-terminal RSK3 kinase domain 1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	77.0	CHEMBL3906	Homo sapiens	Activity	%	77.0
	23125096	CHEMBL4806764	Inhibition of human C-terminal RSK3 kinase domain 2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL3906	Homo sapiens	Activity	%	100.0
	23125097	CHEMBL4806764	Inhibition of human C-terminal RSK3 kinase domain 2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	89.0	CHEMBL3906	Homo sapiens	Activity	%	89.0
	23128545	CHEMBL4807990	Inhibition of RPS6KA2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	=	Activity	%	50.0	CHEMBL3906	Homo sapiens	Activity	%	50.0
	23128546	CHEMBL4807990	Inhibition of RPS6KA2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL3906	Homo sapiens	Activity	%	75.0
	23128547	CHEMBL4807990	Inhibition of RPS6KA2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL3906	Homo sapiens	Activity	%	75.0
	23213442	CHEMBL4822976	Inhibition of human recombinant RSK3 in presence of ATP by Z-lyte kinase assay	B	OC1(c2ccccc2)CSC(=S)N1Cc1ccncc1		CHEMBL4861930	=	Inhibition	%	9.0	CHEMBL3906	Homo sapiens	INH	%	9.0
	23239303	CHEMBL4828828	Inhibition of ADP(ATP)-biotin probe binding to RSK3 domain 1 in human Kelly cells at 1 uM incubated for 6 hrs by KiNativ profiling analysis	B	CN(C)C/C=C/C(=O)Nc1ccc(O[C@@H]2CCC[C@@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)cc1		CHEMBL4754873	=	Inhibition	%	41.6	CHEMBL3906	Homo sapiens	INH	%	41.6
	23251319	CHEMBL4831206	Binding affinity to human N-terminal RSK3 kinase domain 1 at 1 uM by KINOMEscan scanMAX assay relative to control	B	O=C(NCCCN1CCOC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1		CHEMBL2312304	=	Activity	%	67.0	CHEMBL3906	Homo sapiens	Activity	%	67.0
	23251327	CHEMBL4831214	Binding affinity to human N-terminal RSK3 kinase domain 1 by KINOMEscan scanMAX assay	B	O=C(NCCCN1CCOC1=O)c1cnc(NCc2cc(Cl)ccc2Cl)nc1NC1CCCC1		CHEMBL2312304	=	Kd	nM	1300.0	CHEMBL3906	Homo sapiens	Kd	nM	1300.0
	23252621	CHEMBL4831410	Inhibition of wild type human RSK3 expressed in bacterial expression system assessed as protein activity at 0.5 uM relative to control	B	CC(C)(N)CCNc1nc(Nc2ccc(C#N)nc2)ncc1C(F)(F)F		CHEMBL4861256	=	Activity	%	14.0	CHEMBL3906	Homo sapiens	Activity	%	14.0
	23297878	CHEMBL4841336	Inhibition of RSK3 (unknown origin)	B	CC(C)CCN1c2nc(Nc3cc(F)c(O)c(F)c3)ncc2N(C)C(=O)C1C		CHEMBL573107	=	IC50	nM	18.0	CHEMBL3906	Homo sapiens	IC50	nM	18.0
	23297884	CHEMBL4841340	Inhibition of full length recombinant GST-tagged human RSK3 expressed in insect cell using biotin-labelled AGAGRSRHSSYPAGT-OH as substrate in presence of ATP	B	CN1CCN(c2ccc(-c3ccncc3-c3cc(F)c(O)c(F)c3)cc2)CC1		CHEMBL3604793	=	IC50	nM	4.0	CHEMBL3906	Homo sapiens	IC50	nM	4.0
	23297885	CHEMBL4841340	Inhibition of full length recombinant GST-tagged human RSK3 expressed in insect cell using biotin-labelled AGAGRSRHSSYPAGT-OH as substrate in presence of ATP	B	Oc1c(F)cc(-c2cnccc2-c2ccc(N3CCOCC3)cc2)cc1F		CHEMBL3604794	=	IC50	nM	13.0	CHEMBL3906	Homo sapiens	IC50	nM	13.0
Not Active	23297920	CHEMBL4841352	Inhibition of RSK3 in human TE-10 cells assessed as suppression of c-fos phosphorylation at 1 to 10 uM measured after 24 hrs by Western blot analysis	B	CC(C)C1OC(=O)N(C2CCCC2)c2nc(Nc3cc(F)c(O)c(F)c3)ncc21		CHEMBL4847762		Inhibition	%		CHEMBL3906	Homo sapiens	INH		
Not Active	23297921	CHEMBL4841353	Inhibition of RSK3 in human TE-10 cells assessed as suppression of HistoneH3 phosphorylation at residue 34 at 1 to 10 uM measured after 24 hrs by Western blot analysis	B	CC(C)C1OC(=O)N(C2CCCC2)c2nc(Nc3cc(F)c(O)c(F)c3)ncc21		CHEMBL4847762		Inhibition	%		CHEMBL3906	Homo sapiens	INH		
Not Active	23297922	CHEMBL4841354	Inhibition of RSK3 in human TE-10 cells assessed as suppression of HistoneH3 phosphorylation at residue 35 at 1 to 10 uM measured after 24 hrs by Western blot analysis	B	CC(C)C1OC(=O)N(C2CCCC2)c2nc(Nc3cc(F)c(O)c(F)c3)ncc21		CHEMBL4847762		Inhibition	%		CHEMBL3906	Homo sapiens	INH		
	23297925	CHEMBL4841357	Inhibition of RSK3 (unknown origin) at 100 nM relative to control	B	CC(C)C1OC(=O)N(C2CCCC2)c2nc(Nc3cc(F)c(O)c(F)c3)ncc21		CHEMBL4847762	>	Inhibition	%	90.0	CHEMBL3906	Homo sapiens	INH	%	90.0
Not Active	23317643	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	85.0	CHEMBL3906	Homo sapiens	% Control	%	85.0
Not Active	23317644	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23318111	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23318112	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23318777	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	89.0	CHEMBL3906	Homo sapiens	% Control	%	89.0
Not Active	23318778	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	85.0	CHEMBL3906	Homo sapiens	% Control	%	85.0
Not Active	23319261	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23319262	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	98.0	CHEMBL3906	Homo sapiens	% Control	%	98.0
Not Active	23319898	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23319899	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23320373	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	84.7	CHEMBL3906	Homo sapiens	% Control	%	84.7
Not Active	23320374	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	90.2	CHEMBL3906	Homo sapiens	% Control	%	90.2
Not Active	23321051	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	99.0	CHEMBL3906	Homo sapiens	% Control	%	99.0
Not Active	23321052	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23321519	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23321520	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23322149	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	93.0	CHEMBL3906	Homo sapiens	% Control	%	93.0
Not Active	23322150	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	82.0	CHEMBL3906	Homo sapiens	% Control	%	82.0
Not Active	23322617	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23322618	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	81.0	CHEMBL3906	Homo sapiens	% Control	%	81.0
Not Active	23323306	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	90.0	CHEMBL3906	Homo sapiens	% Control	%	90.0
Not Active	23323307	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	95.0	CHEMBL3906	Homo sapiens	% Control	%	95.0
Not Active	23323774	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23323775	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	95.0	CHEMBL3906	Homo sapiens	% Control	%	95.0
Not Active	23324128	CHEMBL4880746	Rsk3 (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	51.0	CHEMBL3906	Homo sapiens	% inhibition	%	51.0
Not Active	23324628	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	85.4	CHEMBL3906	Homo sapiens	% Control	%	85.4
Not Active	23324629	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23325263	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	90.0	CHEMBL3906	Homo sapiens	% Control	%	90.0
Not Active	23325264	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	78.0	CHEMBL3906	Homo sapiens	% Control	%	78.0
Not Active	23325731	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	96.0	CHEMBL3906	Homo sapiens	% Control	%	96.0
Not Active	23325732	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23326378	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23326379	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	89.0	CHEMBL3906	Homo sapiens	% Control	%	89.0
Not Active	23326846	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	91.0	CHEMBL3906	Homo sapiens	% Control	%	91.0
Not Active	23326847	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23327546	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23327547	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	99.0	CHEMBL3906	Homo sapiens	% Control	%	99.0
Not Active	23328014	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	93.0	CHEMBL3906	Homo sapiens	% Control	%	93.0
Not Active	23328015	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23328601	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	85.0	CHEMBL3906	Homo sapiens	% Control	%	85.0
Not Active	23328602	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	86.0	CHEMBL3906	Homo sapiens	% Control	%	86.0
Not Active	23329069	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23329070	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23329517	CHEMBL4881224	Rsk3(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	98.0	CHEMBL3906	Homo sapiens	% residual kinase activity	%	98.0
Not Active	23330015	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23330016	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23330483	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23330484	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23331239	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23331240	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23331707	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23331708	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	92.0	CHEMBL3906	Homo sapiens	% Control	%	92.0
Not Active	23332294	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	90.9	CHEMBL3906	Homo sapiens	% Control	%	90.9
Not Active	23332295	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	65.1	CHEMBL3906	Homo sapiens	% Control	%	65.1
Not Active	23332760	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	84.0	CHEMBL3906	Homo sapiens	% Control	%	84.0
Not Active	23332761	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23333478	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	72.8	CHEMBL3906	Homo sapiens	% Control	%	72.8
Not Active	23333479	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23334117	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23334118	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23334585	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23334586	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23334961	CHEMBL4881581	Rsk3 (h) Upstate kinase activity assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		Inhibition	%	48.0	CHEMBL3906	Homo sapiens	% inhibition	%	48.0
Not Active	23335564	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	82.0	CHEMBL3906	Homo sapiens	% Control	%	82.0
Not Active	23335565	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23336032	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	95.0	CHEMBL3906	Homo sapiens	% Control	%	95.0
Not Active	23336033	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23336659	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23336660	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	84.0	CHEMBL3906	Homo sapiens	% Control	%	84.0
Not Active	23337127	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23337128	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	91.0	CHEMBL3906	Homo sapiens	% Control	%	91.0
Not Active	23337763	CHEMBL4882134	RPS6KA2 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	100.0	CHEMBL3906	Homo sapiens	% Ctrl	%	100.0
Not Active	23338208	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	85.0	CHEMBL3906	Homo sapiens	% Control	%	85.0
Not Active	23338209	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23338676	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23338677	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23339288	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23339289	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	81.0	CHEMBL3906	Homo sapiens	% Control	%	81.0
Not Active	23339756	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	80.0	CHEMBL3906	Homo sapiens	% Control	%	80.0
Active	23339757	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	0.0	CHEMBL3906	Homo sapiens	% Control	%	0.0
Not Active	23340393	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23340394	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	88.0	CHEMBL3906	Homo sapiens	% Control	%	88.0
Not Active	23340861	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23340862	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23341518	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	90.0	CHEMBL3906	Homo sapiens	% Control	%	90.0
Not Active	23341519	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	97.0	CHEMBL3906	Homo sapiens	% Control	%	97.0
Not Active	23341986	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23341987	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	83.0	CHEMBL3906	Homo sapiens	% Control	%	83.0
Not Active	23342602	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	99.0	CHEMBL3906	Homo sapiens	% Control	%	99.0
Not Active	23342603	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23343070	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	86.0	CHEMBL3906	Homo sapiens	% Control	%	86.0
Not Active	23343071	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23343700	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23343701	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	84.0	CHEMBL3906	Homo sapiens	% Control	%	84.0
Not Active	23344168	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23344169	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	98.0	CHEMBL3906	Homo sapiens	% Control	%	98.0
Not Active	23344806	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	84.0	CHEMBL3906	Homo sapiens	% Control	%	84.0
Not Active	23344807	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	89.0	CHEMBL3906	Homo sapiens	% Control	%	89.0
Not Active	23345379	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23345380	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23345847	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	99.0	CHEMBL3906	Homo sapiens	% Control	%	99.0
Not Active	23345848	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	75.0	CHEMBL3906	Homo sapiens	% Control	%	75.0
Not Active	23346424	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23346425	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	86.0	CHEMBL3906	Homo sapiens	% Control	%	86.0
Not Active	23346892	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23346893	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23347492	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	90.7	CHEMBL3906	Homo sapiens	% Control	%	90.7
Not Active	23347493	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	94.1	CHEMBL3906	Homo sapiens	% Control	%	94.1
Not Active	23347984	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23347985	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	95.3	CHEMBL3906	Homo sapiens	% Control	%	95.3
Not Active	23348563	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23348564	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23349031	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23349032	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	80.0	CHEMBL3906	Homo sapiens	% Control	%	80.0
Not Active	23349618	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23349619	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	95.0	CHEMBL3906	Homo sapiens	% Control	%	95.0
Not Active	23350236	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23350237	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23350704	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23350705	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	99.0	CHEMBL3906	Homo sapiens	% Control	%	99.0
Not Active	23351309	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	84.0	CHEMBL3906	Homo sapiens	% Control	%	84.0
Not Active	23351310	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23351777	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	99.0	CHEMBL3906	Homo sapiens	% Control	%	99.0
Not Active	23351778	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23352215	CHEMBL4882904	RPS6KA2 (RSK3) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	7.53	CHEMBL3906	Homo sapiens	% Inhibition	%	7.5303
Not Active	23352801	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	92.0	CHEMBL3906	Homo sapiens	% Control	%	92.0
Not Active	23352802	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23353269	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	88.0	CHEMBL3906	Homo sapiens	% Control	%	88.0
Not Active	23353270	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23354151	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23354152	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23354619	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23354620	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23355351	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23355352	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23355819	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23355820	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23356455	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23356456	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23356923	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23356924	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23357532	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23357533	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23358179	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	80.0	CHEMBL3906	Homo sapiens	% Control	%	80.0
Not Active	23358180	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23358647	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23358648	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23359233	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23359234	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23359831	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	97.0	CHEMBL3906	Homo sapiens	% Control	%	97.0
Not Active	23359832	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	62.0	CHEMBL3906	Homo sapiens	% Control	%	62.0
Not Active	23360299	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	93.0	CHEMBL3906	Homo sapiens	% Control	%	93.0
Not Active	23360300	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23360884	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23360885	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	77.0	CHEMBL3906	Homo sapiens	% Control	%	77.0
Not Active	23361352	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	88.0	CHEMBL3906	Homo sapiens	% Control	%	88.0
Not Active	23361353	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23361925	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23361926	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23362461	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23362462	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23362929	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	95.0	CHEMBL3906	Homo sapiens	% Control	%	95.0
Not Active	23362930	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23364571	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	97.0	CHEMBL3906	Homo sapiens	% Control	%	97.0
Not Active	23364572	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	71.0	CHEMBL3906	Homo sapiens	% Control	%	71.0
Not Active	23365039	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23365040	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23365778	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23365779	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	94.0	CHEMBL3906	Homo sapiens	% Control	%	94.0
Not Active	23366321	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23366322	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23366911	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23366912	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	90.0	CHEMBL3906	Homo sapiens	% Control	%	90.0
Not Active	23367379	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23367380	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	96.0	CHEMBL3906	Homo sapiens	% Control	%	96.0
Not Active	23367734	CHEMBL4884087	RPS6KA2 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	90.0	CHEMBL3906	Homo sapiens	% Residual activity with Skepinone-L	%	90.0
Not Active	23368257	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	97.0	CHEMBL3906	Homo sapiens	% Control	%	97.0
Not Active	23368258	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	79.0	CHEMBL3906	Homo sapiens	% Control	%	79.0
Not Active	23368725	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23368726	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	94.0	CHEMBL3906	Homo sapiens	% Control	%	94.0
Not Active	23369324	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	98.0	CHEMBL3906	Homo sapiens	% Control	%	98.0
Not Active	23369325	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	89.0	CHEMBL3906	Homo sapiens	% Control	%	89.0
Not Active	23369792	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23369793	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23370233	CHEMBL4884473	Rsk3(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	5.0	CHEMBL3906	Homo sapiens	% residual kinase activity	%	5.0
	23370234	CHEMBL4884473	Rsk3(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		IC50	nM	24.0	CHEMBL3906	Homo sapiens	IC50	nM	24.0
Active	23370760	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	0.0	CHEMBL3906	Homo sapiens	% Control	%	0.0
Not Active	23370761	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23371228	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	83.0	CHEMBL3906	Homo sapiens	% Control	%	83.0
Not Active	23371229	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	94.0	CHEMBL3906	Homo sapiens	% Control	%	94.0
Not Active	23372037	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	80.0	CHEMBL3906	Homo sapiens	% Control	%	80.0
Not Active	23372038	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	94.0	CHEMBL3906	Homo sapiens	% Control	%	94.0
Not Active	23372505	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23372506	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
	23372882	CHEMBL4884847	RSK3(R6A1CGE1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL3906	Homo sapiens	pIC50		6.0
	23373291	CHEMBL4885138	RSK3(R6A1CGE1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL3906	Homo sapiens	pIC50		6.0
	23373647	CHEMBL4885424	RSK3(R6A1CGE1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL3906	Homo sapiens	pIC50		6.0
Not Active	23375093	CHEMBL4886081	RSK3 Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	9.0	CHEMBL3906	Homo sapiens	% Inhibition	%	9.0
Not Active	23375370	CHEMBL4886352	ribosomal protein S6 kinase, 90kDa, polypeptide 2  Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1	Outside typical range	CHEMBL2180408		Inhibition	%	-16.0	CHEMBL3906	Homo sapiens	% inhibition	%	-16.0
Not Active	23375932	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23375933	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	92.0	CHEMBL3906	Homo sapiens	% Control	%	92.0
Not Active	23376400	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23376401	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23376977	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23376978	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23377445	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	97.0	CHEMBL3906	Homo sapiens	% Control	%	97.0
Not Active	23377446	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	93.0	CHEMBL3906	Homo sapiens	% Control	%	93.0
Not Active	23378305	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	76.0	CHEMBL3906	Homo sapiens	% Control	%	76.0
Not Active	23378306	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	90.0	CHEMBL3906	Homo sapiens	% Control	%	90.0
Not Active	23378773	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	87.0	CHEMBL3906	Homo sapiens	% Control	%	87.0
Not Active	23378774	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23379940	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23379941	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23380408	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	88.0	CHEMBL3906	Homo sapiens	% Control	%	88.0
Not Active	23380409	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	86.0	CHEMBL3906	Homo sapiens	% Control	%	86.0
Not Active	23381102	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	94.0	CHEMBL3906	Homo sapiens	% Control	%	94.0
Not Active	23381103	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23381750	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23381751	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	94.0	CHEMBL3906	Homo sapiens	% Control	%	94.0
Not Active	23382218	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23382219	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	99.0	CHEMBL3906	Homo sapiens	% Control	%	99.0
Not Active	23382842	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	77.0	CHEMBL3906	Homo sapiens	% Control	%	77.0
Not Active	23382843	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	61.0	CHEMBL3906	Homo sapiens	% Control	%	61.0
Not Active	23383310	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	57.0	CHEMBL3906	Homo sapiens	% Control	%	57.0
Not Active	23383311	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	95.0	CHEMBL3906	Homo sapiens	% Control	%	95.0
Not Active	23383976	CHEMBL4887580	RPS6KA2 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	96.0	CHEMBL3906	Homo sapiens	% Ctrl	%	96.0
Not Active	23384454	CHEMBL4888049	Rsk3(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	10.89	CHEMBL3906	Homo sapiens	% inhibition	%	10.89
Not Active	23384709	CHEMBL4888235	RPS6KA2 (RSK3) SelectScreen Kinase panel (LifeTechnologies)	B	C=CC(=O)Nc1ccc2[nH]c(=O)n(C3CCN(Cc4ccc(-c5nc6cc[nH]c(=O)c6cc5-c5ccccc5)cc4)CC3)c2c1		CHEMBL4795065		Inhibition	%	14.0	CHEMBL3906	Homo sapiens	% Inhibition	%	14.0
Not Active	23385225	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23385226	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	79.0	CHEMBL3906	Homo sapiens	% Control	%	79.0
Not Active	23385692	CHEMBL4879949	KinomeScan assay: inhibition of RSK3(Kin.Dom.1-N-terminal)	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL3906	Homo sapiens	% Control	%	100.0
Not Active	23385693	CHEMBL4879950	KinomeScan assay: inhibition of RSK3(Kin.Dom.2-C-terminal)	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	89.0	CHEMBL3906	Homo sapiens	% Control	%	89.0
Not Active	23385907	CHEMBL4888380	Rsk3 Invitrogen kinase panel	B	COc1nc2ccc([C@@](O)(c3ccccc3)C3CCN(C(C)=O)CC3)cc2c(Cl)c1Cc1ccc(-n2cccn2)cc1		CHEMBL4802042		Inhibition	%	11.0	CHEMBL3906	Homo sapiens	% inhibition	%	11.0
